National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad
Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers,
Govt. of India, New Delhi

Annual Report

2023-24

Patron

Prof. Shailendra Saraf
Director, NIPER-Hyderabad

Compilation by

Dr. Santosh Kumar Guru
Dr. Pankaj Kumar Singh
Abhishek Tiwari

FOREWORD

I am delighted to present the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad's Annual Report for 2023-2024. NIPER Hyderabad has been declared as an 'Institute of National Importance' by the Government of India. It plays a vital role in creating human resource for the ever-growing Indian Pharmaceutical Industry. It is an autonomous body set up under the aegis of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India.

NIPER Hyderabad started its journey in 2007, with post-graduation in three departments. Currently, the institute has a total of eleven academic departments [M.S. (Pharm.) (Medicinal Chemistry, Pharmaceutical Analysis, Pharmacology and Toxicology. Pharmaceutics, Regulatory Toxicology. Natural Products, Pharmacoinformatic, Regulatory Affairs & M. Tech (Process Chemistry & Medical Devices) and MBA (Pharm.)] pursuing post-graduate studies. With the state of art facilities for piloting pharmaceutical sciences. NIPER-Hyderabad started Ph.D. courses in Medicinal Chemistry, Pharmaceutical Analysis, Pharmaceutics, and Pharmacology & Toxicology in 2011.

The continuous efforts made in the last few years by NIPER Hyderabad have resulted in 1st rank in the Pharmacy' category in National Institutional Ranking Framework (NIRF) ranking during the year 2023-24. The Institute faculty is active in a broad spectrum of research in cancer, inflammation, arthritis, diabetes, neurodegenerative and infectious diseases, and anti-microbials, starting from Drug Discovery to Formulation Development and Preclinical studies.

Within a short span of 16 years, the institute has not only established itself as a center of excellence for advanced courses and learning in Pharmaceutical Science but is also pursuing its goal towards new Drug Discovery and Development programmes with its state-of-the-art equipment and analytical facilities. As a part of our national duty and skill India moto, we conducted many training programmes, workshops, and skill development programmes to generate excellent human resources for pharmaceutical research.

Several achievements of our students and faculty continue to make us proud. Our research scholars visited international universities to present their research work in conferences and symposia with the grant in aid from different funding agencies.

Apart from guiding students for their Ph.D. programmes, I am pleased to mention that the faculty successfully obtained projects from agencies like DST. AYUSH, DBT, ICMR, and DRDO.

100% of the students are being placed through campus placements in both national and multi-national pharma companies like Dr. Reddy's, IQVIA, Novartis, Eli Lilly, Johnson & Johnson, Springer Nature Publishing, Vitras, Aragen Life Sciences, Glenmark Pharmaceuticals, Genpact, Lupin Limited, Axtria, Freyr Solutions, Cognizant, Evalueserve and so on.

Last but not least, I appreciate the efforts by the editorial team in bringing out this comprehensive annual report.

Prof. Shailendra Saraf,
Director, NIPER Hyderabad

CONTENTS

1. CHAPTER 1: AN OVERVIEW

1.1 About NIPER Hyderabad

NIPER Hyderabad is an autonomous body established under the aegis of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers as a Centre of Excellence for higher education, research, and development in pharmaceutical sciences. The institute has been declared as an "Institute of National Importance" by the Government of India through an Act of Parliament. In pursuance of the decision of the Government of India, NIPER Hyderabad started functioning as one of the six new NIPERs in September 2007, in the premises of IDPL, R&D center, Balanagar, Hyderabad. The Institute has been serving to develop human resources with excellence through conducting Postgraduate and Ph.D. courses. Students are selected through a Joint Entrance Examination for all the NIPERs every year.

NIPER Hyderabad offers M.S. (Pharm.) in Medicinal Chemistry, Pharmaceutical Analysis, Pharmacology and Toxicology, Pharmaceutics, Regulatory Toxicology, Natural Product, Regulatory Affairs, Pharmacoinformatics & M.Tech (Process Chemistry, Medical Devices), and MBA (Pharmaceutical Managment). In the recent NIRF ranking 2023 given by MHRD, GoI, NIPER-Hyderabad has secured 1nd rank in the Pharmacy' category.

The Institute has well-experienced faculty, spacious, ventilated, and well-furnished classrooms and modern laboratories, an excellent auditorium for seminars/conferences, and an extensive library within the campus. Furnished hostel rooms are available for the accommodation of students. Lectures by eminent guest faculty on specialized subjects in the concerned disciplines are also arranged for the benefit of students. Several conferences/workshops have been organized to acquaint the students and faculty with the latest advances in pharmaceutical sciences. Participation of students in the seminars organized by professional bodies is also encouraged for enhancing interaction with researchers in the field of their expertise.

1.2. Vision

- To become a leading global institute in the field of higher education and research in Pharmaceutical Sciences and Management.

1.3. Mission

- To strive towards excellence in the field of higher education and research in Pharmaceutical

Sciences and Management.

- To be one of the principal sources of the professional workforce in this field, for strengthening the Indian and global Pharma Industries in obtaining quality products at affordable prices.

1.4. Mandate

- Enhancing creativity, motivation, and drive for inculcating professionalism.
- Bringing synergy between academia, R&D, technology, and industry through training and exposure in such an environment.
- Building collaborations in pharmaceutical sciences including, biotechnologies as well as information technologies, thereby, to meet global challenges.
- Preparing professionals to become suitable for academia, R&D, and industries.
- Developing and practicing learning for the professionals and training for teachers, researchers, and regulators in their respective fields.
- Creating a world-class institute of teaching and research in the field of pharmaceutical sciences.
- Expand research activities in new avenues and emerging segments.
- Explore national and international collaborations in areas of relevance.

CHAPTER 2: GOVERNING BODIES

2.1. Board of Governors

1	**Dr. Satyanarayana Chava, CEO, Laurus Labs, Hyderabad**	**Chairperson**
2	Director, NIPER Hyderabad	Member, ex officio
3	Joint Secretary (NIPER), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers	Member, ex officio
4	Secretary, Higher Education, Govt. of Telangana	Member, ex officio
5	Representative of Drug Controller General of India, Ministry of Health & Family Welfare	Member, ex officio
6	Dr. Surinder Singh, VC, JSS University, Mysuru	Member- Eminent pharma expert
7	Dr. Sushma Talegaonkar, Associate Professor, Delhi Pharmaceuticals Science & Research University (DPSRU), New Delhi	Member- Eminent pharma expert
8	Dr. K. Thangraj, Director, Centre for DNA Fingerprinting and Diagnostics, Hyderabad	Member- Eminent pharma expert
9	Mr. Krishna Reddy, MD, Sri Krishna Pharmaceuticals, Hyderabad	Member-Industrialist
10	Mr. Sushrut Kulkarni, Global Head- IPDO, Dr. Reddy's Labs, Hyderabad	Member- Industrialist
11	Dr. Srinivas Nanduri, Professor, NIPER Hyderabad	Member- Professor of the Institute
12	Dr. Saurabh Srivastava, Associate Professor, NIPER Hyderabad	Member- Professor of the institute

2.2. Senate

The Senate is responsible for developing and updating curricula and syllabi for courses offered by various departments. Additionally, manages the conduction of the examinations.

The Senate periodically reviews the operations of departments and centers and takes necessary actions as needed. It also oversees the academic policies of the institute and provides guidance on instructional methods and collaborative teaching.

2.3. Finance Committee

The Finance Committee examines the accounts and scrutinizes proposals for expenditure. It also reviews the actual accounts and financial estimates of the institute and submits them to the Board of Governors (BoG).

2.4. Laboratory Services, Building and Works Committee

The Laboratory Service, Building and Works Committee approves all major capital works after securing the necessary administrative approval and expenditure sanction. It also provides the necessary administrative approval and expenditure sanction for minor works and works related to the maintenance and repairs of buildings and laboratory services.

CHAPTER 3: FACULTY MEMBERS AND STAFFS

3.1. Faculty Members

Currently, NIPER Hyderabad is having seven department and it offers PG and PhD Courses in eleven disciplines these department are managed by the faculties from different backgrounds like Industry, Academia, and Research to cater the need of the entire nation in Human Resource Development and Research. Details of faculty member is given below:

S. No.	Name	Designation	Department
1.	Prof. Shailendra Saraf	Director	NIPER - Hyderabad
2.	Dr. Srinivas Nanduri	Professor	Chemical Sciences
3.	Dr. N. Shankaraiah	Associate Professor	Chemical Sciences
4.	Dr. Jitender Madan	Associate Professor	Pharmaceutics
5.	Dr. Saurabh Srivastava	Associate Professor	Pharmaceutics
6.	Dr. Amit Asthana	Associate Professor	Medical Devices
7.	Dr. S. Gananadhamu	Assistant Professor	Pharnaceutical Analysis
8.	Dr. Pankaj Kumar Singh	Assistant Professor	Pharmaceutics
9.	Dr. Y.V. Madhavi	Assistant Professor	Chemical Sciences
10.	Dr. Chandraiah Godugu	Assistant Professor	Biological Sciences
11.	Dr. B. Lakshmi	Assistant Professor	Pharnaceutical Management
12.	Dr. Venkat Rao Kaki	Assistant Professor	Chemical Sciences
13.	Dr. Neelesh Kumar Mehra	Assistant Professor	Pharmaceutics
14.	Dr. Rajesh Sonti	Assistant Professor	Pharnaceutical Analysis
15.	Dr. Manoj Pandurang Dandekar	Assistant Professor	Biological Sciences
16.	Dr. Vasundhra Bhandari	Assistant Professor	Biological Sciences
17.	Dr. Priyanka Bajaj	Assistant Professor	Chemical Sciences
18.	Dr. Amol Gopalrao Dikundwar	Assistant Professor	Pharnaceutical Analysis
19.	Dr. Nitin Pal Kalia	Assistant Professor	Biological Sciences
20.	Dr. Santosh Kumar Guru	Assistant Professor	Biological Sciences
21.	Dr. Vinay Kumar Kanchupalli	DST Inspire Faculty	Chemical Sciences
22.	Dr. Dharmendra Kumar Khatri	Assistant Professor (Adhoc)	Biological Sciences

23.	Dr. Shantimoy Kar	Assistant Professor (Adhoc)	Medical Devices
24.	Dr. Sandeep Kumar	Assistant Professor (Adhoc)	Regulatory Affairs
25.	Dr. Gautam Kumar	Assistant Professor (Adhoc)	Chemical Sciences
26.	Mr. Sai Kishore	Assistant Professor (Adhoc)	Pharmaceutical Management

Dr. Srinivas Nanduri

Professor, Department of Chemical Sciences
E-mail: nanduri.niperhyd@gov.in

Experienced Chemist in leading integrated drug discovery programs encompassing all stages of drug discovery viz., Hit generation, Hit to Lead, and Lead optimization. His research area is related to "Development of alternate synthetic routes to pharmaceutically important scaffolds, intermediates, and final compounds" as well as his lab also working on "Design and synthesis of new multi drug-resistant anti-bacterial agents acting against gram-positive and gram-negative bacteria." His lab synthesized multiple series of quinazolinones that have been developed with interesting anti-bacterial activity. One of the series exhibited potent and selective anti-bacterial activity against Staphylococcus aureus. Further, these compounds also exhibited low cytotoxic activity against Vero cells, thus possessing a good selectivity index. The compounds were also found to contain potent activity against various drug-resistant clinical strains of S. aureus. Studies on the mechanism of action and in vivo studies are in progress.

Dr. N. Shankaraiah

Associate Professor, Department of Chemical Sciences
E-mail: shankar.niperhyd@gov.in

Dr. N. Shankaraiah's research group focuses on designing and synthesizing small molecular entities inspired by natural products. Using ligand-protein crystallographic studies, molecular modeling, and biological activity data, these entities are assessed for their in vitro cytotoxicity on human cancer cell lines and interactions with targets such as kinases, tubulin, topo-I & II, and DNA intercalators.

The group conducts molecular modeling to understand drug-protein interactions of the new molecules, studying heterocyclic scaffolds like isatin, 3-alkenyl oxindoles, β-carboline, hydantoins, benzimidazole, benzothiazoles, 1,2,3-triazoles, and phenanthrene. They also develop synthetic strategies, including one-pot, multi-component reactions, C-H activation/functionalization, and cascade reactions, to prepare heterocycles and their intermediates. The group explores green methodologies and C-H activation reactions for constructing C–C, C–N, C–O, and C–S bonds with various organo-catalysts, investigated via online ESI-MS/MS.

Dr. Shankaraiah was elected Fellow of the Telangana Academy of Sciences (2021) and has received awards like the OPPI Young Scientist Award (2010) and Best Research Scientist Award from NIPER-Hyd (2016). He received a Young Scientist start-up grant from SERB, DST (2015), and funding from ICMR (2024). He has been listed among the top 2% of scientists worldwide by Elsevier and Stanford University for the past three years.

He has published over 190 research articles, including two book chapters and five patents, delivered more than 50 invited talks, and supervised 18 PhD and 136 MS (Pharm.) students. He is a member of various academic bodies and recently joined the Editorial Board of the "Bioorganic Chemistry" journal.

Dr. Jitender Madan
Associate Professor, Department of Pharmaceutics
E-mail: jitender@niperhyd.ac.in

Major research areas include self-assembled Supramolecular systems viz. liposomes, niosomes, cyclodextrin, nano- & micro-particles, and solid-lipid nanoparticles. The focus is centered on exploiting USFDA approved biomaterials in combination with other potential lipids and polymers to develop innovative dosage forms and drug delivery systems to improve bioavailability, stability, safety (tolerance), and patient compliance. Whilst a wide range of applications are being taken up, particular emphasis is given to augment the aqueous solubility and bioavailability of lipophilic drugs in addition to customization of topical drug delivery systems.

Dr. Saurabh Srivastava
Associate Professor, Department of Pharmaceutics,
E-mail: saurabh@niperhyd.ac.in

Dr. Saurabh Srivastava has pursued his Masters in Pharmaceutical Sciences from “Birla Institute of Technology and Science (BITS), Pilani, Rajasthan and earned his Ph.D. in Pharmaceutics from “Panjab University, Chandigarh”. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Mumbai, Wockhardt research centre, Aurangabad and His latest stint was with Dr. Reddy’s Laboratories, Hyderabad, as Tech Lead for development and commercialization of various NDA and ANDA based products for different regulated markets.

Subsequently, he joined as an Associate Professor in the Department of Pharmaceutics, NIPER-Hyderabad. His Research group is predominantly working on “Micro/Nanostructured” Targeted drug deliveries. His major therapeutic area of research is “Neurodegenerative disorders”, “Dermal diseases”, “Skin and Breast Cancer”. He has been awarded several appreciations and “Special Recognition Awards” from Dr. Reddy’s laboratories for his outstanding contribution to research and development. He has been further elected as a “Fellow of the Telangana Academy of Sciences, in May 2024. He has 12+ “International and National Patents”, 02 Edited books, 50+ Book chapters along with 100+ research publications in Journals of International repute with H-Index: 23 and 2500+ citations further to his credit.

Dr. Amit Asthana
Associate Professor, Department of Medical Sciences
E-mail: amit.asthsana@niperhyd.ac.in

Dr. Amit Asthana’s group focuses on designing, fabricating, and characterizing paper-based and polymer-based micro-device for affordable and equipment-free clinical diagnosis. Such devices include antibody-based assay, aptamer-based assay, and ambient temperature nucleic acid (NA) amplification technology coupled with optical and/or electrochemical detection systems for

quantification. His group is also interested in using microfluidic technology and medical devices as “alternate to animal testing” for drug screening and toxicological studies along with other colleagues of NIPER, Hyderabad, as well as collaborators from CCMB, IIT-Hyderabad, THSTI-Faridabad, and University of Waterloo to name the few. Apart from this, my group is also interested in developing:

- Paper-based devices as Raman immune--sensor.
- Non-conventional methods to fabricate microfluidic devices.
- Biopolymer microfluidic devices for tissue engineering and cell culture.
- 3D printing and 3D cell culture.
- Generation of "site targeted" drug delivery vectors for drug delivery and diagnosis, using microfluidic devices.

Dr. S. Gananadhamu
Assistant Professor, Department of Pharmaceutical Analysis
E-mail: gana.niperhyd@gov.in

Dr. Gananadhamu’s main area of research is forced degradation study of drug substances. The presence of impurities in drug substances and excipients affects the safety and therapeutic efficacy of the drug products. The process-related impurities can be controlled by choosing pure raw materials and optimizing the manufacturing process. The drug degradation impurities are controlled by selecting suitable packaging and storage conditions. The forced degradation studies will be performed to know the drug degradation pathway, which helps design the packaging system and recommend drug product storage conditions. The drug substance is subjected to different degradation conditions such as hydrolysis, oxidation, heat, and light. Then analytical methods will be developed for the separation of degradation products by HPLC and UPLC. The possible degradation products will be identified by LC-Q-TOF-MS/MS and NMR. The major degradation products are tested for toxicity by using in silico toxicity tools and cell-based assays.

Dr. Pankaj Kumar Singh

Assistant Professor, Department of Pharmaceutics
E-mail: drpankajk.niperhyd@nic.in

Dr. Pankaj Kumar Singh's research focuses on formulation development and characterization (in-vitro and in-vivo) of targeted novel drug delivery systems including micelles, nanoparticles, microparticles, and liposomes. His lab is well-versed in cell culture techniques and has firsthand experience in executing several cell culture-based assays, fluorescence microscopy, and flow cytometry. His lab was also engaged in a preclinical drug development program and has acquired the substantial practice in handling various animal models (rat, mice, and hamster) for pharmacokinetic, pharmacodynamic, and acute/chronic toxicity studies. Presently working on design and development of PLGA Nanoparticles bearing cytotoxic drug anchored with macrophage targeting ligands in the management of lung cancer. His Research Group is also engaged in developing targeted liposome-bearing cytotoxic drugs for the management of breast cancer. His research lab also developed an immunity booster formulation.

Dr. Y.V. Madhavi

Assistant Professor, Department of Chemical Sciences
E-mail: yvmadhavi.niperhyd@gov.in

Dr. YV Madhavi has 5 years industrial experience from IPDO, Dr. Reddy's Laboratories, 10+ years of teaching and research at NIPER, Hyderabad. Her area of research primarily on Anti-microbial drug discovery, Process Development of API's and API intermediates, API Process development, total synthesis of biologically active natural products, Development of new methodologies, structure based drug design and synthesis of new anti-infective and anti-cancer agents.

Research Activities:

- Development of synthetic routes to pharmaceutically important scaffolds, intermediates and API's. The products on which we have been working are as follows
- Prussian Blue Insoluble, a decorporation drug for Cs and Tl poisoning

- Arbidol an antiviral drug
- Delamanid, an anti-tuberculosis drug and is on the WHO's list of essential medicines.
- Design and synthesis of new microbial agents, especially antitubercular agents based on pyrazole, isoxazole, rhodanine etc.
- Synthesis of natural product inspired new antitubercular agents
- Design and synthesis of new anti-cancer agents based on the scaffolds of Benzimidazole, isoxazole, coumarin etc.

Societal Impact: Route scouting and development of alternate cheaper routes for the existing drugs would help in making the drugs more affordable to common man and reducing the treatment costs. As the number of deaths due to infective diseases and cancer is increasing across the globe, the development of new anti-cancer and anti-infective drugs is the need of the hour. We at NIPER, Hyderabad are striving for this cause.

Dr. Chandriah Godugu

Assistant Professor, Department of Biological Sciences
E-mail: chandraiah.niperhyd@gov.in

Dr. Chandriah Godugu's research focus revolves around organ fibrosis, inflammatory disorders like acute lung, liver injury, chronic, acute pancreatitis, psoriasis and rheumatoid arthritis, cancer as well as formulation based approaches for targeted drug delivery with an emphasis on deciphering the molecular biology behind the observed protection and interested in solving various therapeutic hurdles associated with the use of potential plant-derived compounds. In addition, through a DST-DAAD-funded international collaboration, his research group is exploring the role of a novel nanoparticle-based formulation against a matrix linking enzyme for liver fibrosis. His research group investigated the potential anti-psoriatic activity of piperlongumine, niclosamide, and its molecular mechanism in an imiquimod-induced psoriatic model. Acute lung injury (ALI) remains a major cause of morbidity and mortality across the world. Rheumatoid arthritis (RA) is a progressive inflammatory disease that can lead to joint destruction and disability without appropriate treatment. His research group unveiled the potent inhibitory activity of nimbolide against inflammatory signaling cascade involved in major inflammatory diseases ALI and RA, which is counter-regulated by antioxidants such as glutathione and Nrf-2 abrogating the LPS triggered TNF-α, p38MAPK, and GSK-3β protein expression.

Dr. B. Lakshmi

Assistant Professor, Department of Pharmaceutical Management
E-mail: lakshmi.niperhyd@gov.in

Dr. B. Lakshmi has around two decades of industry, government research, and academic experience. Her expertise is in teaching and training. She holds a Ph.D. in Business Management from Osmania University.

She is currently Head of the Department of Pharmaceutical Management, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. She has conducted National Workshops and Conferences across various verticals of Pharmaceutical Management. She has several research and training grants from funding agencies like ICSSR, DBT, AICTE etc.

She has published several research papers in reputed journals and presented her research at national and international conferences and seminars.

Dr. Venkat Rao Kaki

Assistant Professor, Department of Chemical Sciences
E-mail: kvenkata.rao@niperhyd.ac.in

Dr. Kaki Venkata Rao is a medicinal chemist working as Assistant Professor from 2020 at NIPER Hyderabad in Chemical Sciences Department. Earlier he worked at Central University of Punjab, Bathinda and International Medical University, Malaysia. He also worked in Pharmaceutical Industries Nicholas Piramal Research Centre, Mumbai and Jubilant Chemsys, NOIDA.

His research is primarily focused on discovery of novel anti-inflammatory and anti-proliferative agents comprise both synthesis and computational studies. Novel Selenated heterocycles, such as selenazolines, Quinolnes are under investigation as Kinase Inhibitors and MMP-9 inhibitors. New synthetic methodologies were also developed to prepare these active molecules. Development of

scale-up process for APIs such as Melitracin and other Grignard reaction-based API products are ongoing.

Further, to develop Natural Products based anti-inflammatory formulations extracts of medicinal plants are under investigation. As a teacher Dr Venkata Rao is keen to develop e-learning contents and learner-centered pedagogical methods.

Dr. Neelesh Kumar Mehra
Assistant Professor, Department of Pharmaceutics
E-mail: neelesh@niperhyd.ac.in

Dr. Neelesh Kumar Mehra acquired more than 13 years of experience in the field of drug delivery, novel formulation approaches complex topical and injectable formulation including liposomes, polymeric nanoparticles, micelles, emulgels, Bilosomes etc for ophthalmic, cancer and diabetic wound healing. He earned B.Pharm, M.Pharm and PhD degree from Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, Sagar, India under Prof. N.K. Jain Professor Emeritus. Later, he completed his PostDoctoral Research program at Texas A& M Health Science Centre, USA for two years. He worked as manager (Team Lead) in Sentiss Research Centre for three years to handle the complex ophthalmic product to regulated market. In early, 2020, joined as Assistant Professor in Department of Pharmaceutics at NIPER-Hyderabad.

He has published 120 primary research articles in high repute international journals, 30 book chapters and edited three books made significant contributions to the pharmaceutical field. His current cumulative impact factor is around 600 with h-index 40.

He is a recipient of the “Team Award” for commercialization of the ophthalmic product, international Young Scientist Award, ICMR Shakuntala Amir Chand. World top 2% Scientist from Stanford University, USA in three consecutive years 2021 to 2023.

Dr. Rajesh Sonti
Assistant Professor, Department of Pharmaceutical Analysis
E-mail: rajesh.sonti@niperhyd.ac.in

During his Ph.D., he has worked on designed and natural peptides that are hybrid beta-sheets, modified alpha-helices, and cyclic disulfide-bonded peptides. He has done the conformational analysis of several peptides and solved 23 structures of peptides by solution NMR. His work resulted in five first-author papers out of nine publications in good profile journals. In Biozentrum, Switzerland, he worked with the protein, Abelson tyrosine kinase (Abl) involved in Chronic Myeloid Leukemia. He tested the interaction of FDA-approved drugs, e.g., Gleevec (Novartis), Tasigna (Novartis), Sprycel (Bristol-Myers Squibb), Iclusig (ARIAD Pharmaceuticals), and Inlyta (Pfizer) that bind at the ATP binding site in a solution using NMR spectroscopy. These studies lead to the identification mechanism of Abl disassembled state upon binding of certain drugs from the assembled state. He characterised activities of several drug-resistant mutants ('gatekeeper,' completely activated P242E/P249E), assessed their conformations, probed inter-domain dynamics by 15N relaxation studies. At EPFL, worked on the determination of lactate concentrations in the mice plasma and also analysed the fragmental labelling, 13C isotope enrichment by NMR. Furthermore, he worked on determining the concentrations of metabolites in mice cortex, hippocampus, and striatum regions using in vivo9T MRS magnet.

Dr. Manoj Dandekar
Assistant Professor, Department of Biological Sciences
E-mail: manoj.dandekar@niperhyd.ac.in

From the past 15 years, Dr. Dandekar has been working in the neuroscience field. After completing his Ph.D. in the Faculty of Medicine (2009), he worked in the pharmaceutical drug discovery and development industry (2009-2016). Then, for the next 4 years, he was associated with the University of Texas Health Science Center and Houston Methodist Research Institute in Houston as a Postdoctoral Research Fellow to strengthen his research background and become an independent

researcher. His research interest is in investigating the neuropathology of CNS disorders, drug screening, and brain injury using in-vivo and in-vitro approaches. His recent research also focused on the microbiome-gut-brain axis.

He has been engaged in guiding the MS (Pharm.) and PhD students. To date, one Ph.D. and 40 MS students have completed their theses under his supervision. Presently, he has been supervising 14 Ph.D. students.

Dr. Vasundhra Bhandari
Assistant Professor, Department of Biological Sciences
E-mail: vasundhra.b@niperhyd.ac.in

Dr. Vasundhra Bhandari earned her PhD from the National Institute of Pathology in New Delhi. Following her doctorate, she served as a DST Fast Track Young Scientist in 2015 at the National Institute of Animal Biotechnology (NIAB-DBT) in Hyderabad. In 2016, she was honored with the prestigious DST INSPIRE Faculty Award, continuing her research tenure at NIAB-DBT. In 2020, she joined the Biological Sciences Department at NIPER Hyderabad as an Assistant Professor. Additionally, she serves as the Faculty Incharge for the Pharmacoinformatics and Biopharmaceuticals departments.

Throughout her PhD and postdoctoral research, Dr. Bhandari identified novel drug targets and elucidated mechanisms of drug resistance in significant human parasitic and bacterial pathogens. At NIPER, her research addresses the critical global issue of antimicrobial resistance. Her team is dedicated to discovering new treatment modalities and exploring alternative therapeutic approaches, including host-directed and antivirulence strategies. Employing a diverse array of methodologies—such as functional genomics, proteomics, epigenetics, gene editing tools, and computational biology—her group aims to identify new therapeutic and diagnostic solutions against ESKAPE pathogens. Dr. Bhandari's work is instrumental in the ongoing battle against antimicrobial resistance, pushing the frontiers of pharmaceutical science and innovation.

Dr. Priyanka Bajaj
Assistant Professor, Department of Chemical Sciences
E-mail: pbajaj.04@niperhyd.ac.in

Dr. Priyanka Bajaj, PhD, is an Assistant Professor at the Department of Chemical Sciences. Her group is working on the cutting-edge field of Biopharmaceutical Enzymes and Biocatalysis based green chemistry, which is a highly interdisciplinary area encompassing chemical biology, biochemistry, synthetic organic chemistry, and process chemistry. The biocatalysts are studied in detail for their structure-activity relationship and are engineered to develop efficient therapeutics and for catalyzing pharmaceutical reactions. The group is exploring a wide range of industrially important enzymes, including P450s, Ketoreductases, Transaminases, and others.

She has 15 years of experience from her two post-doctorates at the University of Rochester, New York, and the University of Michigan, Ann Arbor, MI, USA, as well as in her PhD from NIPER, Mohali. She is the author and co-author of multiple reputed international research articles and patents and has been awarded several national and international academic awards. Her profile was featured in "She is 75 Women in Chemistry," a joint book released by the office of PSA, GoI and the Royal Society of Chemistry, UK. She also got selected amongst top 75 women in industrial research and featured in compendium of Indian Industries (CII) as Women in STEM: Vanguards of India@75 released by Prof. Ajay Sood, PSA, GoI.

Dr. Amol G. Dikundwar
Assistant Professor, Department of Pharmaceutical Analysis
E-mail: amol.dikundwar@niperhyd.ac.in

Dr. Dikundwar's research group specializes in small molecule crystallography and solid-state characterization of pharmaceuticals. Crystallographic research includes structure elucidation using single-crystal X-ray diffraction; periodic and gas-phase computations; experimental and theoretical charge density analysis to understand fine details of molecular and supramolecular properties;

prediction, correlation of physicochemical properties by detailed analysis of crystal structure of API and related molecules from the crystal structure database; structural insights for lead optimization using CADD principles. Pattern indexing, profile fitting, ab initio structure determination using high-resolution powder diffraction data, and advanced amorphous characterization through total scattering/pair distribution function (TS/PDF) analysis are some of the thrust areas of research for the group. Major focus areas from Materials Science and Engineering aspects include form screening of APIs with molecular-level structure elucidation of polymorphs, salts, cocrystals, eutectics, hydrates, solvates, etc.; determination of relative stabilities of polymorphs; understanding solid-solid phase transformations; process optimization for generation of stable or relevant forms on the scale; risk mitigation for the occurrence of undesired forms and particle engineering aspects such as controlling particle shape/size.

Dr. Nitin Pal Kalia
Assistant Professor, Department of Biological Sciences
Email: nitin.kalia@niperhyd.ac.in

Dr. Nitin Pal Kalia's research group focuses on the identification and characterization of new chemical entities for their anti-infective properties. Bacterial pathogens like Mycobacterium tuberculosis (Mtb), Non-tuberculous mycobacteria, Gram-negative bacteria, and ESKAPE pathogens, which are of clinical importance and are listed in the priority list of the Department of Biotechnology and World Health Organization are major parts of his lab's drug discovery programs. The research in his lab involves target identification, development of in-vitro screening assays, and supporting assays to decipher the mechanism of action of molecules using molecular biology approaches and biochemical assays followed by in-vivo evaluation of identified molecules using mice models for infection.

His primary concern is Long-term chemotherapy for tuberculosis, which is responsible for the emergence of multi-drug resistant Mtb strains. Persistence in Mtb is the key player responsible for long-term tuberculosis chemotherapy; therefore, targeting persistence will be helpful in reducing the treatment duration as well as the emergence of MDR-Mtb. He is also concerned about the emerging global threat of Anti-microbial Resistance (AMR) among nosocomial pathogens; hence, developing strategies to target AMR in Gram-negative bacteria and ESKAPE pathogens, which are responsible for hospital-acquired infections, will serve as another area of research for drug discovery. Apart from identifying direct hits, we will also focus on molecules (resistant breakers) that enhance the efficacy of existing antibiotics against resistant bacteria.

Dr. Santosh Kumar Guru
Assistant Professor, Department of Biological Sciences
Email: santoshkumar.guru@niperhyd.ac.in

Dr. SK Guru's research group mainly focuses on basic and applied drug discovery in cancer biology. His group mainly focus on the role of drug-tolerant persister cell and chemotherapy-induced tumor dormancy in cancer. They are exploring the survival mechanism of these dormant tumors through autophagy, epigenetic, and YAP/TAZ mechanism. Cancer drugs typically produce short-lived clinical remissions due to acquired drug resistance, which can be spontaneously reversible over time. Exposure to high doses of anticancer drugs can induce the emergence of a subpopulation of weakly proliferative and drug-tolerant cells/persister cells, which display markers associated with stem cell-like cancer cells. These drug-tolerant cell populations emerged, are highly expressed undruggable transcription factors, epigenetically silenced genes, de-novo mutations, epithelial-mesenchymal transformation/autophagy. Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release and is essential for maintaining gene silencing at heterochromatic loci. His group also focuses on the basic mechanism of chemotherapy-induced extracellular vesicles (exosomes) in breast tumor dormancy and cancer initiation. Above all, Dr. Guru is now developing a 3D organoid model for cancer drug discovery. This organoid drug screening platform can be used to guide patient treatment and clinical trials to accelerate anti-cancer drug development.

Dr. Vinaykumar K.
DST Inspire Faculty, Department of Chemical Sciences
E-mail: vinay.niperhyd@nic.in

Dr. Vinaykumar Kanchupalli has more than seven years of experience in organic chemistry. He pursued an M.Sc. in Organic Chemistry from Andhra University, Visakhapatnam and received a doctoral degree in Synthetic Organic Chemistry from the Indian Institute of Science Education and Research (IISER), Bhopal, India, in 2016 under the supervision of Prof. Sreenivas Katukojvala. Later, he completed two consecutive postdoctoral positions at Loyola University Chicago (LUC), USA and

the Indian Institute of Technology (IIT), Bombay, India. In early 2019, he started his individual career at NIPER-Hyderabad as a DST Inspire Faculty and subsequently transformed into a SERB Research Scientist position in 2024 at the same institute.

Dr Vinaykumar's research group is actively working in the catalysis field. The group focused on the design and synthesis of diverse nitrogen- and oxygen-containing heterocycles using a transition metal and metal-free catalysis approach. In addition, the group focused on the synthesis of diverse novel chemical entities (NCEs), various therapeutic molecules towards anti-cancer, anti-tuberculosis, etc., and also fascinated with an In-depth understanding of the principles of organic chemistry. From that, he published 16 publications in internationally reputed journals such as Org. Lett., Chem. Commun., J. Org. Chem. and Advanced Synthesis & catalysis etc. In addition, he has patented two Indian patents, one He is the recipient of MSc. Gold Medal 2009, DST Inspire Faculty award, OPPI Young Scientist year 2023. of which was recently granted in India.

Dr. Dharmendra Kumar Khatri
Assistant Professor (Adhoc), Department of Biological Sciences

The primary research area of interest is focused on elucidating the pathogenic mechanism of Parkinson’s disease. Specifically, a multidisciplinary approach is being employed to investigate the cellular and molecular mechanism underlying pathogenic degeneration of a specific neuronal population in the PD brain, drug screening of novel molecules isolated from plant sources or synthetic congeners for their neuroprotective and neuronal regeneration properties by using animal and cellular models.

Dr. Shantimoy Kar
Assistant Professor (Adhoc), Department of Medical Devices

Dr. Shantimoy is currently working as Assistant Professor in NIPER Hyderabad. Before moving to NIPER, he worked as a postdoc in University of Glasgow and in TU Darmstadt after completing his PhD from IIT Kharagpur. He published his research works in reputed scientific journals namely Nature Electronics, Lab on a Chip, ACS Sensors, Analyst, Applied Physics Letter, Physical Review Applied and others. Furthermore, findings from his doctoral research works received Gandhian Young Technological Innovation (GYTI) Awards in 2014 and 2017. Till date, he has been actively engaged with different interdisciplinary projects, primarily focused on developing point-of-care diagnostic solutions and for broader communities. His current research interests are broadly focused in two themes namely (I) affordable diagnostics and (II) Organ-on-chip by exploring different microfluidic tools.

Dr. Sandeep Kumar
Assistant Professor (Adhoc), Department of Regulatory Affiars

Dr. Sandeep Kumar got experience of 6 year in academia and 4 year in industry. His area of regulatory affairs research interest is the approach to the identification of critical factors in unexplored domain of regulatory decision from contemporary guidelines with indigenous and/or global scenario. Along with above mentioned, Nanoparticles synthesis and its application in targeted delivery of drugs, possible metabolite determination by forced degradation and biotransformation and enzyme production, purification and immobilization for different applications are other additions in the research interest.

Dr. Gautam Kumar
Assistant Professor (Adhoc), Department of Biological Sciences

Dr. Gautam Kumar's area of research interests are design and synthesis of novels anti-microbial and anti-cancer agents. His research focused on the development of compounds that target the Mycobacterial membrane and reporters for visualization and in situ probing of Mycobacteria . In

addition to that, he is interested in the bioactivity-guided fractionation, standardization of Natural Products using spectroscopy/spectrometry techniques and semi-synthesis of bioactive natural products to improve drug like properties.

Dr. Sai Kishore Vurakaranam
Assistant Professor (Adhoc), Pharmaceutical Management

Mr. Sai Kishore Vurakaranam has done MBA with a dual specialization in Finance and Marketing from Nagpur University. He has 9 years of corporate/industry work experience and 16 years of teaching/academics experience. He had earlier worked for Six Sigma based company in Malaysia as Accounting Systems Manager. He worked for 8 years in Oman in one of the government university colleges as faculty member, besides working for reputed Management institutes/colleges in Nagpur, Pune and Hyderabad. He has vast exposure to Internal Quality Assurance cell (IQAC) activities both in India and abroad. He had earlier conducted workshops for students in the area of finance. He also conducted workshop for faculty members on organisational dynamics. He had won the outstanding performance awards a couple of times in his earlier assignments in the areas of academics, quality assurance and policy making. His current research area of interest is Indian banking industry (Public Sector). There are few research paper publications to his credit in international journals of repute.

3.2. Technical Staffs

Laboratories, research facilities, and instrumentation facilities at NIPER Hyderabad are well-supported by the dedicated technical staff. Their expertise and commitment ensure that all operations run smoothly, enabling high-quality research and efficient use of advanced equipment. The list of Technical Staffs at NIPER Hyderabad is given below:

S. No.	Technical Staff	
1.	Dr. Nandakumar Doijad	Veterinary Officer
2.	Mrs. Srishti Paliwal	Scientist/Technical Supervisor Gr. II
3.	Mr. Hara Prasad Padhy	Scientist/Technical Supervisor Gr.II
4.	Dr. Rahul Kumar	Scientist/Technical Supervisor Gr.I
5.	Dr. Dadi A Srinivasa Rao	Scientist/Technical Supervisor Gr.I
6.	Dr. Meenu Kumari	Scientist/Technical Supervisor Gr.I
7.	Dr. Anamika Sharma	Scientist/Technical Supervisor Gr II

3.3. Administrative Staffs

The entire functioning of the Institute is facilitated by the various sections overseen by the administrative staff. These sections include the Directorate, Registry, Finance and Accounts Section, Stores and Purchase Section, Examination Section, Academics Section, IT Section, and Maintenance Section. The following personnel are the administrative staff assigned to different sections:

S. No.	Administrative Staff	
1.	Mr. Sanjeev Lohani	Finance and Accounts Officer
2.	Mr. Kailash Singh	Estate & Security Officer
3.	Mr Manoj Dhote	Guest House & Hostel Supervisor
4.	Mr. S. Narendra Babu	Secretary to Director
5.	Mr. Bonam Pavana Lakshmana Teja	Secretary to Registrar
6.	Mr. Suresh Reddy Velagala	Receptionist Cum Telephone Operator
7.	Mr. Lokendra	Storekeeper
8.	Mr. Ganesh N S	Assistant Grade I
9.	Mr. Kaila Nandeeshwar Reddy	Assistant Grade II
10.	Mr. Jitendra Bhatt	Assistant Grade II
11.	Mr. Mattaparthi Sai Sandeep	Assistant Grade II
12.	Ms. Nidhi Pandey	Assistant Grade II
13.	Mr. Patel Muni Kumar Rao	Assistant Grade II
14.	Mr. Abhishek Tiwari	Junior Technical Assistant
15.	Mr. Saka VishnuKalyan	Junior Technical Assistant
16.	Ms. Yasala Rishitha	Junior Technical Assistant
17.	Mr. Swaraj Raj	Junior Technical Assistant
18.	Mr. Harsh Vishwakarma	Junior Technical Assistant

CHAPTER 5: ACADEMICS AND RESEARCH

5.1. Students

Every year all NIPER conducts NIPER JEE (Joint Entrance Exam), aspirants from pharma backgrounds participates in this exam seeking admissions in PG and PhD Courses offered by the NIPERs. The details of admissions are given below: -



DEPARTMENT WISE STUDENT STRENGTH (2023-2024)	
Discipline	**Year 2023-24**
M.S.(Pharm.)	
Medicinal Chemistry	14
Pharmaceutical Analysis	16
Pharmacology & Toxicology	21
Pharmaceutics	21
Regulatory Toxicology	10
Regulatory Affairs	11
Pharmacoinformatics	11
Natural Products	9
Biopharmaceuticals	12
M.B.A.(Pharm.)	
Pharmaceutical Management	43
M.Tech.(Pharm.)	
Pharmaceutical Technology (Process Chemistry)	15
M.Tech.(Pharm.)	
Medical Devices	9
Total No. of Master Students	**192**
Ph.D.	
Medicinal Chemistry	10
Pharmaceutical Analysis	9
Pharmacology & Toxicology	14
Pharmaceutics	13
Pharmaceutical Technology (Process Chemistry)	3
Medical Devices	2
Regulatory Affairs	1
Pharmacoinformatics	2
Natural Products	1
Biopharmaceuticals	2
Total No of Ph.D. Students	**57**
I.Ph.D.	
Medicinal Chemistry	1
Pharmacology and Toxicology	1
Pharmaceutics	1
Total No. of I.Ph.D	**3**

PH.D. AWARDED TO STUDENTS IN 2023-2024

S. No	Reg. No.	Name of the Student	Title
1	Mr. P. Ramulu	MC-Ph.D/2017/09-EMR	Design Synthesis and Biological Evaluation of Fused Heterocycles and Phenyl Hydrazine Derivatives

2	Ms. Makhal Priyanka Nirapada	MC-Ph.D/2017/06	Design, Synthesis, Biological Evaluation of Selenium-Based Heterocyclic Compounds and Exploration of their Synthetic Methodologies
3	Ms. Kumari Preeti	PC-Ph.D/2017/202	Evaluating the Protective Effect of Pharmacological Modulators by Targeting the Interferon & Necroptosis Signaling Crosstalk in Experimental Diabetes-Induced Cognitive Impairment
4	Ms. Anika Sood	PC-Ph.D/2018/201	Delineating the role of sphingosine signaling in glial neuron interaction in type 2 diabetes mediated cognitive deficit
5	Ms. Ommi Ojaswitha	MC-Ph.D/2018/01	Design, synthesis and biological evaluation of Pyrazole, and quinoxaline derivatives as antimicrobial/anticancer agents
6	Mr. Ziaur Rahman	PC-Ph.D/2019/205	Evaluation of Neuroprotective Effect of Blood Substitution and Gut Microbiome-Based Interventions in Ischemic Stroke
7	Mr. Siva Nageswararao Gajula	PA-Ph.D/2018/101	Drug metabolism and pharmacokinetic studies of selected drugs by LC-MS/MS
9	Mr. Pawar Gaurav Bhagwan	MC-Ph.D/2018/02/EMR	Design, Synthesis and Biological Evaluation of Diverse Heterocycles: Development of Microwave Assisted Sustainable Strategies Towards C-C/ CN Bond Formation
10	Mr. Shaik Mahammad Ghouse	MC-Ph.D/2018/03	Synthesis, Biological Evaluation of Quinolone/Coumarin based Derivatives as Potential Antimicrobial and Anticancer Agents

STUDENTS PURSUING PH.D. COURSES

S. No.	Name of the Student	Department	Year
1.	Bulti Bakchi	Medicinal Chemistry	2019
2.	Durgesh G V	Medicinal Chemistry	2019
3.	Maddipatla Sarvan	Medicinal Chemistry	2019
4.	Preeti Rana	Medicinal Chemistry	2019
5.	Sanjeev Kumar	Medicinal Chemistry	2019
6.	Vadakattu Manasa	Medicinal Chemistry	2019
7.	Danaboina Srikanth	Medicinal Chemistry	2020

8.	Dastari Sowmya	Medicinal Chemistry	2020
9.	Joshi Swanand Vinayak	Medicinal Chemistry	2020
10.	Mursalim Ali Khan	Medicinal Chemistry	2020
11.	Pardeep	Medicinal Chemistry	2020
12.	Shaikh Arbaz Sujat	Medicinal Chemistry	2020
13.	Singampalli Anuradha	Medicinal Chemistry	2020
14.	Aakansha Negi	Medicinal Chemistry	2021
15.	Kumawat Akshay Ganesh	Medicinal Chemistry	2021
16.	Mary Sravani Galla	Medicinal Chemistry	2021
17.	Narukulla Dinesh Krishna	Medicinal Chemistry	2021
18.	Kotwal Bilal Khurshid	Medicinal Chemistry	2022
19.	Pooja Kumari	Medicinal Chemistry	2022
20.	Singitham Swetha	Medicinal Chemistry	2022
21.	Bellapukonda Sri Mounika	Medicinal Chemistry	2022
22.	Mundhe Priyanka Sudhakar	Medicinal Chemistry	2022
23.	Adarsh Jha	Medicinal Chemistry	2023
24.	Ashish Kumar	Medicinal Chemistry	2023
25.	Devandla Soujanya	Medicinal Chemistry	2023
26.	Gaikwad Vinit Vishwas	Medicinal Chemistry	2023
27.	Ghule Shailendra Shivaji	Medicinal Chemistry	2023
28.	Kshirsagar Prasad Suhas	Medicinal Chemistry	2023
29.	Manchella Sai Supriya	Medicinal Chemistry	2023
30.	Shivam Gupta	Medicinal Chemistry	2023
31.	Subhendu Ghosh	Medicinal Chemistry	2023
32.	Dannarm Srinivas Reddy	Pharmaceutical Analysis	2019
33.	Dhurjad Pooja Sukhdev	Pharmaceutical Analysis	2019
34.	Gangireddy Navitha Reddy	Pharmaceutical Analysis	2019
35.	Vijaya Madhyanapu Golla	Pharmaceutical Analysis	2020
36.	Bhale Nagesh Ashokrao	Pharmaceutical Analysis	2020
37.	Mahajan Rupali Suresh	Pharmaceutical Analysis	2020
38.	Chaganti Lakshmi Sai Sri Sowmya	Pharmaceutical Analysis	2021
39.	Gogikar Shiva Kumar	Pharmaceutical Analysis	2021
40.	Khemchandani Rahul Pradeepkumar	Pharmaceutical Analysis	2021
41.	Nagamalli Naga Sidhartha	Pharmaceutical Analysis	2021
42.	Roshitha K R	Pharmaceutical Analysis	2021
43.	Sapkal Rekha Arun	Pharmaceutical Analysis	2021
44.	Bhatt Nehal Prakashchandra	Pharmaceutical Analysis	2022
45.	Harshada Anil Bhalerao	Pharmaceutical Analysis	2022
46.	Monditoka Hemasree	Pharmaceutical Analysis	2022
47.	Pilli Pushpa	Pharmaceutical Analysis	2022
48.	Pimpre Kavita Ambadas	Pharmaceutical Analysis	2022

49.	Ramakanta Patel	Pharmaceutical Analysis	2022
50.	Shubham Gupta	Pharmaceutical Analysis	2022
51.	Sibu Sen	Pharmaceutical Analysis	2022
52.	Avvaru Subha Jahnavi	Pharmaceutical Analysis	2022
53.	P Shivashankar	Pharmaceutical Analysis	2022
54.	Shaikh Nadeem Nazeemsab	Pharmaceutical Analysis	2022
55.	Suradkar Rushikesh Vasudev	Pharmaceutical Analysis	2022
56.	Talari Sasikala	Pharmaceutical Analysis	2022
57.	Dharipally Harini	Pharmaceutical Analysis	2023
58.	Gottimukkula Bharath Reddy	Pharmaceutical Analysis	2023
59.	H M Chandra Mouli	Pharmaceutical Analysis	2023
60.	Katarpawar Shraddha Naresh	Pharmaceutical Analysis	2023
61.	Shinde Rushikesh Shantilal	Pharmaceutical Analysis	2023
62.	Shaik Khajapeer	Pharmaceutical Analysis	2023
63.	Shaikh Nadeem Nazeemsab	Pharmaceutical Analysis	2023
64.	Suradkar Rushikesh Vasudev	Pharmaceutical Analysis	2023
65.	Talari Sasikala	Pharmaceutical Analysis	2023
66.	Biswajit Panda	Pharmacology & Toxicology	2019
67.	Devabattula Geetanjali	Pharmacology & Toxicology	2019
68.	Mohd Rabi Bazaz	Pharmacology & Toxicology	2019
69.	Palepu Mani Surya Kumar	Pharmacology & Toxicology	2019
70.	Ankita Devi	Pharmacology & Toxicology	2020
71.	Satti Satya Sri Lakshmi	Pharmacology & Toxicology	2020
72.	Hoshiyar Singh	Pharmacology & Toxicology	2020
73.	Shashikanta Sau	Pharmacology & Toxicology	2020
74.	Singothu Siva Nagendra Babu	Pharmacology & Toxicology	2020
75.	P. Tulasi	Pharmacology & Toxicology	2020
76.	Bansood Ankush Vardhaman	Pharmacology & Toxicology	2021
77.	Arnab Roy	Pharmacology & Toxicology	2021
78.	Chilvery Shrilekha	Pharmacology & Toxicology	2021
79.	Gurpreet Singh	Pharmacology & Toxicology	2021
80.	Kamatham Pushpa Tryphena	Pharmacology & Toxicology	2021
81.	Khan Sabiya Samim	Pharmacology & Toxicology	2021
82.	Nusrat Begum Sikandar Khan	Pharmacology & Toxicology	2021
83.	Priyanka Devi	Pharmacology & Toxicology	2021
84.	Puja Kumari Agnivesh	Pharmacology & Toxicology	2021
85.	Swathilakshmi S	Pharmacology & Toxicology	2021
86.	Urati Anuradha	Pharmacology & Toxicology	2021
87.	Akash Kumar Kharwar	Pharmacology & Toxicology	2022
88.	Dharavath Anil	Pharmacology & Toxicology	2022
89.	Bhagyashree Patra	Pharmacology & Toxicology	2022

90.	Kalali Sridivya Goud	Pharmacology & Toxicology	2022
91.	Karthik Mangu	Pharmacology & Toxicology	2022
92.	Kishan Kumar Parida	Pharmacology & Toxicology	2022
93.	Km Neha Sharma	Pharmacology & Toxicology	2022
94.	Naraharisetti Lakshmi Tulasi	Pharmacology & Toxicology	2022
95.	Pasupuleti Vasavi	Pharmacology & Toxicology	2022
96.	Poornima	Pharmacology & Toxicology	2022
97.	Aliva Naik	Pharmacology & Toxicology	2023
98.	Chandrima Saha	Pharmacology & Toxicology	2023
99.	Deepali	Pharmacology & Toxicology	2023
100.	Dhage Omkar Laxman	Pharmacology & Toxicology	2023
101.	Ezhilmathe A	Pharmacology & Toxicology	2023
102.	Mainak Ghosh	Pharmacology & Toxicology	2023
103.	Monali Lahiri	Pharmacology & Toxicology	2023
104.	Nagdev Pavankumar Indarlal	Pharmacology & Toxicology	2023
105.	Preethi K Raman	Pharmacology & Toxicology	2023
106.	Samata Pradhan	Pharmacology & Toxicology	2023
107.	Sandeep Kumar Guin	Pharmacology & Toxicology	2023
108.	Santanu Basak	Pharmacology & Toxicology	2023
109.	Simranjit Kaur	Pharmacology & Toxicology	2023
110.	Katta Chantibabu	Pharmaceutics	2019
111.	Nene Shweta Sudhir	Pharmaceutics	2019
112.	Valamla Bhavana	Pharmaceutics	2019
113.	Anitha S	Pharmaceutics	2020
114.	Gollapalli Spandana	Pharmaceutics	2020
115.	Indrani Maji	Pharmaceutics	2020
116.	Mahajan Srushti Suresh	Pharmaceutics	2020
117.	Mourya Atul Premchand	Pharmaceutics	2020
118.	Padakanti Sandeep Chary	Pharmaceutics	2020
119.	Paras Famta	Pharmaceutics	2020
120.	Rajana Naveen	Pharmaceutics	2020
121.	Shah Saurabh Vijay	Pharmaceutics	2020
122.	Veerabomma Harithasree	Pharmaceutics	2020
123.	Aalhate Mayur Bapu	Pharmaceutics	2021
124.	Anupama Sikder	Pharmaceutics	2021
125.	Deepankar Bahuguna	Pharmaceutics	2021
126.	Etikala Amulya	Pharmaceutics	2021
127.	Pardhi Ekta Ravindra	Pharmaceutics	2021
128.	Pawan Devangan	Pharmaceutics	2021
129.	Pawar Avinash Suresh	Pharmaceutics	2021
130.	Ujala Gupta	Pharmaceutics	2021

131.	Vambhurkar Ganesh Bharat	Pharmaceutics	2021
132.	Vaibhavi Srivastava	Pharmaceutics	2021
133.	Rati Yadav	Pharmaceutics	2021
134.	Bhawale Rohit Dattatray	Pharmaceutics	2022
135.	Bajad Gopal Dnyanba	Pharmaceutics	2022
136.	Giriraj Pandey	Pharmaceutics	2022
137.	K Tejaswini	Pharmaceutics	2022
138.	Loharkar Soham Vivek	Pharmaceutics	2022
139.	Nair Rahul Raghavan	Pharmaceutics	2022
140.	Omar Khan Musa Khan	Pharmaceutics	2022
141.	Paul Priti Gautam	Pharmaceutics	2022
142.	Phatale Vivek Aravind	Pharmaceutics	2022
143.	Khairnar Pooja Sanjay	Pharmaceutics	2022
144.	Shristi Arya	Pharmaceutics	2022
145.	Vasave Ravindra Vija	Pharmaceutics	2022
146.	Bahadure Sumedh Devrao	Pharmaceutics	2023
147.	Bharath M	Pharmaceutics	2023
148.	Chandanapalli Dinesh Kumar	Pharmaceutics	2023
149.	Chigurupati Sri Pada Datta	Pharmaceutics	2023
150.	Dhuri Anish Vivek	Pharmaceutics	2023
151.	Jitendra Kumar	Pharmaceutics	2023
152.	Nalla Ushakumari	Pharmaceutics	2023
153.	Saptarshee Bhattacharjee	Pharmaceutics	2023
154.	Sayyed Soyal Sikandar	Pharmaceutics	2023
155.	Shalini Shukla	Pharmaceutics	2023
156.	Sharma Abhishek Ravindra	Pharmaceutics	2023
157.	Tanmoy Kanp	Pharmaceutics	2023
158.	Wagh Suraj Sanjiv	Pharmaceutics	2023
159.	Kushi Rode	Pharmaceutics	2023
160.	Abdul Kalam	Process Chemistry	2021
161.	Bandela Rani	Process Chemistry	2021
162.	Kamble Pranay Ashok	Process Chemistry	2021
163.	Monika	Process Chemistry	2022
164.	Abdul Kalam	Process Chemistry	2023
165.	Bandela Rani	Process Chemistry	2023
166.	Kamble Pranay Ashok	Process Chemistry	2023
167.	Joga Ramesh	Regulatory Affairs	2021
168.	Sabanis Chetan Dushant	Regulatory Affairs	2021
169.	Simran	Regulatory Affairs	2021
170.	Bellapu Kiran Kumar	Regulatory Affairs	2022
171.	Varpe Priya Changdev	Regulatory Affairs	2022

172.	Yerram Sravani	Regulatory Affairs	2022
173.	Vemula Divya	Pharmacoinformatics	2021
174.	Munagalasetty Sharon	Pharmacoinformatics	2022
175.	Abdur Raafay	Pharmacoinformatics	2023
176.	Katepaka Sony	Pharmacoinformatics	2023
177.	Amrutha C	Natural Products	2021
178.	Nabarun Mukhopadhyay	Natural Products	2021
179.	Tangelloju Ajay	Natural Products	2022
180.	Shreyasi Karmakar	Natural Products	2023
181.	Arjun Jayachandran	Medical Devices	2022
182.	Chandankar Sachin Maroti	Medical Devices	2022
183.	Mosam Preethi	Medical Devices	2022
184.	Dorle Sonam Tryambak	Medical Devices	2023
185.	Kotkar Avinash Annasaheb	Medical Devices	2023
186.	Koyel Panja	Biopharmaceuticals	2023
187.	Pooja Sahu	Biopharmaceuticals	2023
188.	Aman	Pharmacology and Toxicology I/Ph.D	2022
189.	Bojja Bhavana	Pharmaceutics I/Ph.D	2022

RESEARCH PROJECT TITLES OF MASTER STUDENTS GRADUATED IN JUNE 2023

M.S. (PHARM.) - MEDICINAL CHEMISTRY

Reg. No.	Name	Title
MC/2021/01	Ameena Begum	Electrochemistry in API synthesis
MC/2021/02	Ashish Chouhan	Synthesis of 5,6,7,8,-tetrahydrobenzo (4,5)-thieno(2,3-d)-pyrimidin-4 amine derivatives as anti-microbial agents
MC/2021/03	Barve Nandini Manik	Structure based drug design and synthesis of chromone-oxindole Knoevenagel condensates as possible VEGFR inhibitors
MC/2021/04	Beg Uzma Tabaksum Jabbar	Synthesis of alkylidine malanonitrile and triazole substituted thieno pyrimidines as antimicrobial agents
MC/2021/05	Chichanbemo E Kikon	Synthesis of indoloazepinone and N-allyl selenourea derivatives as possible anti-proleferative agents
MC/2021/06	Gaddam Harshini	synthesis of azacarbazole derivatives as possible anti-microbial agents
MC/2021/08	Harsh Dwivedi	Synthesis of 5,6,7,8-tetrahydropyrido[4,3.4,5]-theino[2,3-d]-pyridin-4-amine derivatives as antiproliferative agents
MC/2021/09	Jungare Kalyani Arun	Ruthenium(II) catalysed synthesis of indolo [2,3-c] isoquinolines via (3+3) annulation of N,N'- cyclic azomethine ylide and 3-diazoindolin-2-imines
MC/2021/10	Kale Nandini Bijiram	Design, Synthesis and *In silico* evaluation of Chromone-thiazolidine-2,4-dione based Hybrids as Anti-Cancer Agents.

MC/2021/11	Kuralkar Kanchan Chokharaj	Design and synthesis of heterocyclilc linked dipeptide as HDAC inhibitors
MC/2021/13	Nitika Sharma	Solid phase mediated synthesis of peptide impurities for GLP1 analogues and its characterization
MC/2021/14	Priyanka	HBr catalysed synthesis of dithiocarbamated oxindoles and their biological evaluation
MC/2021/15	Rallabandi Naveen Chand	Development of novel 1,2,3-triazole tethered β-carboline-benzimidazole hybrids as potential Topoisomerase IIα inhibitors
MC/2021/16	Solai MR	Design, synthesis of aryl thiazolidinone and coumarin-based benzoazole derivatives as possible cytotoxic agents.
MC/2021/17	Vilakshan Kale	Extraction and purification of alkaloids from fermentation broth

M.S. (PHARM.) - PHARMACEUTICAL ANALYSIS

Reg. No.	Name	Title
PA/2021/101	Araganlapally Srujana	Analytical Method devlopment and validation for related substances of Varenicline tartrateintermediate by RP-Hplc method
PA/2021/102	Agade Suraj Bhashkar	GC-FID Method Development for Simultaneous Estimation of Five Process Impurities of Menatetrenone
PA/2021/103	Birajdar Ganesh Pandit	HPLC Method Development, solid-state stress stability, and drug-drug Co-crystal screening for the combination of drugs Tadalafil and Finasteride
PA/2021/104	Daravath Sandeep	Establishment of Bioanalytical method Development for simultaneous estimation of Docetaxel & Carvacrol in SNEDDS Formulation
PA/2021/105	Dhanavath Dattu Naik	Characterization of hydrolytic degradation products of Relugolix
PA/2021/106	Dharipally Harini	Study on the forced degradation behavior of bictegravir: characterization of major degradation products using NMR
PA/2021/107	Drishti Jain	Bioanalytical method developed and validation for simulation determination of Baricitinib and Remdesivir in rat plasma by LC-MS-MS
PA/2021/108	Gholap Upasana Ravindra	Characterization of degradation products of mavacamten along with quantification of its drug related impurity by qNMR
PA/2021/109	Gobade Ganesh Pandurang	Solid State Characterization of different batches of Vorinostat and Attempt to Cocrystallization
PA/2021/110	Gottimukkula Bharath Reddy	Identification, characterization and In silico ADMET prediction of Trimethobenzamide degradation products
PA/2021/111	Jagtap Supriya Bhagwat	UPLC MS/MS method development and validation for determination of anticancer phytochemicals in Costus speciosus plant
PA/2021/112	Kalan Pavan Balkrishna	Characterization of Sonidegib Phosphate and it's degradation product using LC-MS/MS and NMR
PA/2021/113	Kamuni Vinathi	Analytical method development and validation for determination of related substances in anti diabetic (DPP-IV inhibitor) oral solid dosage form by RP-HPLC method

PA/2021/114	Nelapati Chagnya	Investigation of in vitro and in vivo metabolic fate of olaparib by high resolution mass spectrometry
PA/2021/115	Sana Essak Naikwadi	Bioanalytical method development and validation of favipiravir in rat plasma using LC-MS/MS
PA/2021/116	Shameer Marvan K	Analytical method development and validation of fixed Dosage combination of candesartan cilexetil and hydrochlorothiazide for determination of related substances by UPLC with Quality by design approach
PA/2021/117	Singh Vartika Ranjit	Establishment of a bioanalytical method for simultaneous quantitation of ponatinib and caffeine and their pharmacokinetic safety profiling
PA/2021/118	Sodnar Ashok Mhatu	Preparation, characterization, and biological evaluation of novel Tolbutamide cocrystal
PA/2021/119	Talari Sasikala	CUMS and gastric ulcers induced pharmacokinetic changes and metabolite identification of encorafenib.
PA/2021/120	Vijay Munjal	Assesment of Drug-Drug interaction between nifedipine and saxagliptin and its consequence on fetal growth in the pregnant rats
PA/2021/121	Wanjari Parita Bhagwat	Synthesis and conformational analysis of prolineproline containing contryphan

M.S. (PHARM.) - PHARMACEUTICS

Reg. No.	Name	Title
PE/2021/301	Aastha Singh	Formulation development of Self Microemulsifying drug delivery system (SMEDDS) of calcineurin inhibitor for the management of lupus nephritis
PE/2021/302	Aayush Singh	Development and Evaluation of Voriconazole Loaded Injectable Microspheres for Pulmonary Candidiasis
PE/2021/303	Aratwar Ashwini Narsingrao	Development and Evaluation of QBD-optimised Emulgel to combat Psoriasis
PE/2021/304	Divya Atram	Formulation and evaluation of an immunosuppressant loaded novel carrier system for the treatment of vitiligo
PE/2021/305	Hade Sagar Ramesh	Development and Evalution of Capsaicin Loaded Novel Topical Gel for Management of Chemotherapy Induced Peripheral Neuropathy(CIPN)
PE/2021/306	Ithape Harshada Anandrao	Boosting the anti-arthritic activity by using hyalurosomal gel of tofacitinib citrate and boric acid in the management of Rheumatoid arthritis
PE/2021/307	Jayapriya P	Formulation and optimization of Immediate Release Tablet using Novel polymorphic Form of a Model drug
PE/2021/308	Jogu Pooja	Design, development and Evaluation of metronidazole and silver nanoparticles combination loaded alginate hydrogel
PE/2021/309	Mammella Aishwarya	Design, development and evaluation of NSAID-loaded fatty acid vesicles for osteoarthritis
PE/2021/310	Mehandole Arti Balakram	Fabrication and Optimization of Dasatinib loaded Lipid Polymer Hybrid Nanoparticle against Cancer
PE/2021/311	Naitik Jain	Combating breast cancer associated metastasis using paclitaxel and tranilast loaded nanocarriers

PE/2021/312	Nalla Usha Kumari	Design, Development, and Evaluation of Antimetabolite Loaded Nanoformulation for Cancer Therapy
PE/2021/313	Pathade Vrushali Shankarrao	Development and optimization of rosuvastatin loaded nanoemulgel for the management of rheumatoid arthritis
PE/2021/314	Patil Rushikesh Kamlakar	Formulation, Development, and Evaluation of Transniosomes for ocular delivery.
PE/2021/315	Radapaka Keerthana	Topical Novel Drug Delivery system of Ibuprofen and glucosamine sulfate combination in the management of osteoarthritis
PE/2021/316	Ratnam Sreya	Topical delivery of ruxolitinib loaded nanoemulgel for the management of psoriasis
PE/2021/317	Shettiwar Arti Chandrakant	Design and development of Oil based nanocarrier for improved oral delivery of Acalabrutinib for the treatment of Mantle cell lymphoma and Chronic lymphocytic leukemia
PE/2021/318	Subham Panigrahy	Development and optimization of piperine loaded nanocarriers for nose to brain delivery for the management of Parkinson's disease
PE/2021/319	Syed Shahrukh Syed Noor	Formulation and evaluation of simvastatin loaded pH-responsive liposome for prostate cancer management
PE/2021/320	Tadkase Anurag Santosh	Formulation development and evaluation of oral anticancer drug to improve solubility and chemical stability by organic polycarboxylic acid
PE/2021/321	Walke Nikita Amrutrao	In-situ thermogel co-loaded with Tamoxifen and Carvacrol nanoemulsion for breast cancer management
PE/2021/322	Yeruva Sri Pooja	Design,Development and Evaluation of CDK4/6 Inhibitor Loaded Ligand conjugated Hybrid Nanoparticles for the treatment of breast cancer.

M.S. (PHARM.) - REGULATORY TOXICOLOGY

Reg. No.	Name	Title
RT/2021/601	Dhage Omkar Laxman	Evaluation of the protective effect of dexamethasone loaded PLGA microparticles in Osteoarthritis
RT/2021/602	Hajare Aditya Dipak	Evaluation of protective effect on dextran-coated nanoceria on dextran sulfate sodium(dss) induced colitis mice model
RT/2021/603	Harapriya Baral	To study the neuroprotective effect of Oxyberberine in rat model of vascular dementia: Involving Rho-kinase signalling
RT/2021/604	Kapaka Jyothi Priya	Evaluation of silver and cerium oxide nanoparticles loaded herbal gel for wound healing in second-degree burn rat model
RT/2021/605	Kulkarni Amrita Milind	Targeting phosphorylation and accumulation of PARIS in Parkinson's Disease
RT/2021/606	Momin Alfiya Ashpak	Evaluation of the protective effect of DNase decorated polydopamine coated nanoceria on LPS-induced acute lung injury model
RT/2021/607	Neha Bingle	Evaluation of the protective effect of DNase decorated cerium oxide nanoparticles in Amphotericin-induced acute kidney injury model

RT/2021/608	Pankaj Minj	Exploiting the potential of natural molecule as NorA multi-drug efflux pump inhibitor against Staphylococcus aureus
RT/2021/609	Pattola Hari Chander Reddy	To investigate the survival of Drug Tolerant TNBC Cells through Glutamine Metabolism.
RT/2021/610	Rachana Yadav	Targeting Neuropilin system for the effective management of Pulmonary Fibrosis : Experimental evidences
RT/2021/611	Shaikh Azhar Shaikh Mukhtar Khatik	To examine the therapeutic potential of Bacillus coagulans Unique IS-2 in rat model of vascular dementia
RT/2021/612	Stuti Bhattacharyya	To explore the contribution of VEGF/NRP2 to the survival of drug tolerant persister cancer cells by means of Angiogenesis pathway
RT/2021/613	Supriya Behera	Isolation and characterization of antibiotics and enzyme producing Actinomycetes from soil sample of the Himalayan region
RT/2021/614	Uppala Sai Nikhil	Troxerutin mediated Epigenetic modulation of TET2 via SIRT1 activation in Parkinson's disease

M. TECH (PHARM.) PHARMACEUTICAL TECHNOLOGY - PROCESS CHEMISTRY

Reg. No.	Name	Title
PTPC/2021/501	Avinash Mandloi	Decoding the structure activity relationship (SAR) of novel nitrating p450 using random mutagenesis (random libraries)
PTPC/2021/502	Borkar Vaishnavi Ramesh	Design and synthesis of 1-naphthols and its derivatives via Transition metal-catalyzed C-H functionalizations
PTPC/2021/503	Devandla Soujanya	Synthesis of structurally diverse Meriolin/Variolin analogues as Potential Kinase Inhibitors and Exploration of Synthetic Strategies towards Nitrosamine Impurities
PTPC/2021/504	Dhopat Priyanka Sudhir	Design, synthesis and biological evaluation of Naphthalene-isoxazole based (thio)urea derivatives as carbonic anhydrase inhibitors
PTPC/2021/505	Jessani Harsil	Optimization of enzyme immobilization on nanopolymers and their activity and stability testing
PTPC/2021/506	Kareena Sinha	Design, Synthesis, and Biological Evaluation of Diphenyl ether-Quinolone hybrids as Anti-Microbial Agents and Process Optimization towards the Synthesis of Key Starting Materials of
PTPC/2021/507	Khushi Gupta	Identification of novel furanyl based benzothiazole-2-iminothiazolidin-4-one derivatives as tubulin polymerization inhibitors: structure based design, synthesis, biological evaluation and computational studies
PTPC/2021/508	Kollu Shanthi	Development Of Synthetic Methodologies Towards Pyrazole / Dihydro pyrazole Containing Heterocycles As Anti-Bacterial Agents
PTPC/2021/509	Manchella Sai Supriya	Design, Synthesis and Biological Evaluation of DNA Gyrase B Inhibitors and Process Optimization for the Synthesis of Desidustat
PTPC/2021/510	Manoj Achole	Site Directed Evalution of Myoglobin for Cis-Cyclopropanation

PTPC/2021/511	Mohd Mujahid Mohd Sagir	Design and synthesis of spirocyclic Teterahydrobenzofurans via Lewis acid catalysis
PTPC/2021/512	Pathan Shehabaz Usman	Decoding the structure activity relationship (SAR) of novel nitrating p450 using site saturation mutagenesis (smart libraries)
PTPC/2021/513	Pingale Rasika Babasaheb	Design and synthesis of aryl-substituted dihydrochalcones via a multi-component cascade process
PTPC/2021/514	Shashank Yadav	Design and synthesis of unsymmetrical aryl substituted pyrimido[1,6-a]indol-1(2H)-ones via Transition metal catalyzed C-H activation
PTPC/2021/515	Shinde Mayura Anil	Design, synthesis and biological evaluation of acetamide linked coumarins as carbonic anhydrase inhibitors
PTPC/2021/516	Tupare Rohini Ramesh	Synthesis and biological evaluation of new isoxazole carboxamide and carbohydrazide derivatives as anti-microbial agents

M.B.A. (PHARM.) PHARMACEUTICAL MANAGEMENT

Reg. No.	Name	Title
PM/2021/401	Abdeali Nahargarhwala	Impact of Green Marketing Strategies on Consumer Buying Behavior of OTC Products
PM/2021/402	Aditi Awasthi	Assessment of self-medication practices and its associated factors among students
PM/2021/403	Aishwarya Thaware	Corporate Social Responsibility of pharmaceutical companies in India
PM/2021/404	Alhat Dnyaneshwar Kisan	Effects Of Advertisement On Consumer Buying Behaviour With References To Fmcg
PM/2021/405	Amanpreet Singh Raheja	Perception of people towards Health care services in government hospitals
PM/2021/406	Bamble Sejal Nitin	Consumer behaviour : Understanding consumer attitude and decision making in digital era
PM/2021/407	Bhutham Ashok	Malnutrition and its impact among the children's in India
PM/2021/408	Charmal Poonam Vasantrao	Consumer's perception towards public and private healthcare in Pune (Maharashtra)
PM/2021/409	Chinchole Vaibhav Uddhav	social media addiction and depression among the Indian population
PM/2021/410	Deepak Prabhu	A study on behavioural pattern about personal finance post covid-19
PM/2021/411	Derle Adhiraj Deeliprao	Consumer perception towards health supplements
PM/2021/412	Divya Tripathi	A study on understanding the acceptance of telemedicine amoung adult patients in and around Hyderabad

PM/2021/413	Eugeine Ashwin Raj S	A study on prevention of Antibiotics Resistance and recent trends for prevention of infection
PM/2021/414	Gedam Ankita Mordhwaj	anxiety among the students during academic activities
PM/2021/415	Kale Shweta Pradip	The effects of social media marketing on the pharmaceutical industry in hyderabad
PM/2021/416	Km Pooja Chaudhari	Primary and secondary research on Uniform Code of Pharmaceutical Marketing Practices
PM/2021/417	Kolekar Shashant Rajesh	Consumer perception towards HealthCare applications
PM/2021/418	Mandadi Sameera	Effect of work life balance on health among the population in india
PM/2021/419	Mansi Srivastava	Circadian rhythm sleep-wake disturbances: Reasons and its effect on health and routine activities amongst youth in Hyderabad
PM/2021/420	Mavuri Sai Saranya	Impact of COVID-19 Pandemic on Retail Pharmaceutical Stores in Narsapur, West Godavari district
PM/2021/421	Muddapogu Sri Lakshmi	impact of startup on economy
PM/2021/422	Nare Geetija Vilas	impact of social media marketing towards consumer behaviour of herbal products
PM/2021/423	Neeraja Ramesan	A study on Use of Over-the-Counter medication among pregnant women in Delhi
PM/2021/424	Neha Aldasani	A Study on Consumer Behaviour Towards ayurvedic and Herbal Products in Ujjain
PM/2021/425	Palak Sahu	A Study on Perception of Mental disorders in India
PM/2021/426	Pannala Keerthi Reddy	Measuring and managing patient satisfaction in healthcare organizations
PM/2021/427	Purohit Sandesh Abhishek	Factors influencing prescribing behaviour of physicians in nagpur
PM/2021/428	Rathi Abhay Rajesh	Effect of gaming on Indian population
PM/2021/429	Sagili Sravani	A knowledge & perception of people towards lozenges
PM/2021/430	Saindane Tushar Asaram	Impact of digital marketing on physicians prescribing pattern.
PM/2021/431	Sharma Yash Roopesh	Procurement in health care industry and factor influencing for decision making in SCM
PM/2021/432	Shinde Vaibhav Machhindra	factors influencing buying behaviour OTC medication on consumer
PM/2021/433	Sonali Yadav	Impact of microplastics in human safety
PM/2021/434	Soni Jeet Ajaykumar	Green Market Segmentation & consumer profiling: a heterogeneous cluster study
PM/2021/435	Tanya Gupta	Assessment of knowledge, attitudes and practice of menstrual hygiene among women in India

PM/2021/436	Thakur Atulsingh Rambhansingh	Effect of Lack of sleep on Adults
PM/2021/437	Tulavi Srushti Raoji	Impact of herbal products on today's generation after covid 19 in Maharashtra
PM/2021/438	Vijay	Impact Of Entrepreneurship Training among NIPERs' Management Students
PM/2021/439	Vinakonda Sai Anila	Effect of Blue light on Adults

5.2. Research Publications

The faculties, scientists, and students of NIPER Hyderabad actively publish their research work in reputed international and national research journals. These publications serve as a testament to the high-quality research being conducted at the institute, showcasing their contributions to the global scientific community.

These research works significantly boost current drug and medical device developments. By sharing their findings in esteemed journals, NIPER Hyderabad’s researchers contribute to advancing knowledge and innovation in the pharmaceutical and medical fields. Their work helps in identifying new drug targets, improving existing therapies, and developing cutting-edge medical devices.

Furthermore, these publications enhance the visibility and reputation of NIPER Hyderabad in the scientific community. They foster collaborations with other research institutions and industry partners, opening doors for further research opportunities and funding. The dissemination of their research findings underscores the institute’s commitment to excellence and its pivotal role in advancing healthcare and pharmaceutical sciences.

The following research publications were published during the year 2023-24:



1. **Meloxicam emulgel potently suppressed cartilage degradation in knee osteoarthritis: Optimization, formulation, industrial scalability and pharmacodynamic analysis;** Author(s): Jyothi V.G.S.; Veerabomma H.; Kumar R.; Khatri D.K.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.1016/j.colsurfb.2023.113399
2. **Partial blood replacement ameliorates middle cerebral artery occlusion generated neurological aberrations by intervening TLR4 and NLRP3 cascades in rats;** Author(s): Rahman Z.; Ghuge S.; Dandekar M.P.; Year: 2023; DOI: 10.1007/s11011-023-01259-7
3. **A review on emerging role of multifunctional carbon nanotubes as an armament in cancer therapy, imaging and biosensing;** Author(s): Chary P.S.; Bhawale R.; Vasave R.; Rajana N.; Singh P.K.; Madan J.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104588
4. **Lipid-based nanomaterials: A brief note on composition, development, and drug delivery applications;** Author(s): Kumar A.; Panwar D.; Bhavana V.; Thakor P.; Singh P.K.; Mehra N.K.; Year: 2023; DOI: 10.1007/978-3-031-30529-0_3
5. **Multicomponent Domino Reaction for Concise Access to 2-Amino-Substituted 1,3,4 Oxadiazoles via Smiles Rearrangement;** Author(s): Yakkala P.A.; Khan I.A.; Dannarm S.R.; Aboti J.; Sonti R.; Shafi S.; Kamal A.; Year: 2023; DOI: 10.1021/acs.joc.3c00516
6. **Naringenin-Capped Silver Nanoparticles Amalgamated Gel for the Treatment of Cutaneous Candidiasis;** Author(s): Katta C.; Shaikh A.S.; Bhale N.; Jyothi V.G.S.S.; Kaki V.R.; Dikundwar A.G.; Singh P.K.; Shukla R.; Mishra K.; Madan J.; Year: 2023; DOI: 10.1208/s12249-023-02581-0
7. **Self-nanoemulsifying drug delivery system (SNEDDS) of docetaxel and carvacrol synergizes the anticancer activity and enables safer toxicity profile: optimization, and in-vitro, ex-vivo and in-vivo pharmacokinetic evaluation;** Author(s): Ateeq M.A.M.; Aalhate M.; Mahajan S.; Kumar G.S.; Sen S.; Singh H.; Gupta U.; Maji I.; Dikundwar A.; Guru S.K.; Singh P.K.; Year: 2023; DOI: 10.1007/s13346-023-01342-7

8. **Cellular aggregation dictates universal spreading behaviour of a whole-blood drop on a paper strip;** Author(s): Laha S.; Kar S.; Chakraborty S.; Year: 2023; DOI: 10.1016/j.jcis.2023.02.048
9. **GaMF1.39's antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876;** Author(s): Ragunathan P.; Ng P.S.; Singh S.; Poh W.H.; Litty D.; Kalia N.P.; Larsson S.; Harikishore A.; Rice S.A.; Ingham P.W.; Müller V.; Moraski G.; Miller M.J.; Dick T.; Pethe K.; Grüber G.; Year: 2023; DOI: 10.1128/spectrum.02282-23
10. **6-Aminocoumarin oxime-ether/sulfonamides as selective hCA IX and XII inhibitors: Synthesis, evaluation, and molecular dynamics studies;** Author(s): Ghouse S.M.; Sinha K.; Bonardi A.; Pawar G.; Malasala S.; Danaboina S.; Mohammed A.; Yaddanapudi V.M.; Supuran C.T.; Nanduri S.; Year: 2023; DOI: 10.1002/ardp.202300316
11. **Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer;** Author(s): Bellapu K.K.; Joga R.; Kannan B.R.; Yerram S.; Varpe P.; Mergu T.; Vasu P.Y.; Srivastava S.; Kumar S.; Year: 2023; DOI: 10.4155/ppa-2023-0024
12. **Artemisinin derivatives induce oxidative stress leading to DNA damage and caspase-mediated apoptosis in Theileria annulata-transformed cells;** Author(s): Barman M.; Dandasena D.; Suresh A.; Bhandari V.; Kamble S.; Singh S.; Subudhi M.; Sharma P.; Year: 2023; DOI: 10.1186/s12964-023-01067-7
13. **Investigating the effectiveness of Difluprednate-Loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery;** Author(s): Kaviarasi B.; Rajana N.; Pooja Y.S.; Rajalakshmi A.N.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.ijpharm.2023.123006
14. **Efflux pump inhibitory potential of indole derivatives as an arsenal against norA over-expressing Staphylococcus aureus;** Author(s): Chandal N.; Tambat R.; Kalia R.; Kumar G.; Mahey N.; Jachak S.; Nandanwar H.; Year: 2023; DOI: 10.1128/spectrum.04876-22
15. **Voriconazole-syringic acid co-crystals reduced voriconazole-induced hepatotoxicity: In vitro and in vivo studies: Voriconazole-syringic acid co-crystals reduced voriconazole-induced hepatotoxicity;** Author(s): Sharma A.; Katta C.B.; Bahuguna D.; Veerabomma H.; Mourya A.; Jyothi V.G.S.S.; Dikundwar A.G.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.1016/j.jddst.2023.104685
16. **A critical review of Roxadustat formulations, solid state studies, and analytical methodology;** Author(s): Mahajan R.; Samanthula G.; Srivastava S.; Asthana A.; Year: 2023; DOI: 10.1016/j.heliyon.2023.e16595
17. **Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update;** Author(s): Kumar G.; Amrutha C.; Year: 2023; DOI: 10.1002/ddr.22063
18. **Prevalence and Resistance Patterns of Streptococcus pneumoniae Recovered from Children in Western Asia;** Author(s): Matran Y.M.; Al-Haddad A.M.; Sharma D.; Kalia N.P.; Sharma S.; Kumar M.; Sharma S.; Year: 2023; DOI: 10.1007/s11908-023-00807-7
19. **Targeting Mycobacterium tuberculosis iron-scavenging tools: a recent update on siderophores inhibitors;** Author(s): Kumar G.; Adhikrao P.A.; Year: 2023; DOI: 10.1039/d3md00201b

20. **DNase based therapeutic approaches for the treatment of NETosis related inflammatory diseases;** Author(s): Yadav R.; Momin A.; Godugu C.; Year: 2023; DOI: 10.1016/j.intimp.2023.110846

21. **Therapeutic targeting of aberrant sialylation for prevention of chemoresistance and metastasis in triple negative breast cancer;** Author(s): Pindiprolu S.K.S.S.; Madhan J.; Srinivasarao D.A.; Dasari N.; Phani Kumar C.S.; Katta C.; Sainaga Jyothi V.G.S.; Year: 2023; DOI: 10.1016/j.jddst.2023.104617

22. **Correction to: Self-nanoemulsifying drug delivery system (SNEDDS) of docetaxel and carvacrol synergizes the anticancer activity and enables safer toxicity profile: optimization, and in-vitro, ex-vivo and in-vivo pharmacokinetic evaluation (Drug Delivery a;** Author(s): Ateeq M.A.M.; Aalhate M.; Mahajan S.; Kumar G.S.; Sen S.; Singh H.; Gupta U.; Maji I.; Dikundwar A.; Guru S.K.; Singh P.K.; Year: 2023; DOI: 10.1007/s13346-023-01356-1

23. **Chitosan reduced in-situ synthesis of gold nanoparticles on paper towards fabricating highly sensitive, stable uniform SERS substrates for sensing applications;** Author(s): Srivastava S.K.; Oggu G.S.; Rayaprolu A.; Adicherla H.; Rao C.M.; Bhatnagar I.; Asthana A.; Year: 2023; DOI: 10.1016/j.ijbiomac.2023.124240

24. **Synthesis, in vitro Cytotoxicity Evaluation, and Docking Studies of Gloriosine Derivatives as Potential Anticancer Agents;** Author(s): Goel B.; Naik A.; Tripathi N.; Khan A.; Bansal S.; Bansal S.; Kumar Guru S.; Jain S.K.; Year: 2023; DOI: 10.1002/slct.202301063

25. **Development of trisubstituted thiophene-3-arboxamide selenide derivatives as novel EGFR kinase inhibitors with cytotoxic activity;** Author(s): Makhal P.N.; Sood A.; Shaikh A.S.; Dayare L.N.; Khatri D.K.; Rao Kaki V.; Year: 2023; DOI: 10.1039/d3md00403a

26. **Variable Cl···O Halogen Bonding Modes in Dimorphs of a Room Temperature Liquid Ethyl Chloroformate Revealed by In Situ Cryo-Crystallography;** Author(s): Bhale N.A.; Sudheendranath A.; Thomas S.P.; Dikundwar A.G.; Year: 2023; DOI: 10.1021/acs.cgd.3c00113

27. **Addressing the preventive and therapeutic perspective of berberine against diabetes;** Author(s): Shrivastava S.; Sharma A.; Saxena N.; Bhamra R.; Kumar S.; Year: 2023; DOI: 10.1016/j.heliyon.2023.e21233

28. **An overview of biomedical applications for gold nanoparticles against lung cancer;** Author(s): Kumari V.; Vishwas S.; Kumar R.; Kakoty V.; Khursheed R.; Babu M.R.; Harish V.; Mittal N.; Singh P.K.; Alharthi N.S.; Hakami M.A.; Aba Alkhayl F.F.; Gupta G.; Rubis G.D.; Paudel K.R.; Singh M.; Zandi M.; Oliver B.G.; Dua K.; Singh S.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104729

29. **Polymeric nanomaterials: Fundamentals and therapeutic applications;** Author(s): Maji I.; Mahajan S.; Sriram A.; Mehra N.K.; Singh P.K.; Year: 2023; DOI: 10.1007/978-3-031-30529-0_2

30. **Tweaking host immune responses for novel therapeutic approaches against Mycobacterium tuberculosis;** Author(s): Roy A.; Kumari Agnivesh P.; Sau S.; Kumar S.; Pal Kalia N.; Year: 2023; DOI: 10.1016/j.drudis.2023.103693

31. **Unraveling the Aurora kinase A and Epstein-Barr nuclear antigen 1 axis in Epstein Barr virus associated gastric cancer;** Author(s): Varshney N.; Murmu S.; Baral B.; Kashyap D.; Singh S.;

Kandpal M.; Bhandari V.; Chaurasia A.; Kumar S.; Jha H.C.; Year: 2023; DOI: 10.1016/j.virol.2023.109901

32. **Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia;** Author(s): Famta P.; Shah S.; Vambhurkar G.; Srinivasarao D.A.; Jain N.; Begum N.; Sharma A.; Shahrukh S.; Kumar K.C.; Bagasariya D.; Khatri D.K.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.ejpb.2023.07.008

33. **Characterization of Degradation Products and Drug–Excipient Interaction Products of Erdafitinib by LC–Q-TOF-MS/MS and NMR;** Author(s): Velip L.; Dhiman V.; Kushwah B.S.; Samanthula G.; Year: 2023; DOI: 10.1007/s10337-023-04268-x

34. **Stereoselective synthesis of dispiropyrrolidinyl oxindole derivatives and evaluation of their antibacterial efficacy;** Author(s): Kondoli B.N.; Vemula D.; Brahma U.; Bhandari V.; Acharya P.C.; Year: 2023; DOI: 10.1016/j.molstruc.2023.135808

35. **Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy;** Author(s): Singh S.; Singh N.; Baranwal M.; Sharma S.; Devi S.S.K.; Kumar S.; Year: 2023; DOI: 10.1007/s13205-023-03826-2

36. **Delivery of gene editing therapeutics;** Author(s): Kevadiya B.D.; Islam F.; Deol P.; Zaman L.A.; Mosselhy D.A.; Ashaduzzaman M.; Bajwa N.; Routhu N.K.; Singh P.A.; Dawre S.; Vora L.K.; Nahid S.; Mathur D.; Nayan M.U.; Baldi A.; Kothari R.; Patel T.A.; Madan J.; Gounani Z.; Bariwal J.; Hettie K.S.; Gendelm; Year: 2023; DOI: 10.1016/j.nano.2023.102711

37. **Acute and sub-acute dermal toxicity of meloxicam emulgel: Analysis of biochemical, hematological, histopathological and immunohistochemical expression;** Author(s): Jyothi V.G.S.S.; Veerabomma H.; Tryphena K.P.; Khatri D.K.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.1016/j.bbrc.2023.04.001

38. **Isoxazole carboxylic acid methyl ester-based urea and thiourea derivatives as promising antitubercular agents;** Author(s): Sahoo S.K.; Ommi O.; Maddipatla S.; Singh P.; Ahmad M.N.; Kaul G.; Nanduri S.; Dasgupta A.; Chopra S.; Yaddanapudi V.M.; Year: 2023; DOI: 10.1007/s11030-022-10543-0

39. **Yttrium Oxide Nanoparticles Attenuate L-Arginine Induced Chronic Pancreatitis;** Author(s): Khurana A.; Saifi M.A.; Godugu C.; Year: 2023; DOI: 10.1007/s12011-022-03446-6

40. **Small molecule inhibitors of NLRP3 inflammasome and GSK-3β in the management of traumatic brain injury: A review;** Author(s): Shaik M.G.; Joshi S.V.; Akunuri R.; Rana P.; Rahman Z.; Polomoni A.; Yaddanapudi V.M.; Dandekar M.P.; Srinivas N.; Year: 2023; DOI: 10.1016/j.ejmech.2023.115718

41. **An overview of in silico methods used in the design of VEGFR-2 inhibitors as anticancer agents;** Author(s): Bhandare R.R.; Bakchi B.; Sigalapalli D.K.; Shaik A.B.; Year: 2023; DOI: 10.1515/psr-2018-0163

42. **Recent Advances of Multifunctional PLGA Nanocarriers in the Management of Triple-Negative Breast Cancer;** Author(s): Dinakar Y.H.; Rajana N.; Kumari N.U.; Jain V.; Mehra N.K.; Year: 2023; DOI: 10.1208/s12249-023-02712-7

43. **Traversing the diverse avenues of exopolysaccharides-based nanocarriers in the management of cancer;** Author(s): Paul P.; Nair R.; Mahajan S.; Gupta U.; Aalhate M.; Maji I.; Singh P.K.; Year: 2023; DOI: 10.1016/j.carbpol.2023.120821

44. **Ru(ii)-catalyzed synthesis of indolo[2,3-c]isoquinolines via [3+3] annulation of N,N'-cyclic azomethine ylides and 3-diazoindolin-2-imines;** Author(s): Valapil D.G.; Mishra P.; Jungare K.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d3nj03009a

45. **Unveiling the potential of marine compounds as quorum sensing inhibitors targeting Pseudomonas aeruginosa's LasI: A computational study using molecular docking and molecular dynamics;** Author(s): Singothu S.; Begum P.J.; Maddi D.; Devsani N.; Bhandari V.; Year: 2023; DOI: 10.1002/jcb.30465

46. **Correction to: Necrostatin-1 S mitigates type-2 diabetes-associated cognitive decrement and lipotoxicity-induced neuro-microglia changes through p-RIPK-RIPK3-p-MLKL axis (Metabolic Brain Disease, (2023), 38, 5, (1581-1612), 10.1007/s11011-023-01185-8);** Author(s): Preeti K.; Fernandes V.; Sood A.; Khan I.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.1007/s11011-023-01235-1

47. **Quality by design (QbD) abetted development of pioglitazone incorporated liposomes-loaded hyaluronic acid-based in situ hydrogel for the management of melanoma;** Author(s): Charankumar K.; Bagasariya D.; Jain N.; Famta P.; Shah S.; Vambhurkar G.; Fernandes V.; Khatri D.K.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2023.104453

48. **Exploration of quinoxaline-benzimidazole hybrids as apoptosis-inducing agents and tubulin polymerisation inhibitors;** Author(s): Ommi O.; Chilvery S.; Dhopat P.S.; Sharma A.; Bhalerao H.A.; Dannaram S.R.; Nanduri S.; Sonti R.; Godugu C.; Yaddanapudi V.M.; Year: 2023; DOI: 10.1016/j.molstruc.2023.136184

49. **Visible-light-mediated photocatalytic sequential N-arylation: an eco-friendly synthetic route to unsymmetrical diarylamines and the imatinib drug;** Author(s): Sana S.; Dastari S.; Reddy D.S.; Tokala R.; Sathish M.; Sonti R.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d3qo00894k

50. **Multistrain probiotic rescinds quinpirole-induced obsessive-compulsive disorder phenotypes by reshaping of microbiota gut-brain axis in rats;** Author(s): Ghuge S.; Rahman Z.; Bhale N.A.; Dikundwar A.G.; Dandekar M.P.; Year: 2023; DOI: 10.1016/j.pbb.2023.173652

51. **Design, synthesis and in vitro cytotoxic evaluation of β-carboline tethered quinoline-4-carboxamide conjugates as DNA-interactive Topo II inhibitors;** Author(s): Soni J.P.; Devi P.; Chemitikanti S.; Sharma A.; Swamy C.V.D.; Phanindranath R.; Sathish M.; Nagesh N.; Godugu C.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.molstruc.2023.136001

52. **Artificial intelligence: Machine learning approach for screening large database and drug discovery;** Author(s): Parvatikar P.P.; Patil S.; Khaparkhuntikar K.; Patil S.; Singh P.K.; Sahana R.; Kulkarni R.V.; Raghu A.V.; Year: 2023; DOI: 10.1016/j.antiviral.2023.105740

53. **Multifaceted roles of pollen in the management of cancer;** Author(s): Kolipaka T.; Khairnar P.; Phatale V.; Pandey G.; Famta P.; Shah S.; Asthana A.; Nanduri S.; Raghuvanshi R.S.; Srivastava S.; Year: 2023; DOI: 10.1016/j.ijpharm.2023.123278

54. **Benzimidazole derivatives as tubulin polymerization inhibitors: Design, synthesis and in vitro cytotoxicity studies;** Author(s): Laxmikeshav K.; Rahman Z.; Mahale A.; Gurukkala Valapil D.; Sharma P.; George J.; Phanindranath R.; Dandekar M.P.; Kulkarni O.P.; Nagesh N.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.bmcl.2023.129494

55. **Proteins and metabolites fingerprints of gestational diabetes mellitus forming protein–metabolite interactomes are its potential biomarkers;** Author(s): Chatterjee B.; Thakur S.S.; Year: 2023; DOI: 10.1002/pmic.202200257

56. **Exploring Penetration Ability of Carbonic Anhydrase Inhibitor–Loaded Ultradeformable Bilosome for Effective Ocular Application;** Author(s): Nair V.S.; Srivastava V.; Bhavana V.; Yadav R.; Rajana N.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1208/s12249-023-02617-5

57. **Involvement of miRNA on epigenetics landscape of Parkinson's disease: From pathogenesis to therapeutics;** Author(s): Uppala S.N.; Tryphena K.P.; Naren P.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.mad.2023.111826

58. **Microtubule acetylation dyshomeostasis in Parkinson's disease;** Author(s): Naren P.; Samim K.S.; Tryphena K.P.; Vora L.K.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1186/s40035-023-00354-0

59. **Sustainable photocatalytic C-H annulation of heteroarenes with sulfoxonium ylides: synthesis and photophysical properties of fused imidazo[1,2-a]pyridine-based molecules;** Author(s): Sana S.; Dannarm S.R.; Tokala R.; Dastari S.; Sathish M.; Kumar R.; Sonti R.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d3qo00923h

60. **Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells;** Author(s): Panwar D.; Thakor P.; Sharma M.; Bakshi A.K.; Bhavana V.; Srivastava V.; Mishra P.R.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.2217/nnm-2023-0132

61. **Emerging trends in combination strategies with phototherapy in advanced psoriasis management;** Author(s): Sreya R.; Nene S.; Pathade V.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1007/s10787-023-01257-2

62. **A comprehensive review of the biomaterial-based multifunctional nanocarriers for therapeutic applications in breast cancer;** Author(s): Shettiwar A.; Gupta U.; Paul P.; Nair R.; Aalhate M.; Mahajan S.; Maji I.; Guru S.K.; Mehra N.K.; Singh P.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104990

63. **Structural characterization and in silico toxicity prediction of degradation impurities of roxadustat;** Author(s): Mahajan R.; Kumar S.; Parupalli R.; Khemchandani R.; Kanchupalli V.; Nanduri S.; Samanthula G.; Asthana A.; Year: 2023; DOI: 10.1016/j.jpba.2023.115517

64. **Nanocarrier-based drug delivery via cell-hitchhiking: Emphasizing pharmacokinetic perspective towards taming the "big-old" tumors;** Author(s): Famta P.; Shah S.; Jain N.; Srinivasarao D.A.; Vambhurkar G.; Shahrukh S.; Murthy A.; Ahmed T.; Pandey G.; Sharma A.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2023.105050

65. **Synthesis and Biological Evaluation of Diphenyl Ether-Linked Quinolone Derivatives as Antibacterial Agents;** Author(s): Ghouse S.M.; Akhir A.; Sinha K.; Pawar G.; Saxena D.; Akunuri

R.; Malik P.; Roy A.; Parida K.K.; Dasgupta A.; Kalia N.P.; Yaddanapudi V.M.; Chopra S.; Nanduri S.; Year: 2023; DOI: 10.1002/slct.202303083

66. **Quality by design (QbD) commended exploration of bosutinib loaded lipid nanocarriers for food effect attenuation and bioavailability enhancement in breast cancer;** Author(s): Famta P.; Shah S.; Vambhurkar G.; Srinivasarao D.A.; Bagasariya D.; Kumar K.C.; Begum N.; Sharma A.; Shahrukh S.; Jain N.; Singh G.; Prasad S.B.; Shinde A.; Khatri D.K.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2023.105180

67. **Microemulsions, nanoemulsions and emulgels as carriers for antifungal antibiotics;** Author(s): Padaraju A.; Dwivedi F.; Kumar G.; Year: 2023; DOI: 10.4155/tde-2023-0076

68. **Aptamer guided nanomedicine strategies in prostate cancer: Targeting and diagnosis;** Author(s): Shahrukh S.; Jain N.; Shah S.; Famta P.; Srinivasarao D.A.; Khatri D.K.; Asthana A.; Singh S.B.; Raghuvanshi R.S.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2023.104593

69. **A validated high-performance liquid chromatography method for the determination of brassinin, an indoleamine 2,3-dioxygenase inhibitor in rat plasma;** Author(s): Dhurjad P.; Gupta K.; Sakla A.P.; Shankaraiah N.; Sonti R.; Year: 2023; DOI: 10.1002/sscp.202300073

70. **The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications;** Author(s): Kundu S.; Nayak S.; Rakshit D.; Singh T.; Shukla R.; Khatri D.K.; Mishra A.; Year: 2023; DOI: 10.1111/ene.15767

71. **Quality by design accredited self-nanoemulsifying delivery of ibrutinib for extenuating the fast-fed variability, ameliorating the anticancer activity and oral bioavailability in prostate cancer;** Author(s): Shah S.; Famta P.; Vambhurkar G.; Srinivasarao D.A.; Kumar K.C.; Bagasariya D.; Begum N.; Sharma A.; Jain N.; Shahrukh S.; Singh G.; Shinde A.; Prasad S.B.; Khatri D.K.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2023.105052

72. **P-Selectin mediates targeting of a self-assembling phototherapeutic nanovehicle enclosing dipyridamole for managing thromboses;** Author(s): Liu C.-H.; Jheng P.-R.; Rethi L.; Godugu C.; Lee C.Y.; Chen Y.-T.; Nguyen H.T.; Chuang E.-Y.; Year: 2023; DOI: 10.1186/s12951-023-02018-7

73. **Forced degradation study of baricitinib and structural characterization of its degradation impurities by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy;** Author(s): Chaganti S.; Dhiman V.; Madhyanapu Golla V.; Roshitha K.R.; Khemchandani R.; Samanthula G.; Year: 2023; DOI: 10.1002/rcm.9605

74. **Regioselective synthesis and in vitro cytotoxicity evaluation of 3-thiooxindole derivatives: Tubulin polymerization inhibition and apoptosis inducing studies;** Author(s): Sakla A.P.; Panda B.; Mahale A.; Sharma P.; Laxmikeshav K.; Ali Khan M.; Kulkarni O.P.; Godugu C.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.bmc.2023.117297

75. **Oxidative Folding Catalysts of Conotoxins Derived from the Venom Duct Transcriptome of C. frigidus and C. amadis;** Author(s): Shekh S.; Dhurjad P.; Vijayasarathy M.; Dolle A.; Dhannura S.; Sahoo D.K.; Sonti R.; Gowd K.H.; Year: 2023; DOI: 10.1021/acs.biochem.3c00320

76. **Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection;** Author(s): Nagdev P.K.; Agnivesh P.K.; Roy A.; Sau S.; Kalia N.P.; Year: 2023; DOI: 10.1007/s10096-023-04663-0

77. **Nanosuspension encapsulated chitosan-pectin microbeads as a novel delivery platform for enhancing oral bioavailability;** Author(s): Sampathi S.; Haribhau C.J.; Kuchana V.; Junnuthula V.; Dyawanapelly S.; Year: 2023; DOI: 10.1016/j.carbpol.2023.121177

78. **CRISPR/Cas9 Genome Editing for Tissue-Specific In Vivo Targeting: Nanomaterials and Translational Perspective;** Author(s): Sahel D.K.; Vora L.K.; Saraswat A.; Sharma S.; Monpara J.; D'Souza A.A.; Mishra D.; Tryphena K.P.; Kawakita S.; Khan S.; Azhar M.; Khatri D.K.; Patel K.; Singh Thakur R.R.; Year: 2023; DOI: 10.1002/advs.202207512

79. **Neutrophil membrane-based nanotherapeutics: Propitious paradigm shift in the management of cancer;** Author(s): Phatale V.; Famta P.; Srinivasarao D.A.; Vambhurkar G.; Jain N.; Pandey G.; Kolipaka T.; Khairnar P.; Shah S.; Singh S.B.; Raghuvanshi R.S.; Srivastava S.; Year: 2023; DOI: 10.1016/j.lfs.2023.122021

80. **New cycloartane triterpenoids from Dysoxylum malabaricum and their cytotoxic evaluation;** Author(s): Bhardwaj N.; Sharma A.; Tripathi N.; Goel B.; Ravikanth G.; Kumar Guru S.; Jain S.K.; Year: 2023; DOI: 10.1016/j.steroids.2023.109315

81. **Recent trends and updates on ultradeformable and elastic vesicles in ocular drug delivery;** Author(s): Srivastava V.; Singh V.; Kumar Khatri D.; Kumar Mehra N.; Year: 2023; DOI: 10.1016/j.drudis.2023.103647

82. **Natural products acting against S. aureus through membrane and cell wall disruption;** Author(s): Kumar G.; Engle K.; Year: 2023; DOI: 10.1039/d2np00084a

83. **Formulation and optimization of aceclofenac loaded hyaluronic-oleic acid based micellar gel for the management of osteoarthritis;** Author(s): Sharma R.; Jain H.; Pratibha; Godugu C.; Chella N.; Year: 2023; DOI: 10.1016/j.jddst.2023.104560

84. **Neuroepigenetic Changes in DNA Methylation Affecting Diabetes-Induced Cognitive Impairment;** Author(s): Fernandes V.; Preeti K.; Sood A.; Nair K.P.; Khan S.; Rao B.S.S.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.1007/s10571-022-01278-5

85. **Implication of microbiota gut-brain axis in the manifestation of obsessive-compulsive disorder: Preclinical and clinical evidence;** Author(s): Kamble S.R.; Dandekar M.P.; Year: 2023; DOI: 10.1016/j.ejphar.2023.176014

86. **Effect of chronopharmacology and food on in vivo pharmacokinetic profile of mavacamten;** Author(s): Rao Gajula S.N.; Talari S.; Nathani T.N.; Munjal V.; Rahman Z.; Dandekar M.P.; Sonti R.; Year: 2023; DOI: 10.4155/bio-2023-0030

87. **Multifaceted personality and roles of heme enzymes in industrial biotechnology;** Author(s): Bhardwaj M.; Kamble P.; Mundhe P.; Jindal M.; Thakur P.; Bajaj P.; Year: 2023; DOI: 10.1007/s13205-023-03804-8

88. **Vesicular nanomaterials: Types and therapeutic uses;** Author(s): Mahajan S.; Maji I.; Mehra N.K.; Singh P.K.; Year: 2023; DOI: 10.1007/978-3-031-30529-0_4

89. **Real-time detection of plasma ferritin by electrochemical biosensor developed for biomedical analysis;** Author(s): Gautam N.; Chattopadhyay S.; Kar S.; Sarkar A.; Year: 2023; DOI: 10.1016/j.jpba.2023.115579

90. **Colloidal therapeutics in the management of traumatic brain injury: Portray of biomarkers and drug-targets, preclinical and clinical pieces of evidence and future prospects;** Author(s): Arya S.; Bahuguna D.; Bajad G.; Loharkar S.; Devangan P.; Khatri D.K.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.1016/j.colsurfb.2023.113509

91. **Therapeutic potential of GDNF in neuroinflammation: Targeted delivery approaches for precision treatment in neurological diseases;** Author(s): Singh G.; Sikder A.; Phatale V.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104876

92. **Multimodal lemongrass oil based topical nanoemulgel ingrained with ferulic acid for wound healing activity;** Author(s): Bhavana V.; Chary P.S.; Rajana N.; Devabattula G.; Sau S.; Godugu C.; Kalia N.P.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.molliq.2023.122870

93. **Unravelling the potential of microbots in cancer therapy;** Author(s): Shah S.; Famta P.; Srinivasarao D.A.; Shahrukh S.; Jain N.; Vambhurkar G.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.apmt.2023.101887

94. **Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies;** Author(s): Pardhi E.; Yadav R.; Chaurasiya A.; Madan J.; Guru S.K.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.lfs.2023.121771

95. **Dimethyl fumarate ameliorates parkinsonian pathology by modulating autophagy and apoptosis via Nrf2-TIGAR-LAMP2/Cathepsin D axis;** Author(s): Khot M.; Sood A.; Tryphena K.P.; Pinjala P.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.brainres.2023.148462

96. **Exploration of 3-aryl pyrazole-tethered sulfamoyl carboxamides as carbonic anhydrase inhibitors;** Author(s): Ommi O.; Paoletti N.; Bonardi A.; Gratteri P.; Bhalerao H.A.; Sau S.; Nanduri S.; Mohammed A.; Kalia N.P.; Sonti R.; Supuran C.T.; Yaddanapudi V.M.; Year: 2023; DOI: 10.1002/ardp.202300309

97. **Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model;** Author(s): Pragyandipta P.; Pedapati R.K.; Reddy P.K.; Nayek A.; Meher R.K.; Guru S.K.; Kantevari S.; Naik P.K.; Year: 2023; DOI: 10.1016/j.cbi.2023.110606

98. **Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro;** Author(s): Kattula B.; Reddi B.; Jangam A.; Naik L.; Adimoolam B.M.; Vavilapalli S.; Are S.; Thota J.R.; Jadav S.S.; Arifuddin M.; Addlagatta A.; Year: 2023; DOI: 10.1016/j.ijbiomac.2023.124772

99. **A review on Stimuli-pH responsive liposomal formulation in cancer therapy;** Author(s): Jayapriya P.; Pardhi E.; Vasave R.; Guru S.K.; Madan J.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.105172

100. **Mesomorphic and computational evaluation of C[tbnd]N···I halogen bonded complexes of 4-alkoxy-4'-cyanobiphenyls systems with 1,6- diiodoperfluorohexane;** Author(s): Ingle K.S.; Thakur J.S.; Bhale N.A.; Dikundwar A.G.; Nayak S.K.; Year: 2023; DOI: 10.1016/j.molstruc.2023.135995

101. **Tissue engineering and chitosan: a wonder biomaterial;** Author(s): Goli S.; Mudrakola D.P.; Turagam N.; Thomas M.; Asthana A.; Bhatnagar I.; Year: 2023; DOI: 10.1016/B978-0-323-98827-8.00004-7

102. **Enhanced Pharmacokinetics and Anti-inflammatory Activity of Curcumin Using Dry Emulsion as Drug Delivery Vehicle;** Author(s): Nayakula M.; Jeengar M.K.; Naidu V.G.M.; Chella N.; Year: 2023; DOI: 10.1007/s13318-023-00819-7

103. **Lactoferrin-Decorated Cerium Oxide Nanoparticles Prevent Renal Injury and Fibrosis;** Author(s): Aslam Saifi M.; Hirawat R.; Godugu C.; Year: 2023; DOI: 10.1007/s12011-022-03284-6

104. **Benzimidazole based bis-carboxamide derivatives as promising cytotoxic agents: Design, synthesis, in silico and tubulin polymerization inhibition;** Author(s): Laxmikeshav K.; Sharma P.; Palepu M.; Sharma P.; Mahale A.; George J.; Phanindranath R.; Dandekar M.P.; Kulkarni O.P.; Nagesh N.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.molstruc.2022.134078

105. **Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/NRAS mutated metastatic melanoma cells;** Author(s): Thatikonda S.; Pooladanda V.; Tokala R.; Nagula S.; Godugu C.; Year: 2023; DOI: 10.1016/j.tiv.2023.105579

106. **Synthesis and anti-plasmodial activity of isoandrographolide acetals;** Author(s): Tamang N.; Mavileti S.K.; Yadav M.; Nanduri S.; Sahal D.; Golakoti N.R.; Year: 2023; DOI: 10.1007/s11696-023-02684-9

107. **Topical delivery of tofacitinib citrate loaded novel nanoemulgel for the management of 2,4-Dichlorodinitrobenzene induced atopic dermatitis in mice model;** Author(s): Atmakuri S.; Nene S.; Jain H.; Joga R.; Devabattula G.; Godugu C.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jddst.2022.104145

108. **CADD, AI and ML in drug discovery: A comprehensive review;** Author(s): Vemula D.; Jayasurya P.; Sushmitha V.; Kumar Y.N.; Bhandari V.; Year: 2023; DOI: 10.1016/j.ejps.2022.106324

109. **Tackling multidrug-resistant Staphylococcus aureus by natural products and their analogues acting as NorA efflux pump inhibitors;** Author(s): Kumar G.; Kiran Tudu A.; Year: 2023; DOI: 10.1016/j.bmc.2023.117187

110. **Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease;** Author(s): Rajan S.; Tryphena K.P.; Khan S.; Vora L.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.arr.2023.101915

111. **Anxiolytic- and antidepressant-like effects of Bacillus coagulans Unique IS-2 mediate via reshaping of microbiome gut-brain axis in rats;** Author(s): Satti S.; Palepu M.S.K.; Singh A.A.; Jaiswal Y.; Dash S.P.; Gajula S.N.R.; Chaganti S.; Samanthula G.; Sonti R.; Dandekar M.P.; Year: 2023; DOI: 10.1016/j.neuint.2023.105483

112. **Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease;** Author(s): Tryphena K.P.; Anuradha U.; Kumar R.; Rajan S.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.3233/JAD-220449

113. **Photolytic and Oxidative Degradation Behavior of Anticancer Drug Venetoclax: Characterization of New Degradation Products Using High Resolution Mass Spectrometry;** Author(s): Dhiman V.; Ahirwar S.; Chaganti S.; Gananadhamu S.; Year: 2023; DOI: 10.1134/S1061934823040081

114. **Nanoceria Ameliorates Fibrosis, Inflammation, and Cellular Stress in Experimental Chronic Pancreatitis;** Author(s): Khurana A.; Saifi M.A.; Godugu C.; Year: 2023; DOI: 10.1021/acsbiomaterials.2c00933

115. **Paradigm of lyotropic liquid crystals in tissue regeneration;** Author(s): Shah S.; Joga R.; Kolipaka T.; Sabnis Dushyantrao C.; Khairnar P.; Simran; Phatale V.; Pandey G.; Srivastava S.; Kumar S.; Year: 2023; DOI: 10.1016/j.ijpharm.2023.122633

116. **Role of transcription termination factor Rho in anti-tuberculosis drug discovery;** Author(s): Kumar S.; Sau S.; Agnivesh P.K.; Roy A.; Kalia N.P.; Year: 2023; DOI: 10.1016/j.drudis.2023.103490

117. **In Silico Tools to Thaw the Complexity of the Data: Revolutionizing Drug Research in Drug Metabolism, Pharmacokinetics and Toxicity Prediction;** Author(s): Kommalapati H.S.; Pilli P.; Golla V.M.; Bhatt N.; Samanthula G.; Year: 2023; DOI: 10.2174/0113892002270798231201111422

118. **Niclosamide nanocrystal for enhanced in-vivo efficacy against gastrointestinal stromal tumor via regulating EGFR/STAT-3/DR-4 axis;** Author(s): Syamprasad N.P.; Madje N.; Bachannagari J.; Jannu A.K.; Jain S.; Tene K.; Shantanu P.A.; Naidu V.G.M.; Chella N.; Year: 2023; DOI: 10.1016/j.jddst.2023.104221

119. **Nanomedicine: A pragmatic approach for tackling melanoma skin cancer;** Author(s): Prajapat V.M.; Mahajan S.; Paul P.G.; Aalhate M.; Mehandole A.; Madan J.; Dua K.; Chellappan D.K.; Singh S.K.; Singh P.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104394

120. **Chronopharmacokinetics: a critical missing step in drug discovery and development;** Author(s): Rao Gajula S.N.; Godugu C.; Sonti R.; Year: 2023; DOI: 10.4155/bio-2023-0080

121. **Role of gut microbiota in depression: Understanding molecular pathways, recent research, and future direction;** Author(s): Rathour D.; Shah S.; Khan S.; Singh P.K.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.bbr.2022.114081

122. **Acute respiratory distress syndrome enhances tumor metastasis into lungs: Role of BRD4 in the tumor microenvironment;** Author(s): Pooladanda V.; Thatikonda S.; Priya Muvvala S.; Godugu C.; Year: 2023; DOI: 10.1016/j.intimp.2023.109701

123. **Targeting mycobacterial membranes and membrane proteins: Progress and limitations;** Author(s): Kumar G.; Kapoor S.; Year: 2023; DOI: 10.1016/j.bmc.2023.117212

124. **Inter and intracellular mitochondrial transfer: Future of mitochondrial transplant therapy in Parkinson's disease;** Author(s): Jain R.; Begum N.; Tryphena K.P.; Singh S.B.; Srivastava S.; Rai S.N.; Vamanu E.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.biopha.2023.114268

125. **Complex ophthalmic formulation technologies: Advancement and future perspectives;** Author(s): Srivastava V.; Chary P.S.; Rajana N.; Pardhi E.R.; Singh V.; Khatri D.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104317

126. **Polymer-Drug Conjugates: Linker Chemistry, Protocols and Applications;** Author(s): Madan J.; Baldi A.; Chaudhary M.; Chopra N.; Year: 2023; DOI: 10.1016/C2021-0-00903-2

127. **LC and LC-MS/MS studies for identification and characterization of degradation products of d-tubocurarine chloride;** Author(s): Grover P.; Maheshwari S.; Nagarajan K.; Mehta L.; Kumar S.; Rastogi C.; Year: 2023; DOI: 10.1016/j.jpba.2022.115119

128. **In-silico investigation of E8 surface protein of the monkeypox virus to identify potential therapeutic agents;** Author(s): Podduturi S.; Vemula D.; Singothu S.; Bhandari V.; Year: 2023; DOI: 10.1080/07391102.2023.2245041

129. **Nanocarrier-mediated delivery for targeting stomach cancer;** Author(s): Mohd Ateeq M.A.; Aalhate M.; Mahajan S.; Gupta U.; Maji I.; Khaparkhuntikar K.; Dhuri A.; Mohan C N.; Srivastava S.; Singh P.K.; Year: 2023; DOI: 10.1016/B978-0-323-95303-0.00006-X

130. **Cancer stem cell research: a phosphoproteomic approach;** Author(s): Chatterjee B.; Thakur S.S.; Year: 2023; DOI: 10.1016/B978-0-443-13212-4.00024-6

131. **Exploration of novel drug delivery systems in topical management of osteoarthritis;** Author(s): Patil P.; Nene S.; Shah S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1007/s13346-022-01229-z

132. **CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease;** Author(s): Pinjala P.; Tryphena K.P.; Prasad R.; Khatri D.K.; Sun W.; Singh S.B.; Gugulothu D.; Srivastava S.; Vora L.; Year: 2023; DOI: 10.1186/s40824-023-00381-y

133. **Chemistry of conjugation in drug delivery: The prospects of biodegradable bonds in polymer–drug conjugates;** Author(s): Choudhary S.; Sethi S.; Dudhe R.; Dudhe A.; Sharma R.; Bajwa N.; Singh P.A.; Baldi A.; Madan J.; Singh K.K.; Year: 2023; DOI: 10.1016/B978-0-323-91663-9.00003-5

134. **Small extracellular vesicle biomarkers in breast cancer: a real-time snapshot for early diagnosis and prognosis?;** Author(s): Gajula S.N.R.; Nalla L.V.; Year: 2023; DOI: 10.4155/bio-2023-0038

135. **Exo-trig selenocyclization of secondary allylic carboxamides using Woollins' reagent: en route to 2,5-disubstituted selenazolines;** Author(s): Makhal P.N.; Dannarm S.R.; Shaikh A.S.; Ahmed R.; Chilvery S.; Dayare L.N.; Sonti R.; Godugu C.; Kaki V.R.; Year: 2023; DOI: 10.1039/d2cc06782j

136. **Hyaluronate decorated polyethylene glycol linked poly(lactide-co-glycolide) nanoparticles encapsulating MUC-1 peptide augmented mucosal immune response in Balb/c mice through**

inhalation route; Author(s): Jyoti K.; Malik G.; Chaudhary M.; Madan J.; Kamboj A.; Year: 2023; DOI: 10.1016/j.bbagen.2023.130317

137. **Inhibition of AGEs formation, antioxidative, and cytoprotective activity of Sumac (Rhus typhina L.) tannin under hyperglycemia: molecular and cellular study;** Author(s): Sekowski S.; Olchowik-Grabarek E.; Dubis A.T.; Sharan L.; Kumar A.; Abdulladjanova N.; Markiewicz P.; Zamaraeva M.; Year: 2023; DOI: 10.1007/s11010-022-04522-0

138. **Synthesis of cis-stilbene-based 1,2,4-triazole/1,3,4-oxadiazole conjugates as potential cytotoxic and tubulin polymerization inhibitors;** Author(s): John S.E.; Sharma A.; Gulati S.; Bora D.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d2nj04955d

139. **Drug delivery: The conceptual perspectives and therapeutic applications;** Author(s): Dewangan P.; Mourya A.; Singh P.K.; Chaudhary M.; Sharma R.; Bajwa N.; Baldi A.; Singh K.K.; Singh S.B.; Madan J.; Namdeo K.P.; Year: 2023; DOI: 10.1016/B978-0-323-91663-9.00010-2

140. **Design, synthesis and in vitro cytotoxicity evaluation of indolo-pyrazoles grafted with thiazolidinone as tubulin polymerization inhibitors;** Author(s): Soni J.P.; Chilvery S.; Sharma A.; Reddy G.N.; Godugu C.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d2md00442a

141. **Historical Developments of Various Adhesives for Biomedical Applications;** Author(s): Kommineni N.; Saka R.; Sainaga Jyothi V.G.S.; Butreddy A.; Vitore J.G.; Khan W.; Year: 2023; DOI: 10.1002/9781394209897.ch1

142. **Reminiscing the microwave-assisted chemistry of 5- and 6-membered benzene-fused N-heterocycles;** Author(s): Soni J.P.; Valapil D.G.; Joshi S.V.; Shankaraiah N.; Year: 2023; DOI: 10.24820/ark.5550190.p011.928

143. **Necrostatin-1S mitigates type-2 diabetes-associated cognitive decrement and lipotoxicity-induced neuro-microglia changes through p-RIPK-RIPK3-p-MLKL axis;** Author(s): Preeti K.; Fernandes V.; Sood A.; Khan I.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.1007/s11011-023-01185-8

144. **The glycoprotein gp63– a potential pan drug target for developing new antileishmanial agents;** Author(s): Devsani N.; Vemula D.; Bhandari V.; Year: 2023; DOI: 10.1016/j.biochi.2022.11.015

145. **Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk;** Author(s): Shirgadwar S.M.; Kumar R.; Preeti K.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.3233/JAD-220793

146. **Exploration of cytotoxic potential and tubulin polymerization inhibition activity of cis-stilbene-1,2,3-triazole congeners;** Author(s): Bora D.; Samir K.M.; Sharma A.; Chilvery S.; Bansod S.; John S.E.; Ali Khan M.; Godugu C.; Shankaraiah N.; Year: 2023; DOI: 10.1039/d2md00400c

147. **Disease Models in Viral Research;** Author(s): Roy T.K.; Dasgupta S.; Roy A.; Mazumder B.; Year: 2023; DOI: 10.1007/978-3-031-20521-7_10

148. **Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer;** Author(s): Sharma S.; Chandra K.; Naik A.; Sharma A.; Sharma R.; Thakur A.; Grewal A.S.; Dhingra A.K.; Banerjee A.; Liou J.P.; Guru S.K.; Nepali K.; Year: 2023; DOI: 10.1080/14756366.2023.2276665

149. **Rh(III)-Catalyzed C–H Annulation of Sulfoxonium Ylides and 1,3-Diynes: A Rapid Access to Alkynyl-1-Naphthol Derivatives;** Author(s): Kumar S.; Borkar V.; Nunewar S.; Yadav S.; Kanchupalli V.; Year: 2023; DOI: 10.1002/asia.202201201

150. **Fundamentals of Image-Based Assay (IBA) System for Affordable Point of Care Diagnostics;** Author(s): Parween S.; Asthana A.; Nahar P.; Year: 2023; DOI: 10.1016/j.microc.2022.108345

151. **Microwave-assisted Cu(i)-catalyzed one-pot tandem synthesis of pyridoimidazole-fused quinolines as new antimycobacterial agents: DFT and ESI-HRMS study;** Author(s): Pawar G.; Ghouse S.M.; Joshi S.V.; Ahmad M.N.; Dasgupta A.; Yaddanapudi V.M.; Chopra S.; Nanduri S.; Year: 2023; DOI: 10.1039/d2nj06165a

152. **Mahamanalactone A, a new triterpenoid from Dysoxylum malabaricum bark: a case study for rapid identification of new metabolites via LC-HRMS profiling and database mining strategy;** Author(s): Bhardwaj N.; Swathilakshmi S.; Tripathi N.; Kumar S.; Lal U.R.; G R.; Guru S.K.; Jain S.K.; Year: 2023; DOI: 10.1080/14786419.2023.2298721

153. **Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19;** Author(s): Navitha Reddy G.; Jogvanshi A.; Naikwadi S.; Sonti R.; Year: 2023; DOI: 10.1080/14787210.2023.2241638

154. **Multifaceted applications of ulvan polysaccharides: Insights on biopharmaceutical avenues;** Author(s): Shah S.; Famta P.; Shahrukh S.; Jain N.; Vambhurkar G.; Srinivasarao D.A.; Raghuvanshi R.S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.ijbiomac.2023.123669

155. **Exploration of seryl tRNA synthetase to identify potent inhibitors against leishmanial parasites;** Author(s): Narsimulu B.; Qureshi R.; Jakkula P.; Singh P.; Arifuddin M.; Qureshi I.A.; Year: 2023; DOI: 10.1016/j.ijbiomac.2023.124118

156. **Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier;** Author(s): Amulya E.; Sikder A.; Vambhurkar G.; Shah S.; Khatri D.K.; Raghuvanshi R.S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jconrel.2023.01.031

157. **Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant Staphylococcus aureus and Mycobacterium tuberculosis;** Author(s): Ommi O.; Naiyaz Ahmad M.; Gajula S.N.R.; Wanjari P.; Sau S.; Agnivesh P.K.; Sahoo S.K.; Kalia N.P.; Sonti R.; Nanduri S.; Dasgupta A.; Chopra S.; Yaddanapudi V.M.; Year: 2023; DOI: 10.1039/d3md00079f

158. **Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents;** Author(s): Mukhopadhyay N.; Shukla A.; Makhal P.N.; Kaki V.R.; Year: 2023; DOI: 10.1016/j.heliyon.2023.e14569

159. **Synthesis and cytotoxicity evaluation of DNA-interactive β-carboline indolyl-3-glyoxamide derivatives: Topo-II inhibition and in silico modelling studies;** Author(s): Soni J.P.; Nikitha

Reddy G.; Rahman Z.; Sharma A.; Spandana A.; Phanindranath R.; Dandekar M.P.; Nagesh N.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.bioorg.2022.106313

160. **Triazolo-linked benzimidazoles as tubulin polymerization inhibitors and DNA intercalators: Design, synthesis, cytotoxicity, and docking studies;** Author(s): Laxmikeshav K.; Sayali M.; Devabattula G.; Valapil D.G.; Mahale A.; Sharma P.; George J.; Phanindranath R.; Godugu C.; Kulkarni O.P.; Nagesh N.; Shankaraiah N.; Year: 2023; DOI: 10.1002/ardp.202200449

161. **Fingolimod Alleviates Cognitive Deficit in Type 2 Diabetes by Promoting Microglial M2 Polarization via the pSTAT3-jmjd3 Axis;** Author(s): Sood A.; Fernandes V.; Preeti K.; Khot M.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.1007/s12035-022-03120-x

162. **Quality by design-oriented formulation optimization and characterization of guar gum-pectin based oral colon targeted liquisolid formulation of xanthohumol;** Author(s): Chatterjee S.; Corrie L.; Hanmantrao M.; Vishwas S.; Kumar R.; Alotaibi F.; Ansari M.J.; Rehman Z.U.; Porwal O.; Khursheed R.; Harish V.; Gupta G.; Kumar B.; Singh P.K.; Gowthamarajan K.; De A.; Sudhakar S.; Umashankar M.S.; Gulati M.; Dua K.; Singh S.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104350

163. **Characterization of potential degradation products of brexpiprazole by liquid chromatography/quadrupole–time-of-flight mass spectrometry and nuclear magnetic resonance, and prediction of their physicochemical properties by ADMET Predictor™;** Author(s): Kushwah B.S.; Singh S.; Thummar M.M.; Balhara A.; Samanthula G.; Year: 2023; DOI: 10.1002/rcm.9415

164. **GSK-3β: An exuberating neuroinflammatory mediator in Parkinson's disease;** Author(s): Samim Khan S.; Janrao S.; Srivastava S.; Bala Singh S.; Vora L.; Kumar Khatri D.; Year: 2023; DOI: 10.1016/j.bcp.2023.115496

165. **The portrayal of macrophages as tools and targets: A paradigm shift in cancer management;** Author(s): Jain N.; Srinivasarao D.A.; Famta P.; Shah S.; Vambhurkar G.; Shahrukh S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.lfs.2023.121399

166. **Development and evaluation emulgel for effective management of the imiquimod-induced psoriasis;** Author(s): Sulthana S.; Chary P.S.; Bhavana V.; Pardhi E.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1007/s10787-022-01131-7

167. **Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics;** Author(s): Saifi M.A.; Sathish G.; Bazaz M.R.; Godugu C.; Year: 2023; DOI: 10.1016/j.bbcan.2023.188895

168. **Instigation of the epoch of nanovaccines in cancer immunotherapy;** Author(s): Shah S.; Famta P.; Tiwari V.; Kotha A.K.; Kashikar R.; Chougule M.B.; Chung Y.H.; Steinmetz N.F.; Uddin M.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1002/wnan.1870

169. **Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics;** Author(s): Kulkarni A.; Preeti K.; Tryphena K.P.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.arr.2022.101816

170. **Transethosome as a versatile nano vehicle for various indications and its regulatory insights;** Author(s): Joga R.; Kannan B.; Yerram S.; Nandagawale A.; Gawai M.; Behera H.K.; Kumar N.;

Grover P.; Srivastava S.; Monga G.; Kumar S.; Year: 2023; DOI: 10.1080/10837450.2023.2289127

171. **Implication of Paraprobiotics in Age-Associated Gut Dysbiosis and Neurodegenerative Diseases;** Author(s): Rahman Z.; Dandekar M.P.; Year: 2023; DOI: 10.1007/s12017-022-08722-1

172. **Involvement of Microbiome Gut–Brain Axis in Neuroprotective Effect of Quercetin in Mouse Model of Repeated Mild Traumatic Brain Injury;** Author(s): Balasubramanian R.; Bazaz M.R.; Pasam T.; Sharief N.; Velip L.; Samanthula G.; Dandekar M.P.; Year: 2023; DOI: 10.1007/s12017-022-08732-z

173. **Green sample preparation in bioanalysis: where are we now?;** Author(s): Kommalapati H.S.; Pilli P.; Samanthula G.; Year: 2023; DOI: 10.4155/bio-2023-0062

174. **Drug–polymer conjugates: Challenges, opportunities, and future prospects in clinical trials;** Author(s): Bajwa N.; Mahal S.; Singh P.A.; Jyoti K.; Dewangan P.; Madan J.; Baldi A.; Year: 2023; DOI: 10.1016/B978-0-323-91663-9.00011-4

175. **Integration of miRNA's theranostic potential with nanotechnology: Promises and challenges for Parkinson's disease therapeutics;** Author(s): Tryphena K.P.; Singh G.; Jain N.; Famta P.; Srivastava S.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.1016/j.mad.2023.111800

176. **Synthesis and biological evaluation of 1-phenyl-4,6-dihydrobenzo[b]pyrazolo[3,4-d]azepin-5(1H)-one/thiones as anticancer agents;** Author(s): Parupalli R.; Akunuri R.; Spandana A.; Phanindranath R.; Pyreddy S.; Bazaz M.R.; Vadakattu M.; Joshi S.V.; Bujji S.; Gorre B.; Yaddanapudi V.M.; Dandekar M.P.; Reddy V.G.; Nagesh N.; Nanduri S.; Year: 2023; DOI: 10.1016/j.bioorg.2023.106478

177. **Formulation of inclusion complex of Abiraterone acetate with 2-Hydroxypropyl-Beta-Cyclodextrin: physiochemical characterization, molecular docking and bioavailability evaluation;** Author(s): Tamizhmathy M.; Gupta U.; Shettiwar A.; Kumar G.S.; Daravath S.; Aalhate M.; Mahajan S.; Maji I.; Sriram A.; Modak C.; Rajalakshmi A.N.; Dikundwar A.G.; Doijad N.; Guru S.K.; Singh P.K.; Year: 2023; DOI: 10.1016/j.jddst.2023.104321

178. **An expanding horizon of complex injectable products: development and regulatory considerations;** Author(s): Panchal K.; Katke S.; Dash S.K.; Gaur A.; Shinde A.; Saha N.; Mehra N.K.; Chaurasiya A.; Year: 2023; DOI: 10.1007/s13346-022-01223-5

179. **1,3-Diynes: A Versatile Precursor in Transition-Metal Catalyzed (Mediated) C–H Functionalizations;** Author(s): Kumar S.; Kumar Sabbi T.; Pingale R.; Girase P.; Kanchupalli V.; Year: 2023; DOI: 10.1002/tcr.202200228

180. **Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development;** Author(s): Gupta D.; Singh P.K.; Yadav P.K.; Narender T.; Patil U.K.; Jain S.K.; Chourasia M.K.; Year: 2023; DOI: 10.1016/j.intimp.2022.109649

181. **PET radiotracers and fluorescent probes for imaging human carbonic anhydrase IX and XII in hypoxic tumors;** Author(s): Nerella S.G.; Singh P.; Thacker P.S.; Arifuddin M.; Supuran C.T.; Year: 2023; DOI: 10.1016/j.bioorg.2023.106399

182. **Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems;** Author(s): Singh M.; Barua H.; Jyothi V.G.S.S.; Dhondale M.R.; Nambiar A.G.; Agrawal A.K.; Kumar P.; Shastri N.R.; Kumar D.; Year: 2023; DOI: 10.3390/pharmaceutics15041161

183. **Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents;** Author(s): Bagul C.; Rao G.K.; Veena I.; Kulkarni R.; Tamboli J.R.; Akunuri R.; Shaik S.P.; Pal-Bhadra M.; Kamal A.; Year: 2023; DOI: 10.1007/s11030-022-10481-x

184. **Peptide Cysteine Thiols Act as Photostabilizer of Avobenzone through Stabilizing the Transition State of Keto-Enol Tautomerization;** Author(s): Moi S.; Shekh S.; Reddy K.K.A.; Dhurjad P.; Sonti R.; Gowd K.H.; Year: 2023; DOI: 10.1111/php.13691

185. **LC-HRMS and NMR studies for characterization of forced degradation impurities of ponatinib, a tyrosine kinase inhibitor, insights into in-silico degradation and toxicity profiles;** Author(s): Golla V.M.; Kushwah B.S.; Dhiman V.; Velip L.; Gananadhamu; Year: 2023; DOI: 10.1016/j.jpba.2023.115280

186. **SNAC for Enhanced Oral Bioavailability: An Updated Review;** Author(s): Kommineni N.; Sainaga Jyothi V.G.S.; Butreddy A.; Raju S.; Shapira T.; Khan W.; Angsantikul P.; Domb A.J.; Year: 2023; DOI: 10.1007/s11095-022-03459-9

187. **Molecular docking and molecular dynamics studies of natural products unravel potential inhibitors against OmpA of Acinetobacter baumannii;** Author(s): Singothu S.; Devsani N.; Jahidha Begum P.; Maddi D.; Bhandari V.; Year: 2023; DOI: 10.1080/07391102.2023.2250446

188. **Nanomedicine in therapeutic warfront against estrogen receptor–positive breast cancer;** Author(s): Aalhate M.; Mahajan S.; Singh H.; Guru S.K.; Singh P.K.; Year: 2023; DOI: 10.1007/s13346-023-01299-7

189. **Mass spectrometry: A key tool in anti-doping;** Author(s): Dhurjad P.; Jaiswal P.; Gupta K.; Wanjari P.; Sonti R.; Year: 2023; DOI: 10.1002/sscp.202200058

190. **Sphingosine 1 phosphate lyase inhibition rescues cognition in diabetic mice by promoting anti-inflammatory microglia;** Author(s): Sood A.; Fernandes V.; Preeti K.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.1016/j.bbr.2023.114415

191. **Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay;** Author(s): Naren P.; Cholkar A.; Kamble S.; Khan S.S.; Srivastava S.; Madan J.; Mehra N.; Tiwari V.; Singh S.B.; Khatri D.K.; Year: 2023; DOI: 10.3233/JAD-220682

192. **Multiplex ddPCR: A Promising Diagnostic Assay for Early Detection and Drug Monitoring in Bovine Theileriosis;** Author(s): Murthy S.; Suresh A.; Dandasena D.; Singh S.; Subudhi M.; Bhandari V.; Bhanot V.; Arora J.S.; Sharma P.; Year: 2023; DOI: 10.3390/pathogens12020296

193. **Piceatannol promotes neuroprotection by inducing mitophagy and mitobiogenesis in the experimental diabetic peripheral neuropathy and hyperglycemia-induced neurotoxicity;** Author(s): Khan I.; Preeti K.; Kumar R.; Kumar Khatri D.; Bala Singh S.; Year: 2023; DOI: 10.1016/j.intimp.2023.109793

194. **M. tuberculosis relies on trace oxygen to maintain energy homeostasis and survive in hypoxic environments;** Author(s): Kalia N.P.; Singh S.; Hards K.; Cheung C.-Y.; Sviriaeva E.; Banaei-Esfahani A.; Aebersold R.; Berney M.; Cook G.M.; Pethe K.; Year: 2023; DOI: 10.1016/j.celrep.2023.112444

195. **Development of hydrazide hydrazone-tethered combretastatin-oxindole derivatives as antimitotic agents;** Author(s): Bora D.; Sharma A.; John S.E.; Shankaraiah N.; Year: 2023; DOI: 10.1016/j.molstruc.2022.134675

196. **Oxyberberine an oxoderivative of berberine confers neuroprotective effects in controlled-cortical impact mouse model of traumatic brain injury;** Author(s): Tentu P.M.; Bazaz M.R.; Pasam T.; Shaikh A.S.; Rahman Z.; Mourya A.; Kaki V.R.; Madan J.; Dandekar M.P.; Year: 2023; DOI: 10.1080/00207454.2023.2286209

197. **Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways;** Author(s): Kadagothy H.; Nene S.; Amulya E.; Vambhurkar G.; Rajalakshmi A.N.; Khatri D.K.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.ejphar.2023.175668

198. **Fecal microbiota transplantation unveils sex-specific differences in a controlled cortical impact injury mouse model;** Author(s): Pasam T.; Dandekar M.P.; Year: 2023; DOI: 10.3389/fmicb.2023.1336537

199. **Design of layer-by-layer lipid-polymer hybrid nanoparticles to elicit oral bioavailability of buspirone hydrochloride;** Author(s): Dangre P.; Sonawane K.; Moravkar K.; Pethe A.; Chalikwar S.; Borse V.; Year: 2023; DOI: 10.1080/00914037.2023.2255720

200. **Computational and experimental therapeutic efficacy analysis of andrographolide phospholipid complex self-assembled nanoparticles against Neuro2a cells;** Author(s): Mourya A.; Pingle P.; Babu C.K.; Veerabomma H.; Sainaga Jyothi V.G.S.; Novak J.; Pathak P.; Grishina M.; Verma A.; Kumar R.; Singh P.K.; Khatri D.K.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.1016/j.bbagen.2022.130283

201. **Perspective on Cav-1 for its Potential as Newer Therapeutics for Parkinson's Disease;** Author(s): Singh G.; Pushpa T.K.; Gupta S.K.; Srivastava S.; Khatri D.K.; Singh S.B.; Year: 2023; DOI: 10.2174/1871527321666220909150406

202. **Nanotechnology for Biomedical Applications;** Author(s): Pasika S.R.; Bulusu R.; Rao B.V.K.; Kommineni N.; Bolla P.K.; Kala S.G.; Godugu C.; Year: 2023; DOI: 10.1007/978-981-19-7963-7_11

203. **Novel pyrimidine-piperazine hybrids as potential antimicrobial agents: in-vitro antimicrobial and in-silico studies;** Author(s): Rejinthala S.; Endoori S.; Vemula D.; Bhandari V.; Mondal T.; Year: 2023; DOI: 10.1016/j.rechem.2023.100951

204. **Hypoxic pulmonary vascular response can screen subclinical lifestyle disease in healthy population;** Author(s): Khatri R.; Gupta R.; Vats P.; Bansal V.; Yadav A.K.; Reddy P.K.; Bharadwaj A.; Chaudhary P.; Sharma S.; Bajaj A.C.; Singh S.B.; Varshney R.; Year: 2023; DOI: 10.1016/j.mvr.2022.104454

205. **Implementation of the QbD Approach to the Development and Validation of an Analytical Method for Alpha-beta Arteether;** Author(s): Bajwa N.; Mahal S.; Madan J.; Baldi A.; Year: 2023; DOI: 10.2174/1570180819666220826112814

206. **Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics;** Author(s): Famta P.; Shah S.; Jain N.; Srinivasarao D.A.; Murthy A.; Ahmed T.; Vambhurkar G.; Shahrukh S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.jconrel.2022.11.034

207. **Rare earth cerium oxide nanoparticles attenuated liver fibrosis in bile duct ligation mice model;** Author(s): Godugu C.; Khurana A.; Saifi M.A.; Year: 2023; DOI: 10.1016/j.jtemb.2022.127102

208. **Multistrain Probiotics with Fructooligosaccharides Improve Middle Cerebral Artery Occlusion–Driven Neurological Deficits by Revamping Microbiota-Gut-Brain Axis;** Author(s): Rahman Z.; Bhale N.A.; Dikundwar A.G.; Dandekar M.P.; Year: 2023; DOI: 10.1007/s12602-023-10109-y

209. **Isolation of a new cytotoxic colchinoid from Gloriosa superba roots;** Author(s): Goel B.; Reddy H.; Cholkar A.; Kumar S.; Guru S.K.; Jain S.K.; Year: 2023; DOI: 10.1080/14786419.2022.2158464

210. **β-CD/Lewis Acid Dual Catalytic System for Efficient Synthesis of Pyranopyrazoles in Aqueous Environment;** Author(s): Sethi A.; Alvala M.; Year: 2023; DOI: 10.2174/1570178620666221122121021

211. **Thymoquinone-Loaded Essential Oil–Based Emulgel as an Armament for Anti-psoriatic Activity;** Author(s): Kharat P.; Chary P.S.; Bhavana V.; Rajana N.; Devabattula G.; Godugu C.; Singh S.B.; Mehra N.K.; Year: 2023; DOI: 10.1208/s12249-022-02482-8

212. **Current updates on phytopharmaceuticals for cancer treatment;** Author(s): Gupta Soni A.; Mahajan S.; Kumar Singh P.; Year: 2023; DOI: 10.1016/B978-0-443-19143-5.00023-2

213. **Investigation of molecular interaction and conformational stability of disease concomitant to HLA-DRβ3;** Author(s): Kumar S.; Gupta M.K.; Gupta S.K.; Katara P.; Year: 2023; DOI: 10.1080/07391102.2022.2134211

214. **Coumarin and Piperazine Conjugates as Selective Inhibitors of the Tumor-associated Carbonic Anhydrase IX and XII Isoforms;** Author(s): Sethi A.; Munagalasetty S.; Arifuddin M.; Carradori S.; Supuran C.T.; Alvala R.; Alvala M.; Year: 2023; DOI: 10.2174/1871520623666230202123535

215. **Potential of Phytomolecules in Alliance with Nanotechnology to Surmount the Limitations of Current Treatment Options in the Management of Osteoarthritis;** Author(s): Mourya A.; Shubhra; Bajwa N.; Baldi A.; Singh K.K.; Pandey M.; Singh S.B.; Madan J.; Year: 2023; DOI: 10.2174/1389557522666220511140527

216. **Hijacking Chemical Reactions of P450 Enzymes for Altered Chemical Reactions and Asymmetric Synthesis;** Author(s): Rajakumara E.; Saniya D.; Bajaj P.; Rajeshwari R.; Giri J.; Davari M.D.; Year: 2023; DOI: 10.3390/ijms24010214

217. **Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances;** Author(s): Joga R.; Behera H.K.; Sabanis C.D.; Simran; Kumar S.; Kumar N.; Year: 2023; DOI: 10.4155/ppa-2022-0046

218. **Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy;** Author(s): Dhuri A.; Sriram A.; Aalhate M.; Mahajan S.; Parida K.K.; Singh H.; Gupta U.; Maji I.; Guru S.K.; Singh P.K.; Year: 2023; DOI: 10.1080/10837450.2023.2206668

219. **Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy;** Author(s): Khatri D.K.; Preeti K.; Tonape S.; Bhattacharjee S.; Patel M.; Shah S.; Singh P.K.; Srivastava S.; Gugulothu D.; Vora L.; Singh S.B.; Year: 2023; DOI: 10.2174/1570159X20666220507022701

220. **Andrographolide-Soya-L-α-Phosphatidyl Choline Complex Augmented Solubility and Drug Delivery in Leishmania donovani, a Causative Agent for Cutaneous and Visceral Leishmaniasis;** Author(s): Pingle P.; Mourya A.; Namdeo M.; Babu K.C.; Veerabomma H.; Maurya R.; Singh P.K.; Mehra N.K.; Srivastava S.; Madan J.; Year: 2023; DOI: 10.1208/s12249-023-02507-w

221. **Emerging insights of peptide-based nanotherapeutics for effective management of rheumatoid arthritis;** Author(s): Pathade V.; Nene S.; Ratnam S.; Khatri D.K.; Raghuvanshi R.S.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.lfs.2022.121257

222. **LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage;** Author(s): Gajula S.N.R.; Khairnar A.S.; Jock P.; Kumari N.; Pratima K.; Munjal V.; Kalan P.; Sonti R.; Year: 2023; DOI: 10.1080/14789450.2023.2191845

223. **Acetaminophen induced hepatotoxicity: An overview of the promising protective effects of natural products and herbal formulations;** Author(s): Chilvery S.; Yelne A.; Khurana A.; Saifi M.A.; Bansod S.; Anchi P.; Godugu C.; Year: 2023; DOI: 10.1016/j.phymed.2022.154510

224. **Quest for selective MMP9 inhibitors: a computational approach;** Author(s): Shaikh A.S.; Sethi A.; Makhal P.N.; Rathi B.; Kaki V.R.; Year: 2023; DOI: 10.1080/07391102.2023.2186710

225. **Forging Ahead the Repositioning of Multitargeted Drug Ivermectin;** Author(s): Atmakuri S.; Nene S.; Khatri D.; Singh S.B.; Sinha V.R.; Srivastava S.; Year: 2023; DOI: 10.2174/1567201819666220516163242

226. **Identification of Potent Bioactive Molecules Against NMDA Receptor and Tau Protein by Molecular Docking Approach;** Author(s): Parvatikar P.; Bagali S.; Hippargi S.; Singh P.K.; Singh S.B.; Biradar M.S.; Patil A.V.; Das K.K.; Year: 2023; DOI: 10.2174/1570180819666220616142153

227. **Development of Novel Indole-3-sulfonamide-heteroaryl Hybrids as Carbonic Anhydrase Inhibitors: Design, Synthesis and in-vitro Screening;** Author(s): Chinchilli K.K.; Singh P.; Swain B.; Goud N.S.; Sigalapalli D.K.; Choli A.; Angeli A.; Nanduri S.; Yaddanapudi V.M.; Supuran C.T.; Arifuddin M.; Year: 2023; DOI: 10.2174/1871520623666230227092821

228. **Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli;** Author(s): Sau S.; Roy A.; Agnivesh P.K.; Kumar S.; Guru S.K.; Sharma S.; Kalia N.P.; Year: 2023; DOI: 10.1099/jmm.0.001695

229. **Immune cell–camouflaged surface-engineered nanotherapeutics for cancer management;** Author(s): Jain N.; Shahrukh S.; Famta P.; Shah S.; Vambhurkar G.; Khatri D.K.; Singh S.B.; Srivastava S.; Year: 2023; DOI: 10.1016/j.actbio.2022.11.001

230. **Development of stability-indicating method for separation and characterization of benidipine forced degradation products using LC–MS/MS;** Author(s): Kushwah B.S.; Thummar M.M.; Yadav A.S.; Dhiman V.; Samanthula G.; Year: 2023; DOI: 10.1002/bmc.5517

231. **Trimethylsilyl azide-promoted acid-amine coupling: A facile one-pot route to amides from carboxylic acids and amines;** Author(s): Tangella Y.; Soni J.P.; Shankaraiah N.; Abril D.; Sathish M.; Year: 2023; DOI: 10.24820/ark.5550190.p011.914

232. **Synthesis and biological evaluation of new 3-substituted coumarin derivatives as selective inhibitors of human carbonic anhydrase IX and XII;** Author(s): Mahammad Ghouse S.; Bahatam K.; Angeli A.; Pawar G.; Chinchilli K.K.; Yaddanapudi V.M.; Mohammed A.; Supuran C.T.; Nanduri S.; Year: 2023; DOI: 10.1080/14756366.2023.2185760

233. **Core–Shell Type Lipidic and Polymeric Nanocapsules: the Transformative Multifaceted Delivery Systems;** Author(s): Mehandole A.; Walke N.; Mahajan S.; Aalhate M.; Maji I.; Gupta U.; Mehra N.K.; Singh P.K.; Year: 2023; DOI: 10.1208/s12249-023-02504-z

234. **Microfluidics-Based Blood Typing Devices: An In-Depth Overview;** Author(s): Jayachandran A.; Parween S.; Asthana A.; Kar S.; Year: 2024; DOI: 10.1021/acsabm.3c00995

235. **Oxindoline Containing Thiazolidine-4-one Tethered Triazoles Act as Antimitotic Agents by Targeting Microtubule Dynamics;** Author(s): Shahjahan S.; Naraharisetti L.T.; Begum A.; Yakkala P.A.; Lakshmi Soukya P.S.; Godugu C.; Begum S.A.; Kamal A.; Year: 2024; DOI: 10.1002/slct.202400539

236. **QbD-driven thymoquinone laden nanoemulsion for glaucoma management: In vitro, ex vivo, and pre-clinical evaluation;** Author(s): Srivastava V.; Pardhi E.R.; Yadav R.; Singh V.; Khatri D.K.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.jddst.2024.105493

237. **Reverse-phase high-performance liquid chromatography methodology for film-forming mafenide spray: Compatibility, assay, and in-vitro release evaluation using Franz vertical diffusion cell apparatus;** Author(s): Mahajan R.; Chandragiri S.T.; Borse V.; Samanthula G.; Asthana A.; Year: 2024; DOI: 10.1002/sscp.202300148

238. **Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight;** Author(s): Damare R.; Engle K.; Kumar G.; Year: 2024; DOI: 10.1002/ptr.8166

239. **A comprehensive review of genomics, transcriptomics, proteomics, and metabolomic insights into the differentiation of Pseudomonas aeruginosa from the planktonic to biofilm state: A multi-omics approach;** Author(s): Vohra M.; Kour A.; Kalia N.P.; Kumar M.; Sharma S.; Jaglan S.; Kamath N.; Sharma S.; Year: 2024; DOI: 10.1016/j.ijbiomac.2023.128563

240. **Gallstone: a factor for acute pancreatitis;** Author(s): Bhattacharya T.; Nandi A.; Chander S.; Year: 2024; DOI: 10.1016/B978-0-443-16098-1.00015-1

241. **Design, synthesis, and biological evaluation of 3-benzenesulfonamide-linked 3-hydrazinoisatin derivatives as carbonic anhydrase inhibitors;** Author(s): Swain B.; Marde V.S.; Singh P.; Angeli A.; Khan A.; Yaddanapudi V.M.; Ullah Q.; Supuran C.T.; Arifuddin M.; Year: 2024; DOI: 10.1002/ardp.202300718

242. **Synergy between cyclooxygenase-2 inhibitors and hyaluronic acid in the treatment of osteoarthritis: Illumination of signaling cascade, nanotechnology-driven delivery strategies and future prospects;** Author(s): Thote S.; Gorella P.; Arya S.; Mourya A.; Devangan P.; Jyothi V.G.S.S.; Katta C.; Singh S.B.; Mehra N.K.; Madan J.; Year: 2024; DOI: 10.1016/j.jddst.2024.105380

243. **Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic;** Author(s): Nair R.; Paul P.; Maji I.; Gupta U.; Mahajan S.; Aalhate M.; Guru S.K.; Singh P.K.; Year: 2024; DOI: 10.1016/j.carbpol.2023.121644

244. **Tailoring micellar nanocarriers for pemetrexed in breast cancer: design, fabrication and in vitro evaluation;** Author(s): Kumari N.U.; Chary P.S.; Pardhi E.; Mehra N.K.; Year: 2024; DOI: 10.2217/nnm-2024-0013

245. **In vivo and in vitro metabolite profiling of nirmatrelvir using LC–Q-ToF–MS/MS along with the in silico approaches for prediction of metabolites and their toxicity;** Author(s): Chaganti S.; Kushwah B.S.; Velip L.; Tiwari S.S.; Chilvery S.; Godugu C.; Samanthula G.; Year: 2024; DOI: 10.1002/bmc.5849

246. **Exosome-mediated delivery and regulation in neurological disease progression;** Author(s): Singh G.; Mehra A.; Arora S.; Gugulothu D.; Vora L.K.; Prasad R.; Khatri D.K.; Year: 2024; DOI: 10.1016/j.ijbiomac.2024.130728

247. **Quality by design approach-based fabrication and evaluation of self-nanoemulsifying drug delivery system for improved delivery of venetoclax;** Author(s): Rajana N.; Chary P.S.; Pooja Y.S.; Bhavana V.; Singh H.; Guru S.K.; Singh S.B.; Mehra N.K.; Year: 2024; DOI: 10.1007/s13346-023-01462-0

248. **Enzymatic Synthesis of 3-Hydroxy Bisindoles and Further C-3 Sulfenylation via Combining a Carbocatalytic Approach in the Same Pot;** Author(s): Kamboj P.; Bhardwaj M.; Sahu P.; Bajaj P.; Tyagi V.; Year: 2024; DOI: 10.1002/slct.202304826

249. **An apprise on novel drug delivery systems for management of diabetes mellitus;** Author(s): Pardhi E.; Bhor Y.; Singh P.K.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.jddst.2024.105473

250. **Revolutionizing pancreatic islet organoid transplants: Improving engraftment and exploring future frontiers;** Author(s): Abraham N.; Kolipaka T.; Pandey G.; Negi M.; Srinivasarao D.A.; Srivastava S.; Year: 2024; DOI: 10.1016/j.lfs.2024.122545

251. **Fingolimod exerts neuroprotection by regulating S1PR1 mediated BNIP3-PINK1-Parkin dependent mitophagy in rotenone induced mouse model of Parkinson's disease;** Author(s): Rajan S.; Sood A.; Jain R.; Kamatham P.T.; Khatri D.K.; Year: 2024; DOI: 10.1016/j.neulet.2023.137596

252. **Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape;** Author(s): Kirthiga Devi S.S.; Singh S.; Joga R.; Patil S.Y.; Meghana Devi V.; Chetan Dushantrao S.; Dwivedi F.; Kumar G.; Kumar Jindal D.; Singh C.; Dhamija I.; Grover P.; Kumar S.; Year: 2024; DOI: 10.1016/j.ejpb.2024.114323

253. **Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer;** Author(s): Samia S.; Sandeep Chary P.; Khan O.; Kumar Mehra N.; Year: 2024; DOI: 10.1016/j.ijpharm.2024.123889

254. **Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes;** Author(s): Prajapat V.M.; Aalhate M.; Sriram A.; Mahajan S.; Maji I.; Gupta U.; Kumari D.; Singh K.; Kalia N.P.; Dua K.; Singh S.K.; Singh P.K.; Year: 2024; DOI: 10.1016/j.parint.2023.102848

255. **Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations;** Author(s): Kumar G.; Sakharam K.A.; Year: 2024; DOI: 10.1016/j.ejmech.2024.116172

256. **Study on the hydrolytic degradation behaviour of bictegravir by LC-PDA-Q/TOF-MS/MS NMR and in silico toxicity assessment;** Author(s): Dannarm S.R.; Harini D.; Reddy G.N.; Ali N.; Sonti R.; Year: 2024; DOI: 10.1016/j.jpba.2023.115909

257. **Deciphering the role of nanocarrier-based nucleic acid delivery to the brain for the management of neurodegenerative disorders;** Author(s): Panigrahy S.; Sikder A.; Amulya E.; Shah S.; Khairnar P.; Saraf S.; Srivastava S.; Year: 2024; DOI: 10.1016/j.jddst.2023.105325

258. **Isolation of cytotoxic cycloartane triterpenoids from Dysoxylum malabaricum;** Author(s): Bhardwaj N.; Sharma V.K.; Tripathi N.; Pimpre K.; Sonti R.; Ravikanth G.; Koch B.; Jain S.K.; Year: 2024; DOI: 10.1039/d3nj04057g

259. **Enzymes as indispensable markers in disease diagnosis;** Author(s): Pathan S.U.; Kharwar A.; Ibrahim M.A.; Singh S.B.; Bajaj P.; Year: 2024; DOI: 10.4155/bio-2023-0207

260. **Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy;** Author(s): Kumari N.U.; Pardhi E.; Chary P.S.; Mehra N.K.; Year: 2024; DOI: 10.4155/tde-2023-0092

261. **Essential oils for clinical aromatherapy: A comprehensive review;** Author(s): Vora L.K.; Gholap A.D.; Hatvate N.T.; Naren P.; Khan S.; Chavda V.P.; Balar P.C.; Gandhi J.; Khatri D.K.; Year: 2024; DOI: 10.1016/j.jep.2024.118180

262. **In-vitro and preclinical testing of bacillus subtilis UBBS-14 probiotic in rats shows no toxicity;** Author(s): Negi A.; Pasam T.; Farqadain S.M.; Mahalaxmi Y.; Dandekar M.P.; Year: 2024; DOI: 10.1093/toxres/tfae021

263. **Biaryl carboxamide-based peptidomimetics analogs as potential pancreatic lipase inhibitors for treating obesity;** Author(s): Pandey V.; Adhikrao P.A.; Motiram G.M.; Yadav N.; Jagtap U.; Kumar G.; Paul A.; Year: 2024; DOI: 10.1002/ardp.202300503

264. **Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review;** Author(s): Galla M.S.; Sharma N.; Mishra P.; Shankaraiah N.; Year: 2024; DOI: 10.1039/d4md00142g

265. **Synthesis and biological evaluation of new naphthalimide-thiourea derivatives as potent antimicrobial agents active against multidrug-resistant Staphylococcus aureus and Mycobacterium tuberculosis;** Author(s): Rana P.; Parupalli R.; Akhir A.; Saxena D.; Maitra R.; Imran M.; Malik P.; Mahammad Ghouse S.; Joshi S.V.; Srikanth D.; Madhavi Y.V.; Dasgupta A.; Chopra S.; Nanduri S.; Year: 2024; DOI: 10.1039/d4md00062e

266. **Unlocking the potential of flavonoid-based co-crystal and co-amorphous systems;** Author(s): Rode K.; Maji I.; Mahajan S.; Singh P.K.; Year: 2024; DOI: 10.1016/j.drudis.2024.104050

267. **Nanocarrier-Integrated Microneedles: Divulging the Potential of Novel Frontiers for Fostering the Management of Skin Ailments;** Author(s): Khairnar P.; Phatale V.; Shukla S.; Tijani A.O.; Hedaoo A.; Strauss J.; Verana G.; Vambhurkar G.; Puri A.; Srivastava S.; Year: 2024; DOI: 10.1021/acs.molpharmaceut.4c00144

268. **Chitosan revokes controlled-cortical impact generated neurological aberrations in circadian disrupted mice via TLR4-NLRP3 axis;** Author(s): Bazaz M.R.; Asthana A.; Dandekar M.P.; Year: 2024; DOI: 10.1016/j.ejphar.2024.176436

269. **Design of experiment-oriented development and validation of novel bioanalytical reverse phase high performance liquid chromatography method of palbociclib in rat plasma and tissues, and its application in pharmacokinetic studies;** Author(s): Rajana N.; Pooja Y.S.; Bhavana V.; Chary P.S.; Dukka K.; Deshmukh R.; Mehra N.K.; Year: 2024; DOI: 10.1002/bmc.5815

270. **Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation;** Author(s): Thakur A.; Chu Y.-H.; Rao N.V.; Mathew J.; Grewal A.S.; Prabakaran P.; Guru S.; Liou J.P.; Pan C.-H.; Nepali K.; Year: 2024; DOI: 10.1016/j.ejmech.2024.116507

271. **Fabrication of β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin inclusion complexes of Palbociclib: Physicochemical characterization, solubility enhancement, in -silico studies, in vitro assessment in MDA-MB-231 cell line;** Author(s): Paul P.; Gupta U.; Kumar R.; Munagalasetty S.; Padhy H.P.; Nair R.; Mahajan S.; Maji I.; Aalhate M.; Bhandari V.; Guru S.K.; Singh P.K.; Year: 2024; DOI: 10.1016/j.molliq.2024.124458

272. **Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences;** Author(s): Paul P.; Veerabomma H.; Gupta U.; Atram D.; Singh P.K.; Mehra N.K.; Godugu C.; Baldi A.; Madan J.; Year: 2024; DOI: 10.1016/j.jddst.2024.105666

273. **Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review;** Author(s): Sen S.; Ganta B.; Rachel V.N.; Gogikar S.K.; Singh V.; Sonti R.; Dikundwar A.G.; Year: 2024; DOI: 10.1016/j.xphs.2024.04.025

274. **Design, synthesis and in vitro evaluation of novel thiazole-coumarin hybrids as selective and potent human carbonic anhydrase IX and XII inhibitors;** Author(s): Singh P.; Nerella S.G.;

Swain B.; Angeli A.; Ullah Q.; Supuran C.T.; Arifuddin M.; Year: 2024; DOI: 10.1016/j.ijbiomac.2024.131548

275. **Lipid engineered nanomaterials: A novel paradigm shift for combating stroke;** Author(s): Amulya E.; Bahuguna D.; Negi M.; Phatale V.; Sikder A.; Vambhurkar G.; Katta C.B.; Dandekar M.P.; Madan J.; Srivastava S.; Year: 2024; DOI: 10.1016/j.apmt.2024.102194

276. **Design, development, and evaluation of CDK-4/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer;** Author(s): Pooja Y.S.; Rajana N.; Yadav R.; Naraharisetti L.T.; Godugu C.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.ijbiomac.2023.128821

277. **Targeted delivery and apoptosis induction of CDK-4/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells;** Author(s): Rajana N.; Sandeep Chary P.; Bhavana V.; Deshmukh R.; Dukka K.; Sharma A.; Kumar Mehra N.; Year: 2024; DOI: 10.1016/j.ijpharm.2024.123787

278. **Chalcone derivatives as efflux pump inhibitor of Staphylococcus aureus;** Author(s): Kaur B.; Kour A.; Sharma S.; Kathik G.; Kalia N.P.; Sharma S.; Year: 2024; DOI: 10.33472/AFJBS.6.5.2024.1831-1838

279. **Role of liver in gallstone formation;** Author(s): Bhattacharya T.; Nandi A.; Das A.; El-Shazly M.; Year: 2024; DOI: 10.1016/B978-0-443-16098-1.00014-X

280. **Nanotechnology invigorated drug delivery and tissue engineering strategies for the management of diabetic foot ulcers: Therapeutic approaches and clinical applications;** Author(s): Pandey G.; Kolipaka T.; Srinivasarao D.A.; Abraham N.; Tickoo V.; Khatri D.K.; Raghuvanshi R.S.; Srivastava S.; Year: 2024; DOI: 10.1016/j.jddst.2024.105665

281. **LC-HRMS and NMR studies for the characterization of degradation impurities of ubrogepant along with the in silico approaches for the prediction of degradation and toxicity;** Author(s): Chaganti S.; Chauhan U.; Bhatt N.; Kommalapati H.; Golla V.M.; Pilli P.; Samanthula G.; Year: 2024; DOI: 10.1016/j.jpba.2024.116117

282. **Design, development and characterization of the Apremilast and Indomethacin coamorphous system;** Author(s): Pardhi E.; Tomar D.S.; Khemchandani R.; Samanthula G.; Singh P.K.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.molstruc.2023.137045

283. **SCFAs Supplementation Rescues Anxiety- and Depression-like Phenotypes Generated by Fecal Engraftment of Treatment-Resistant Depression Rats;** Author(s): Palepu M.S.K.; Gajula S.N.R.; Malleshwari K.; Sonti R.; Dandekar M.P.; Year: 2024; DOI: 10.1021/acschemneuro.3c00727

284. **Nanocrystal technologies in biomedical science: From the bench to the clinic;** Author(s): Pardhi E.; Vasave R.; Srivastava V.; Yadav R.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.drudis.2024.103913

285. **Small Peptide Conjugates of Benzothiazole-2-Carboxylic Acids Targeting DprE1 Against Tuberculosis;** Author(s): Samoon R.; Sau S.; Khan A.; Latief I.; Kalia N.P.; Abdin M.Z.; Shafi S.; Year: 2024; DOI: 10.1002/slct.202400320

286. **Nano voyagers: Pioneering a new frontier in cancer treatment with nanorobots as drug transporters;** Author(s): Shinde A.; Prasad S.B.; Srinivasarao D.A.; Shah S.; Famta P.; Khairnar P.; Pandey G.; Vambhurkar G.; Hedaoo A.; Kumar R.; Srivastava S.; Year: 2024; DOI: 10.1016/j.apmt.2024.102162

287. **The Potential Pharmacological Effects of Natural Product Withaferin A in Cancer: Opportunities and Challenges for Clinical Translation;** Author(s): Devabattula G.; Panda B.; Yadav R.; Godugu C.; Year: 2024; DOI: 10.1055/a-2289-9600

288. **Epidrugs: alternative chemotherapy targeting Theileria annulata schizont stage parasites;** Author(s): Kamble S.; Singh S.; Suresh A.; Singothu S.; Dandesena D.; Bhandari V.; Sharma P.; Year: 2024; DOI: 10.1128/spectrum.03258-23

289. **Repurposing of Food and Drug Admnistration (FDA) approved library to identify a potential inhibitor of trypanothione synthetase for developing an antileishmanial agent;** Author(s): Vemula D.; Mohanty S.; Bhandari V.; Year: 2024; DOI: 10.1016/j.heliyon.2024.e27602

290. **Investigation on photo-isomeric impurity of Roxadustat: Structure conformation, physicochemical characterization, interconversion feasibility and in vitro toxicological evaluation;** Author(s): Mahajan R.; Sharma A.; Patra B.; Mani L.; Grover P.; Kumar S.; Guru S.K.; Samanthula G.; Dikundwar A.G.; Asthana A.; Year: 2024; DOI: 10.1016/j.molstruc.2023.137017

291. **Anti-melanoma and antioxidant properties of the methanol extract from the leaves of Phragmenthera capitata (Spreng.) Balle and Globimetula braunii (Engl.) Van Tiegh;** Author(s): Evariste Leonce A.A.; Devi P.; Richard T.S.; Panda B.; Devabattula G.; Godugu C.; Phelix Bruno T.; Year: 2024; DOI: 10.1515/jcim-2023-0225

292. **Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift;** Author(s): Yadav R.; Bhawale R.; Srivastava V.; Pardhi E.; Bhalerao H.A.; Sonti R.; Mehra N.K.; Year: 2024; DOI: 10.1208/s12249-024-02759-0

293. **Oxyberberine protects middle cerebral artery occlusion triggered cerebral injury through TLR4/NLRP3 pathway in rats;** Author(s): Rahman Z.; Shaikh A.S.; Rao K.V.; Dandekar M.P.; Year: 2024; DOI: 10.1016/j.jchemneu.2024.102393

294. **(3,19)-4-Bromobenzylidene-isoandrographolide Induces Apoptosis and Causes Loss of Mitochondrial Membrane Potential in MCF-7 Breast Cancer Cells;** Author(s): Tamang N.; Inabathina Y.; Mavileti S.K.; Sripada L.; Nanduri S.; Golakoti N.R.; Karanam B.; Year: 2024; DOI: 10.1002/slct.202302498

295. **Stimuli-responsive polysaccharide-based smart hydrogels for diabetic wound healing: Design aspects, preparation methods and regulatory perspectives;** Author(s): Kolipaka T.; Pandey G.; Abraham N.; Srinivasarao D.A.; Raghuvanshi R.S.; Rajinikanth P.S.; Tickoo V.; Srivastava S.; Year: 2024; DOI: 10.1016/j.carbpol.2023.121537

296. **Evaluation of preclinical efficacy of apremilast-loaded liquid crystalline nanoparticulate gel in amelioration of atopic dermatitis;** Author(s): Nene S.; Vambhurkar G.; Tryphena K.P.; Singh P.K.; Khatri D.K.; Srivastava S.; Year: 2024; DOI: 10.1016/j.jddst.2024.105653

297. **Investigation, scaffold hopping of novel donepezil-based compounds as anti-Alzhiemer's agents: synthesis, in-silico and pharmacological evaluations;** Author(s): Gupta M.; Pant S.;

Rana P.; Kumar A.; Prasun C.; Nair M.S.; Paliwal S.; Nain S.; Year: 2024; DOI: 10.1038/s41598-024-51713-4

298. **Covalent organic frameworks: spotlight on applications in the pharmaceutical arena;** Author(s): Pilli P.; Kommalapati H.S.; Golla V.M.; Khemchandani R.; Ramachandran R.K.; Samanthula G.; Year: 2024; DOI: 10.4155/bio-2023-0256

299. **Multifunctional Wound Curation Dressing Material FemuFrost—An Antioxidant-Loaded Nanoemulsion Frosted Patch of Poly(vinyl alcohol) and Hyaluronic Acid;** Author(s): Valamla B.; Charry S.; Rajana N.; Urati A.; Devabattula G.; Sau S.; Godugu C.; Kalia N.P.; Mehra N.K.; Year: 2024; DOI: 10.1021/acsabm.3c00996

300. **Natural Products and Traditional Herbal Medicines as Managerial Therapies to Combat Rheumatoid Arthritis;** Author(s): Ghosh N.; Pathak S.; Malsawmdawngkimi; Kumar G.; Gull A.; Year: 2024; DOI: 10.1007/s12018-024-09290-7

301. **Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review;** Author(s): Murugappan S.; Dastari S.; Jungare K.; Barve N.M.; Shankaraiah N.; Year: 2024; DOI: 10.1016/j.molstruc.2024.138012

302. **Discerning the stability behaviour of mavacamten availing liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy: In silico toxicity and mutagenicity prediction of degradation products;** Author(s): Golla V.M.; Kalyan M.; Gholap U.; Padhy H.P.; Ramachandran R.K.; Samanthula G.; Year: 2024; DOI: 10.1002/jms.5007

303. **Rh(iii)-catalysed C-H annulation of cis-stilbene acids with 2-diazo-1,3-diketones: facile access to 6,7-dihydrobenzofuran-4(5H)-one and α-pyrone scaffolds;** Author(s): Galla M.S.; Kale N.B.; Kumawat A.; Bora D.; Shankaraiah N.; Year: 2024; DOI: 10.1039/d4ob00151f

304. **Neuroprotective role of Carvacrol via Nrf2/HO-1/NLRP3 axis in Rotenone-induced PD mice model;** Author(s): Shah S.; Pushpa Tryphena K.; Singh G.; Kulkarni A.; Pinjala P.; Kumar Khatri D.; Year: 2024; DOI: 10.1016/j.brainres.2024.148954

305. **Synthesis and antibacterial evaluation of new naphthalimide-coumarin hybrids against multidrug-resistant S. aureus and M. tuberculosis;** Author(s): Rana P.; Supriya M.S.; Kalam A.; Eedulakanti C.; Kaul G.; Akhir A.; Sindhuja R.H.; Roy A.; Agnivesh P.K.; Saxena D.; Ahmad M.N.; Madhavi Y.V.; Dasgupta A.; Kalia N.P.; Nagesh N.; Chopra S.; Nanduri S.; Year: 2024; DOI: 10.1016/j.molstruc.2024.137957

306. **Transdermal delivery and exploration of preclinical anti-rheumatoid efficacy of pirfenidone embedded nanoemulgel in adjuvant-induced rat model;** Author(s): Nooreen R.; Nene S.; Vambhurkar G.; Srivastava S.; Year: 2024; DOI: 10.1016/j.jddst.2024.105428

307. **Sulfo-butyl ether β-cyclodextrin inclusion complexes of bosutinib: in silico, in vitro and in vivo evaluation in attenuating the fast-fed variability;** Author(s): Shah S.; Famta P.; Vambhurkar G.; Bagasariya D.; Kumar K.C.; Srinivasarao D.A.; Begum N.; Sharma A.; Shahrukh S.; Jain N.; Khatri D.K.; Srivastava S.; Year: 2024; DOI: 10.1007/s13346-023-01453-1

308. **Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer;** Author(s): Shah S.; Famta P.; Kumar R.; Sharma A.; Vambhurkar G.; Pandey G.; Singh G.; Kumar P.; Mehra A.; Mourya A.; Srinivasarao D.A.; Shinde

A.; Prasad S.B.; Khatri D.K.; Madan J.; Srivastava S.; Year: 2024; DOI: 10.1016/j.colsurfb.2023.113732

309. **Computational quality-by-design strategy to validate high-performance liquid chromatography method for the estimation of meloxicam in bulk dosage forms and milk samples;** Author(s): Jyothi V.G.S.S.; Veerabomma H.; Katta C.; Madan J.; Year: 2024; DOI: 10.1007/s44211-023-00448-9

310. **Microwave-Assisted Ru(II)-Catalyzed Regioselective Methyl Acylation of 2-Arylbenzoazoles: Synthesis of Benzofuran Conjugates via C-H Activation/Annulation;** Author(s): Dastari S.; Murugappan S.; John S.E.; Shankaraiah N.; Year: 2024; DOI: 10.1021/acs.joc.4c00402

311. **Non-carbohydrate Galectin-1 inhibitors as promising anticancer agents: Design strategies, structure activity relationship and mechanistic insights;** Author(s): Nerella S.G.; Year: 2024; DOI: 10.1016/j.ejmcr.2024.100170

312. **Resveratrol in the management of diabetes mellitus;** Author(s): Joshi S.; Rana M.; Bisht S.S.; Joshi B.C.; Bahuguna D.; Rana A.J.; Devi M.; Jyoti; Rani N.; Kataria R.; Year: 2024; DOI:

313. **Integrative analysis of tepotinib forced degradation: Combining in-silico and liquid chromatography-quadrupole time-of-flight-tandem mass spectrometry approaches for structural elucidation;** Author(s): Mahajan R.; Bishnani A.; Sapkal R.; Dikundwar A.G.; Gananadhamu S.; Asthana A.; Year: 2024; DOI: 10.1002/sscp.202300227

314. **Unlocking nature's arsenal: Nanotechnology for targeted delivery of venom toxins in cancer therapy;** Author(s): Chary P.S.; Shaikh S.; Rajana N.; Bhavana V.; Mehra N.K.; Year: 2024; DOI: 10.1016/j.bioadv.2024.213903

315. **Vaccine safety, efficacy, and ethical considerations;** Author(s): Shukla R.; Vyas K.; Khadela A.; Vora L.K.; Khatri D.K.; Year: 2024; DOI: 10.1016/B978-0-443-18564-9.00020-5

316. **Raloxifene loaded D-α-tocopherol polyethylene glycol 1000 succinate stabilized poly (ε-caprolactone) nanoparticles augmented drug delivery and apoptosis in breast cancer cells;** Author(s): Mourya A.; Famta P.; Shah S.; Srinivasarao D.A.; Sharma A.; Vambhurkar G.; Bojja B.; Arya S.; Devanagan P.; Prasad S.B.; Shinde A.; Singh G.; Khatri D.K.; Srivastava S.; Madan J.; Year: 2024; DOI: 10.1016/j.jddst.2024.105399

317. **Nanomedicine-RNAi interface: Architypes in prostate cancer therapeutics;** Author(s): Shah S.; Famta P.; Srinivasarao D.A.; Shahrukh S.; Jain N.; Shinde A.; Prasad S.B.; Vambhurkar G.; Pandey G.; Kumar R.; Saraf S.; Srivastava S.; Year: 2024; DOI: 10.1016/j.jddst.2024.105349

5.3. Research Projects

In addition to funding from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, NIPER Hyderabad secures extramural grants from various funding agencies and industries to support its research projects. These external grants enable the institute to undertake diverse research initiatives tailored to meet specific needs. The projects received by NIPER Hyderabad during the year 2023-24 are listed in the table below:



GRANTS/ PROJECTS SANCTIONED

Name of Investigator	Title of the Project	Funding Agency	Year	Amount Sanctioned in Lakhs
Industry-Sponsored Projects				
Dr. Manoj Dandekar	Immunomodulatory effects of a multistain probiotic formulation on cyclophospahmide induced immunosuppression in mice	Unique Biotech Ltd	2023-24	10.20
Dr. Pankaj Kumar Singh	Design and Development of intravenous liposomal preparation of Irinotecan	M/s Incozen Therapeutics Pvt. Ltd.	2023-24	6.08
Dr. Manoj Dandekar	Examine the effect of polyherbal formulation on cognitive functions in aged rats	Transformative Learning Solutions Pvt Ltd	2023-24	12.50
Dr. Amit Asthana	Development Optimization and Characterization of Polymeric Nanocarrier system towards the establishment of drug-eluting	Involution Healthcare Pvt Ltd	2023-24	19.42

	balloon for the management of atherosclerosis			
Dr. Manoj Dandekar	Acute and subchronic toxicity study of clostridium butyricum UBCB-70 formulation in sprague-dawley rats	Unique Biotech Ltd	2023-24	4.50
Dr. Amit Asthana	Fabrication of prototype micofluidic paper based amalytical devices to be used for inflammatory bowel disease and diarrhoea infections	Babycure pvt. Ltd	2023-24	5.71
Government Sponsored Projects				
Dr. Amol Dikundwar	Centre for testing nutritional supplements	NADA & FSSAI	2023-24	631.20
Dr. Jitendra Madan	Summer Research Internship Program	GSBTM, Gujarat	2023-24	7.00
Dr. YV Madhavi	Novel sythetic process and formulation development of eliglustat tartarate	DST-TDT	2023-24	41.89
Dr. Santosh Kumar Guru	Targeting CDK-9 by coumairn based Inhibitors: Design, Preparation and Biological Evaluation	SERB	2023-24	30.47
Dr. Srinivas Nanduri	Creation of nodal centres for the production of impoted APIs, KSMs and intermediate to achieve self sufficiency in health care sector	DST	2023-24	24.51
Dr.Pankaj kumar Singh	Hands on practive with advance techniques and instruments for nanotechnology based drug delivery system- workshop	DoP	2023-24	4.20
Dr. Vasundhra Bandari	Global proteome and phosphoproteome characterisation to identify biomarkers and pathogenesis of sepsis	ICMR	2023-24	64.21
Dr. Manoj Dandekar	Impact of STN and ALIC deep mbrain stimulation on cognitive improvement in obsessive compulsive disorder model	DST	2023-24	75.04
Dr. Chandraiah Godugu	Innovative strategies for the design and development of FXR/TGR5 dual agonists for	ICMR	2023-24	155.93

	Hepatic Steatosis and fibrosis in NASH			
Dr.Amit Asthana	Affordable paper based point of care device for rapid detection of glycocalyx markers for sepsis patients in ICU	ICMR	2023-24	62.39
Dr. Jitender Madan	Process scale up, validatrion, preclinical and safety evaluation of intravaginal metformin hydrochloride thermosensitive gel in polycystic ovary syndrome	ICMR	2023-24	52.13
Dr. Dadi Srinivas	Design and development of a mucoadhesive micelle-based dual drug delivery system for the non-invasive treatment of diabetic cataract and retinopathy	ICMR	2023-24	81.13
Dr. Chandraiah Godugu	Overcoming the inflammatory cascade in neonatal sepsis: a nanomedicine approach	ICMR	2023-24	149.14
Dr.N.Shankaraiah	Development of novel 2-amino pyrimidine based molecular hybrids as selective CDK-9 inhibitors	ICMR	2023-24	51.49
Dr. Nanduri Srinivas	Synthesis and therapeutic evaluation of new FabI and InhA inhibitors as potent antibacterial and antimycobacterial agents	SERB	2023-24	35.24
Dr. Priynka Bajaj	DST INSPIRE Fellowship to Ms. Pooja Sahu	DST	2023-24	5.84
Dr. Nitin Pal Kalia	Exploiting synthetic lethality of type II NADH dehydrogenases for complete sterilization of mycobacterium tuberculosis	ICMR	2023-24	68.46
Dr. Santosh Kumar Guru	Design, synthesis and preclinical validation of selective CDK7/ Cyclin H/MAT1 Inhibitors as a potential treatment for triple-negative breast cancer	ICMR	2023-24	120.46
Dr. Neelesh Kumar Mehra	Ex-Vivo and in-vivo evaluation of novel therapeutic regimen of the cyclin dependent kinase 4/6 inhibitors loaded hybrid lipid-polymeric nanoparticles against triple-negative breast cancer	SERB	2023-24	32.17

Dr. Vinay Kumar Kanchupally	Synthesis of novel y-lactums via an uncommon directing group migration strategy by transitionmetal catalysis	SERB	2023-24	46.00
Dr. Nitin Pal Kalia	Targeting cytochrome bd oxidase inhibitor for the development of rational drug combination for complete sterilization of mycobacterium tuberculosis	ICMR	2023-24	28.11
Dr. Anamika Sharma	Elucidating the role of cellular senescence in immunological aging in dendritic cells and its modulation through nutritional immunotherapy interventions	SERB	2023-24	25.21
Dr. Dadi A Srinivas Rao	Design and development of a non-invasive controlled release sol-gel based dual drug delivery system for simultaneous alleviation of intraocular pressure and retinal ganglionic cells degeneration in glucoma	SERB	2023-24	29.40
Dr. Manoj Dandekar	DST INSPIRE Fellowship to Mr. Shivkumar Sammeta	DST	2023-24	5.84

5.4. Placements

The institute actively facilitates the placement of final semester students by inviting various industries and organizing campus recruitment drives. These initiatives ensure that students have ample opportunities to connect with potential employers and showcase their skills.

To prepare students for placement interviews, the institute provides training in communication skills through sessions conducted by HR experts. These sessions focus on enhancing students' presentation abilities, ensuring they are well-equipped to perform confidently during interviews.

As a result of these efforts, nearly 100% of the students were placed during the academic year 2023-24. Additionally, some students chose to join reputed organizations to pursue their Ph.D. programs. Recent recruiters include esteemed companies such as Novartis, Sanofi, Genpact, Dr. Reddy's Laboratories, Pfizer, Biocon, Piramal, Sai Life Sciences, Aragen, Alembic Pharmaceuticals, Macleods Pharmaceuticals, Orbicular, Teadus Pharma Private Limited, Global Data, Enveda, PharmaACE, Schrodinger, and many more.

CHAPTER 4: RESEARCH AND ACADEMIC FACILITIES

4.1. NABL Accredited Analytical Testing Laboratory

Analytical Testing Laboratory caters to the needs of researchers within the institute as well as outside the institute such as MSMEs, academic institutes and government. The same aims to provide the institute, MSMEs, academic institutes with the latest and the most advanced analytical techniques for research in various areas. The sophisticated instrumentation facility established at NIPER Hyderabad represents institutes commitment to raising the Research and Testing quality to the international standards. The analytical testing facility is equipped with several state-of-the-art instruments like LC-MS (Liquid



DSC

LC-QTOF-MS/MS

NMR Bruker 500 MHz

Chromatography-Mass Spectrometry), NMR, GC-MS, XRD (X-ray Diffraction), FTIR, ICPMS, DSC, TGA, etc. These facilities span across broad scientific disciplines being studied in the institute and offer capabilities that range from molecular identification and structure determination to environmental analysis and materials characterization. Some of the facilities shown below:

The Analytical Testing Laboratory is NABL accredited (ISO 17025) and follows the requirement of regulated testing as per its Quality Manual. The Analytical Testing laboratory emphasizes adherence to international standards and any specific industry standards as per needs of the customers. The laboratory has successfully completed customer audits from various pharmaceutical companies namely, Alembic Pharmaceutical Limited, Nakoda Chemicals Limited, Synthokem Labs, Jodas Pharma and is currently serving to many small and mid-sized companies for their testing needs.

Powder XRD



ICPMS



The facility is an empaneled Government Lab for testing of generic medicines under PM-BJP scheme catering to the testing of various medicines such as Paracetamol, Ramipril, rosuvastatin, etc. Importantly, the analytical testing facility serves as a direct linkage for Industry-Academia collaboration and provides a first-hand experience to the graduating students to be industry ready.

4.2. Biosafety Level-3 Research Facility

The whole world has witnessed a number of pandemics, starting from the Black Death (bubonic plague) to COVID-19. Every time researchers around the globe tried to identify the cause behind and while doing their job, most of them lost their lives due to exposure to these agents. Hence, in every biomedical and medical setting worldwide, biosafety is a significant concern. All the pathogens have been categorized under different groups, from level 1 to level 4, based on their virulence, pathogenesis, and available treatment options. The pathogens from group-3 pathogens can spread within the community; hence, research involving group-3 pathogens requires sophisticated Biosafety level-3 (BSL-3) containment laboratories. The prime objective of a biohazard containment facility is to minimize or eliminate exposures of the researcher and the outside environment to potentially hazardous agents. Tuberculosis (TB) is still a major challenge to global health even after sincere, combined, and continuous efforts from both scientific and medical communities throughout the world. Based on the current pandemic situation and the worldwide presence of tuberculosis, we proposed to establish a BSL-3 facility at NIPER Hyderabad to support drug discovery against the pathogens categorized under risk group 3, and Mycobacterium tuberculosis is one among those pathogens.

The BSL-3 facility at NIPER Hyderabad is a container-based facility with three Class II, type B2 biosafety cabinets and other necessary instruments. This facility will support the ongoing institutional anti-tuberculosis drug discovery research programs. The facility at NIPER Hyderabad will also be made available for utilization during any pandemic situation in the coming future.

4.3. Centre for Testing of Nutritional Supplements at NIPER Hyderabad

A Centre for the testing of nutritional supplements towards contamination by doping agents is being established at NIPER Hyderabad under a tripartite MoU with Ministry of Youth Affairs and Sports (MoYS) and Food Safety Standards Authority of India (FSSAI). A funding of Rs. 6.3 Cr. has been granted by MoYS, Government of India for the creation of this facility at the institute.

Through this national centre for testing of nutritional supplements at its premises in the south zone of India, NIPER Hyderabad aims to contribute towards fine testing of nutraceuticals and food supplements to substantiate broader national causes on anti-doping under the able guidance of National Anti-Doping Agency (NADA), New Delhi and National Dope testing Laboratory (NDTL), New Delhi.

Nutritional supplements have emerged as significant contributors to unintentional doping. A significant number of documented doping cases stem from undisclosed substances found in dietary supplements. There is a lack of harmonization in regulations on the quality of these products from regulatory bodies worldwide. Implementing regulated testing and certification protocols for such supplements can effectively prevent instances of inadvertent doping. However, there are only a handful of laboratories capable of testing supplements for the contamination with doping agents worldwide and there is no single designated laboratory in India to carry out such testing. In view of

the critical need of suitable laboratories for the testing of nutritional supplements, Department of Sports have taken proactive steps to establish two laboratories at different parts of the country namely, at National Forensic Science University, Gandhinagar in the West Zone and at NIPER Hyderabad in the South Zone.

The Centre aims to cover the testing of nutritional supplements for about 283 WADA-prohibited substances. Other aspects of the Centre involve capacity building for athlete awareness programs through classroom & on-field training sessions. In a long term, the Centre also aims to facilitate Research & Development on new methodologies and rapid test kits for on-site and non-invasive testing contributing the broader field of anti-doping Science.

The testing and certification of nutritional supplements will ease athletes while making informed choices and will also ensure public safety at large given various adverse effects of doping agents on the human health. A combined report with findings will periodically be shared with the regulatory agencies such as NADA and FSSAI to strengthen Safe and True Play for the Nation, Food Safety, and Quality Assurance for better human health.

The Centre is currently examining over-the-counter nutritional supplements to detect the presence of prohibited doping substances, including Anabolic agents, Steroids, Diuretics, Stimulants, β-Agonist, Narcotics, and other substances banned by the World Anti-Doping Agency (WADA) using



LC-HRMS/MS & GC-MS/MS. It is also planned to carry out focused testing on various nutritional supplements categories such as Tablets, Powder, Gel, Capsule, Liquid, etc., type of dietary supplements usages such as Whey Proteins, Weight Gainers, Weight Loss/ Fat Burners, Pre-Workouts, Intra-Workouts, Post-Workouts, and Essentials, type of nutritional supplements specially categorized for Males, Females & Under 18 age consumers, targeted on the supplements claiming to be “Safe” through FSDU logo, Third-party Certification, Dope Free, No Banned Substances logos on the packing.

4.4. Central Animal House Facility

Research in biomedical science is essential for enhancing the quality of human life. This progress is achieved through advancements in treating human diseases and disabilities, improvements in animal health and veterinary medicine, and a deeper understanding of the intricate biological systems of human and animal physiology and their disorders. Working with living animals is crucial for continued progress in many areas of clinical and basic research. Although alternatives like cell and tissue cultures, lower animal studies, or computer simulations exist, the use of whole animals remains irreplaceable. The mission of the NIPER, Hyderabad animal facility is to provide animals that meet the required specifications for research projects at this Institute and to conduct continuous research on laboratory animals.

From unicellular organisms to more complex species, a variety of animals contribute annually to medical breakthroughs that save millions of human lives. Research on these animals has led to the discovery of cures and preventive measures for numerous human and animal diseases. While humane treatment of animals and the development of alternative techniques have significantly reduced the wastage of animal lives, it is imperative to ensure animals are not subjected to unnecessary distress or discomfort. This facility is committed to upholding the 3Rs (Replacement, Reduction, and Refinement) of animal experimentation and adhering to the ethical principles of animal use as per CPCSEA guidelines.

Animal House CPCSEA Registration

The animal house facility is registered with CPCSEA under Registration No. 1548/PO/ReBi/S/11/CPCSEA.

Institutional Animal Ethics Committee (IAEC)

All experiments involving animals are approved by the IAEC, which is constituted by CPCSEA. IAEC meetings are held regularly to obtain ethical clearance for the use of animals in academics and research. The facility maintains all relevant records to ensure compliance with the approvals granted by the committee, and the progress of each approved protocol is reviewed regularly by IAEC in each meeting.

Pharmacological and Toxicological Screening Facilities

Our Institute is equipped to conduct the following screening procedures using various animal models:

- Acute, sub-acute, and chronic toxicity studies of drugs
- Screening of analgesic, anti-inflammatory, antipyretic, and anti-arthritic drugs

- Screening of anti-cancer drugs
- Screening of hepato-protective agents
- Screening of anti-diabetic drugs
- Screening of anti-ulcer drugs
- Screening of psoriasis model
- Screening of pulmonary fibrosis model
- Screening of anti-parkinson agents
- Screening of pharmacokinetic (PK) studies
- Screening of xenograft nude mice models

This comprehensive approach ensures that our research adheres to the highest ethical standards while making significant contributions to medical science.

4.5. Instrumentation Facilities



LC/MS



Scanning Electron Microscope (SEM)

500 MHz NMR Spectrometer

Single Crystal X-Ray Diffraction

Powder X-Ray Diffraction



Differential scanning calorimetry (DSC) & Modulated DSC



Thermogravimetric Analyzer

Super Critical Fluid Chromatography

Other important facilities:

- Flow Cytometer
- 500 MHz NMR Spectrometer
- UV/Vis/NIR Spectrophotometer
- Nano Drop Spectrophotometer
- Scanning Electron Microscope
- Confocal Microscope
- Blood Cell Counter

- Histopathology – Embedding Unit & Microtome
- RT – PCR
- Cascade Impactor
- Flourescent Microscope
- High content screening system
- Microplate Readers
- 1260 Quaternary HPLC System
- Large Scale Rotary Evaporator with Vacuum Pump (20 Ltrs)
- Radleys Reactor Ready
- Bioreactor
- Ultra Microbalance
- Nitrogen Evaporator
- Karl Fisher Auto Titrator
- Rotary Evaporator
- Evoqua Water Purification System
- Parallel Synthesizer
- Micro Ultra Centrifuge
- Extra Cellular Flux Analyzer
- Individually Ventilated Cages
- ECT Unit
- Rota Rod Apparatus
- BIOPAC with ECG and EEG
- Elevated plus maze
- Plethysmo meter
- Any-maze video tracking system
- Automatic Blood Analyzer
- UV-VIS Spectrometers
- High-Speed Refrigerated Centrifuge
- Laser dopplers system with OXY measurement
- Tail flick analgesia meter
- Phase contrast microscope
- Spectramax M4 Multi mode Microplate Detection System
- Benchpro 4100 instrument card processing station
- Muse Cell Analyzer
- Veriti 96w Thermal Cycler
- Small Animal Anaesthesia System
- HPLCs (Analytical & Preparative)
- Agilent HPLC
- ACQUITY UPLC H-Class Bio
- LC-MS/MS Q-tof 6540
- Gas Chromatograph: GC-2014
- Automatic Digital Polarimeter
- FT-IR Spectrophotometers
- Parallel synthesizer 12 reaction station
- Dissolution test apparatus
- Stability Chambers
- Spray Dryer/ Fluidized Bed Dryer /Freeze Dryer
- Tablet Punching and Coating Machine
- Dissolution/ Disintegration Test Apparatus
- Brook Field Viscometer
- Differential scanning calorimetry (DSC) & Modulated DSC
- Thermogravimetric Analyzer
- Zetasizer Nano ZS
- Millipore Water Purification System
- GCMS (QQQ)
- ICPMS
- CAMAG TLC Visualizer 2

4.6. Library and Information Center

NIPER-Hyderabad library serves as a source of information Centre for the Pharmaceutical industry and academic institutions. It has a rare collection of old chemical and biological abstracts from the year 1907 to 1993. NIPER-Hyderabad Library has 9038 textbooks, 430 research journals with bound volumes of 10579 copies, and 2049 chemical and biological abstracts. In addition to this, the NIPER-H library has nine (7) newspapers. The library provides the facilities, such as books and journal borrowing, literature search, photocopying, news clipping service, etc. The selected Science Direct online journals (92 journals) are available from the year 2013 onwards. Later, from 2018 onwards, for MBA (Pharm.) EBSCO online journals and video contents (Total = 915) were made available. The library also hosts 1028 NIPER- student's thesis (Dissertation) from 2009 to 2024 along with Ph.D. research scholar's thesis (102 No's) from 2011 onwards. In addition, software tools like Turnitin are available from 2016 onwards. Similarly, other software tools for research like **Sci Finder E-Database software from 2021, Chem office Professional Site, QIAGEN PUB.CLC GENOMICS Work Bench Premium Network, DNASTAR Laser Gene Suite Software and Design of Expert Academic Stand Lone Software, CCDC Crystallography Software, and Schrödinger software are also available in the library.**

S. No.	Description	Total No of Copies					
		Added in 2018-19	Added in 2019-2020	Added in 2020-2021	Added in 2021-2022	Added in 2022-2023	Added in 2023-2024
1	Text Books	82	37	164	269	39	Nil
2	All the NIPER's Consortium for Online International Journals from : M/s. Elsevier Pub. , American Chemical Society (ACS) and Royal Society of Chemistry (RSC) from all the faculties selected related / concerned Online subject Journals	Renewed	Renewed	Renewed	Available	List of (3)Three vendors like Elsevier , Royal Society of Chemistry and American Chemical Society Consortium Online International Journals	List of (3)Three vendors like **Elsevier , Royal Society of Chemistry and American Chemical Society and Reaxys E-Database newly added e-**Consortium Online International Journals
3	EBSCO Online Journals	915 Online journals	915 Online journals	915 Online Journals	Not renewed	Not renewed	Not renewed

4	Print Journals (Loose) 2 deducted	Same as renewed	9 Renewed	9 Renewed	Not renewed	5 2 International and 2 National journals	5 2 International and 2 National journals
5	Magazines (hard copies)	Same as renewed	2 Renewed	2 Renewed	Not renewed	1 Time Magazine	1 Time Magazine
6	News Papers & Employment News 3 deducted	-1	9 News papers	9 News papers	9 News papers	6 News Papers	6 News Papers
7	Reaxys Electronic Database	Same as renewed	Same as renewed	Same as renewed	Not renewed	Not renewed	Reaxys 2024 February onwards available in the All the NIPER e--Consortium
8	Turnitin (E-thesis - Software)	Same as renewed	Same as renewed	Renewed	Renewed	Renewed (Under Process)	Renewed
9	Phonix Winnolin Software (renewed 2023)	Available	Available	Not available, Renewal under processed	Renewed	Renewed	Renewed
10	End Note Software (perpetual access) (25 no's User license)	Available	Available	Available	Perpetual Access	Perpetual Access	Perpetual Access
11	NIPER- Students- Thesis (Dissertation) from 2009 to 2023	161	126	42	79	183	
12	NIPER- Research Scholars (Ph.D.)- Thesis (Dissertation) from 2011 to 2023	35	6	11	41	15	9
13	Renewal of Schrödinger LLC Software	45 Tokens	45 Tokens	45 Tokens	45 Tokens	50 Tokens	50 Tokens
14	Dassault Systems India Pvt. Ltd (Material Studio Software) – Academic Base – I and Academic Crystallization – II	2	Available	Not renewed	Not renewed	Not renewed	Not renewed

15	DNASTAR (Lasergene Suite V-17 for Win) (Cat No 5986) PAC base	------	------	01	01	N/a	N/a
16	QIAGEN (CLC Genomics Bioinformatics Software) Pac Base	-----	-----	01	01	N/a	N/a
17	M/s. Chemical Abstracts Services (Scifinder E- Database)	-----	-----	IP Based Unlimited Access Plan	Renewed	Renewed	It was available till February-2024 Not Renewed for 2024
18	Chem Office Professional (CHEM DRAW) Site License Annual Subscription	-----	-----	150	150	Renewed (Under process)	200 License
20	Design of Expert Software (PAC BASE)	-----	-----	01	01	N/a	N/a
21	Crystallography Software (CCDC)	-----	-----	01	01	N/a	N/a
Total till - 2021		**23883**	**25032**	**26383**	**26980**	**27230**	**27289**

4.7. Computer Center

Computer Centre (CC) caters to the IT and computational related needs of the Institute as well as the Hostel community at NIPER Hyderabad

The main facilities provided by CC are:

Installation & Maintenance of Servers for:

- Internet access.
- E-mail facilities.
- FTP sharing facility.
- Computation facilities.
- VPN facilities for accessing journals and E-contents from outside of the institute.
- Maintenance of the official NIPER Hyderabad website (www.niperhyd.ac.in / www.niperhyd.edu.in).
- Management of Wi-Fi-Enabled environment in the institute & hostels
- Management of the centralized computer lab accessible to students and research scholars.
- Maintaining 100 Mbps NKN internet leased line, BSNL 20 Mbps stand-by internet leased line

and 1Gbps Act Fibernet corporate line, seamlessly connected about 600 nodes.

- Providing technical assistance to the faculty, academic and administrative staff of the institute.

- Administrative maintenance of commercial software for specialized research and general use by the staff members.
- Biometric system for taking attendance of Faculty, Staff, Master Students and Research Scholars.
- Office 365 applications for all Faculty and Staff members

NIPER-H has the provision of four computer labs, i.e., CC-1, CC-2, CC-3, and CC-4. Each lab is equipped with 25 desktops of Windows CC-2 and CC-4 are fitted with 2 Linux operating system desktops for molecular modelling facility (Schrödinger), which is dedicated for research. There are no restrictions for accessing CC labs for students and members of NIPER. The computer labs remain open for 10 hours (8:00 AM to 6:00PM) in a day, and the students visit the labs for their general and routine computing tasks. CC services are extended for hands-on sessions on particular software packages as part of the curriculum, placement activities & examination.

Also, several Linux/VMware-based servers cater to the institute's IT services like Webserver and FTP, as well as for academic requirements and research purposes. Availability of the servers and resources is ensured with power backup provided by the UPS grid.

Local area network (LAN) caters to the needs of the institute's students, faculty, and staff. The complete LAN solution has three layers viz. 10 Gigabit core with redundancy, dual-homed distribution layer with redundancy and dual-homed PoE (Power on Ethernet) enabled access layer. Network support is available 24 × 7. High-speed and uninterrupted internet access is provided across the campus to everyone through multiple ISP (Internet Service Provider) leased lines provided by BSNL (20 Mbps) and NKN (100 Mbps). The computer centre is solely responsible for maintaining the Information and Communication Technology. Computation-related facilities are available to every member of NIPER Hyderabad. These facilities are constantly upgraded to meet the evolving standards of NIPER Hyderabad. New hardware and software are procured regularly to provide a state-of-the-art computing facility to the NIPER Hyderabad family.

Fully Wi-Fi Enabled Campus & Hostels: In the year 2016, the Computer Centre installed WLAN on 802.11b/g to allow accessing NIPER-Hyderabad computing resources (Local network and Internet) through the Wireless communication in campus and Hostels. WLAN employs mobile network access through the Wireless Access Points. All hostels are Wi-Fi enabled for internet connectivity. Wi-Fi solution is based on Cisco wireless controllers for the entire academic areas and Hostels. A total of 45 Cisco Access Points (dual-band 802.11a/g/n/ac) has been installed.

The National Knowledge Network (NKN) project aims to establish a strong and robust internal Indian network capable of providing secure and reliable connectivity. Using NKN, all vibrant institutions with vision and passion will be able to transcend space and time limitations in accessing information and knowledge and derive the associated benefits for themselves and the society towards ushering

in a knowledge revolution in the country. NKN is intended to connect all the knowledge and research institutions in the country using a high bandwidth / low latency network.

Molecular Modeling Lab: An IT-based Computer Centre with a molecular modelling Lab (MML) facility is operational with licensed software like Schrodinger, SYBYL, Gaussian 09w, and Material Studio to support faculty, research scholars and students for research and Academics. Three workstations are available and are being used for molecular modelling studies.

Display Panels: NIPER Hyderabad has display panel systems to display banners (as E-banners) and relevant information/messages to dignitaries during conferences, workshops, and events. The auditorium is also equipped with an impressive display system for easy visibility of the content of data to the speaker on the dais.

Digital Classrooms: NIPER Hyderabad has Digital classrooms (Smart Boards) in every lecture hall, CC-1 and CC-2. Virtual classrooms are more engaging and interactive than **traditional classrooms.** The use of technology in the classroom has brought an accelerating range of technology that the students can get exposure to learn about the dynamic environment of technology and accelerate their growth.

NIPER Hyderabad has taken the lead in creating a common portal for all NIPERs. It has been given to DoP for maintenance.

Computer Center also maintains R&D software tools for research like Sci-Finder E-Database software from 2021, Chem Office Professional Site, DNASTAR Laser gene Suite Software and Design of Expert Academic Stand Lone Software, CCDC Crystallography Software and Schrödinger software.

4.8. NIPER Hostels

The students of NIPER-Hyderabad have been currently provided accommodation at NIPER hostel located at IDPL Township, around 2 km away from NIPER campus situated in Balanagar, Hyderabad. Students are provided bus service from the hostel to college and again back to the hostel. Student's

hostels have pleasant surroundings and are intellectually stimulating. The layout of the hostel, in general, is appealing.

HOSTEL MANAGEMENT

The hostel is administered by a hostel in charge, Mr.Manoj Dhote. The Hostel Management team comprises Chief Warden (Boys) Dr. Rajesh Sonti and Chief Warden (Girls) Dr. Y. V. Madhavi, and one lady caretaker for Ladies Hostel.

External agencies have been contracted to provide security and housekeeping services at the hostels. The hostel in charge monitors these services.

ACCOMMODATION

NIPER Hyderabad provides separate accommodation for both boys and girls. Currently, the hostel block houses 287 students, of which 142 are girl students. Both hostels have large, well-ventilated rooms, each well furnished with a cot, wardrobe, chair, study table to accommodate two students each. Each room has a garden view. Each room also has an attached bathroom with facilities for hot and cold water. The hostels have 24-hour constant water and power supply. Hostel maintenance like cleaning, sweeping, pest control is outsourced. Electrical repairs and security services are available round the clock. All the rooms have been equipped with a LAN connection for each occupant.

FACILITIES

The hostel provides students with an atmosphere much like a home away from home. It provides them with all the necessary facilities which help them to acclimatize well with this new ambiance. Each occupant is equipped with a cot, a study table, a chair, and an almirah. It has its mess which is managed and run by students. Keeping in view the different tastes of the students, the mess caters them to healthy and tasty food.

- Several recreational, sports, literary and social activities take place in the hostel during the academic year.
- TV rooms are equipped with 54’ inch flat television and cable connections in both girls’ and boys’ hostels.
- A separate gym facility is provided for both girls and boys.
- Table tennis room with two playing boards.



- Sports grounds are situated at a close distance to encourage students to stay fit by regularly engaging in playing different games. The playground is a considerable size, and courts for Volleyball, Badminton, Cricket are constructed.
- A water purifier for providing pure water is also available
- The hostel is surrounded by a good number of trees and houses a beautiful garden.
- Morning walk track for joggers is also available
- Bus service is provided for pick up & return of students to and fro hostel and NIPER-H campus.

MEDICAL SUPPORT

- NIPER Hyderabad has tied up with a reputed local hospital in proximity to the hostel campus. A qualified visiting doctor is available to provide regular and intensive medical care to NIPER-H students
- The proximity of other hospitals within 1 km from the campus

CHAPTER 6: OUTREACH ACTIVITIES

6.1. Collaborations

The institute actively engages in various collaborative academic and research activities with numerous research institutes, industries, and universities. These partnerships are formalized through Memorandum of Understanding (MoUs).

MoUs facilitate the exchange of knowledge, expertise, and resources between the institute and its partners. Through these agreements, students and faculty gain access to advanced research facilities, cutting-edge technologies, and specialized training programs. This exposure helps in enhancing the academic curriculum, promoting innovation, and fostering a culture of research excellence. Moreover, they provide students with valuable hands-on experience and opportunities to work alongside leading experts in their fields.

MoUs also pave the way for joint conferences, workshops, and seminars, facilitating the dissemination of knowledge and best practices. The MoUs signed by the institute during the year 2023-24 are listed below, highlighting the institute's commitment to building strong, collaborative networks that drive academic and research excellence.

1. MoU signed with Gujarat State Biotechnology Mission (GSBTM), Gujarat on Janurary 02, 2023 for summer internship programme.

2. MoU signed with Epigeneres Biotech Private Limited, Mumbai on February 04, 2023 to provide research & consultancy projects, training facilities, and campus placements.

3. MoU signed with Tripartite Agreement with Ministry of Youth Affairs & Sports (MYAS), Food Safety & Standard Authority of India (FSSAI) & NIPER Hyderabad on February 15, 2023 to explore the possibility of whether 'Nutritional Supplements for Sports Persons contain any 'Prohibited substances' as declared by the WADA from time to time as per the requirement of NADA.

4. MoU signed with Acharya Nagarjua University, Guntur, Andhra Pradesh on February 21, 2023 for Teaching, Research, Training, collaborate and write project proposals.

5. MoU signed with Dharmsinh Desai University (DDU), Nadiad, Gujarat on March 16, 2023 for the purpose of collaborative research and education.

6. MoU signed with SVNIT Surat on March 27, 2023 for academics & Research.

7. MoU signed with College of Pharmacy, Taipei Medical University, Taiwan on April 17, 2023 for Academic & Research.

8. MoU signed with KRIAM (Pharmaceutical Company), Surat, Gujarat on May 08, 2023 for research collaboration, exchange of scientific personnel, Joint Workshops, Conferences etc.

9. MoU signed with CCRUM, New Delhi on December 14, 2023 for research.

10. MoU signed with National Institute of Sowa Rigpa (NISR), Leh on January 19, 2024 for academic & research.

6.2. Events, Workshops and Training Programmes

11th Convocation 🎓 of NIPER Hyderabad

NIPER Hyderabad celebrated its 11th Convocation on January 19, 2024. The event was graced by Shri Arunish Chawla Ji, IAS, Secretary of the Department of Pharmaceuticals, who served as the Chief Guest.

Dr. Satyanarayana Chava Ji, Chairman of the Board of Governors at NIPER Hyderabad and CEO of Laurus Labs, attended as the Guest of Honour. The convocation marked a significant milestone for the institute and its graduates.

Foundation Day

NIPER Hyderabad marked its 17th Foundation Day on October 20, 2023. The event was graced by the presence of Prof. Basuthkar Jagadeeshwar Rao, the Vice-Chancellor of Hyderabad University, as the chief guest.

Recognition to NIPER faculty members

Three esteemed faculty members at NIPER Hyderabad—Dr. N. Shankaraiah, Associate Professor; Dr. Chandraiah Godugu, Assistant Professor; and Dr. Neelesh Kr. Mehra, Assistant Professor—received well-deserved recognition, being ranked among the top 2% of scientists worldwide by Elsevier in 2023.

Dr. Saurabh Srivastava, Associate Professor, Department of Pharmaceutics, NIPER Hyderabad and Dr. Chandraiah Godugu, Assistant Professor, Department of Biological Sciences, NIPER Hyderabad, have been elected as “Fellow of Telangana Academy of Sciences.”

NIPER Hyderabad organized the 'Swachhata Special Campaign 3.0' and conducted various outdoor activities, including:

i) A march to encourage public participation in achieving the Swachh Bharat mission.

ii) Cleaning activities at Zilla Parishad High School (ZPHS) Moosapet.

iii) Educational sessions on the importance of cleanliness and hygiene for ZPHS students.

iv) Distribution of cleaning materials to government primary and high schools.

v) Enthusiastic participation of NIPER Hyderabad students, faculty, and staff in cleaning activities at the local market.

Inauguration of Foundation Stone of the Permanent Campus:

On January 12, 2024, Shri Bhagwant Khuba, Hon'ble Minister of State for Chemicals and Fertilizers & New and Renewable Energy, inaugurated the foundation stone of the permanent campus in the presence of Dr. Mansukh Mandviya, Hon'ble Minister of Chemicals & Fertilizers and Health & Family Welfare.

Visit of US-FDA Delegation

A delegation from US_FDA INO led by Sarah McMullen, Ph.D., India Office Director visited NIPER Hyderabad on 14th Dec 2023. Dr. Shailendra Saraf, Director, @NIPERHyd welcomed the guests and discussed on exploration of Joint training programs and collaborative research opportunities.

Visit of DoP officials viz.

On April 18, 2024, Dr. Richa Pandey, Deputy Secretary (R&D, NIPER), visited NIPER Hyderabad. Accompanying her was Ms. Geetha Ashok, Under Secretary to NIPER Hyderabad.
Their visit focused on reviewing the construction progress of the permanent campus. This visit marked an important step in the development of the institute's new facilities.

The Parliamentary Standing Committee on Chemicals & Fertilizers

NIPER Hyderabad had the privilege of hosting Dr. Shashi Tharoor Ji, Chairman of the Parliamentary Standing Committee on Chemicals & Fertilizers, along with esteemed Members of Parliament on May 27, 2023. Their visit aimed to assess the progress of the institute's permanent campus construction and its research & development endeavors.

During the visit, the committee toured the labs and engaged with talented students and faculty members, appreciating NIPER Hyderabad's recent achievements.

NIRF Ranking 2023

NIPER Hyderabad secures the #1 position in NIRF Ranking 2023 (Pharmacy). This remarkable achievement is a testament to our dedicated faculty, students, staff, and leadership (05th June 2023)

Cyber Awareness in current Scenario

On May 15, 2024, NIPER Hyderabad organized a guest talk titled "Cyber Awareness in the Current Scenario," featuring Mr. Kasi Viswanath, Joint Director (IT) / Scientist-D from the National Infrastructure Unit in Hyderabad. The talk aimed to address the importance of cyber awareness amidst contemporary challenges.

Mr. Viswanath shared valuable insights and expertise during the session, enlightening the audience about key aspects of cyber awareness relevant to the present environment. The event contributed significantly to enhancing understanding and preparedness in dealing with cyber-related issues.

NIPER Hyderabad Sports Event 2024

From February 15, 2024, NIPER Hyderabad hosted a five-day event encompassing diverse sports competitions. These competitions featured popular sports like football, volleyball, tennis, cricket, table tennis, and also included E-sports such as BGMI.

Participants engaged in spirited contests across these sports, showcasing their skills and sportsmanship throughout the event. The variety of sports offered something for everyone, creating an exciting and inclusive atmosphere for all participants and spectators alike.

CHAPTER 7: CITIZEN'S CENTRIC GOVERNANCE

7.1. Right to Information

As per the provisions of the RTI Act, 2005, the RTI cell has been established which acts as Nodal Cell for RTI matters. RTI applications are transferred to the CPIO.

RTI cell also coordinates follow-up action on the appeals/orders received from Central Information Commission and submits returns etc. The list of Central Public Information Officer (CPIO) and Appellate Authorities are updated regularly on the Department's website. Proactive action is taken under Section 4 of the RTI Act for suo-moto disclosures on the website in pursuance of transparency.

7.2. Centralised Public Grievance Redress and Monitoring System (CPGRMS)

Public grievances received through CPGRAMS are systematically monitored and promptly addressed to ensure timely resolution.

This systematic approach helps address citizen concerns effectively, promoting accountability and responsiveness in government services.

7.3. Implementation of IP in Public Procurement

According to guidelines from the Department of Expenditure dated 19.07.2011, all Ministries, Departments, Organizations, and autonomous bodies were directed to implement Integrity Pact (IP). NIPER Hyderabad has adhered to these directives by instituting an Integrity Pact overseen by Independent External Monitors (IEMs) appointed by the Vigilance Commission. This framework guarantees transparency, fairness, and competitiveness in the process of public procurement.

The implementation of Integrity Pact at NIPER Hyderabad is pivotal in fostering trust and accountability in procurement practices. By involving Independent External Monitors nominated by the Vigilance Commission, the institution ensures that all procurement activities are conducted with utmost transparency and adhere to ethical standards.

#NIPERHyderabadCampus

Main Entrance

Auditorium